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Abstract  
 
Laminin N-terminus α31 (LaNt α31), a member of the relatively new LaNt protein 
family, is a product of alternative splicing from the laminin (LM) α3 encoding gene 
(LAMA3). Prior to these studies, very little was known about LaNt α31 biology; it 
had been shown to co-localise with LM α3β3γ2 (LM332) in the basement membrane 
(BM) of the skin and to play a role in adhesion and migration of epidermal cells. 
Still, no direct insight into the mechanism behind this effect has been described.  
In this study, we performed the first analysis of LaNt α31 in the eye. 
Immunohistochemistry reveals that the protein is differentially distributed across the 
regions of the epithelium in the anterior surface of the eye. Specifically, LaNt α31 
localises intracellularly through all layers of the corneal epithelium, but is restricted 
to the basal layers of the limbus and conjunctiva. Hence, we sought to investigate 
about LaNt α31 functional roles in corneal epithelial cells (hTCEpi) and its interplay 
with LM during corneal epithelial matrix assembly. 
Our functional studies demonstrate that knockdown of intracellular LaNt α31 has no 
discernible effect on hTCEpi, in which LaNt α31 is not normally matrix-associated. 
However, when overexpressed by adenoviral delivery, LaNt α31 is deposited into the 
extracellular matrix (ECM) and causes a number of phenotypic effects including; 
impaired cell adhesion to LM111, changes to LM organisation, increased cell 
spreading, early recruitment of Collagen (Col) type XVII to β4 integrin in 
hemidesmosome (HD) like-complexes and mislocalisation of focal adhesions (FAs). 
Increased LaNt α31 expression also leads to significantly decreased motility at times 
of new matrix synthesis, with this migration defect rescued when hTCEpi are 
provided with a cell-derived preformed ECM. Live imaging experiments indicate 
13 
 
that GFP-tagged LaNt α31 clusters at the periphery of cells, where it co-distributes 
and is deposited along with LM β3. As cells move across a preformed matrix, 
clusters of LaNt α31 rapidly form and dissociate intracellularly, alongside LM 
deposits.  
To study the effects of overexpression in-vivo, we generated a human keratin 14 
(hK14) promoter-driven LaNt α31 overexpressing mouse model by embryo 
microinjection. Using this construct, we obtained far fewer offspring than would 
normally be expected and were not able to detect expression of the protein product 
from the transgene in the animals carrying the construct. Based on these data, we 
hypothesise that, in this model system, LaNt α31 overexpression has induced 
lethality.  
Together, these data demonstrate that LaNt α31 influences the assembly of LM 
matrix in hTCEpi affecting fundamental cell functions, and implicate the LaNt 
proteins as regulators of other LM dependent processes including wound repair, 
differentiation and tissue homeostasis. 
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The work described in this thesis represents the first study of LaNts outside the skin 
and provides a much deeper analysis of LaNt α31 function and interplay with 
laminins (LMs) in corneal matrix and cell adhesion devices. To put these findings 
into context, a fundamental appreciation of the different players and complexes 
involved is required. Therefore, this introduction will briefly describe the basement 
membrane (BM) main components and functions (section 1), the laminins with their 
domain architecture and known roles (section 2), the cell to LM adhesive devices 
that were investigated in this work, specifically the hemidesmosomes (HDs) and 
focal adhesions (FAs) (section 3) and, finally, what was known about the LaNt 
family of proteins prior to the initiation of these studies (section 4). 
 
Section 1. The Basement Membrane  
1.1.0 General Structure 
 
BMs are thin, specialised forms of cell-associated ECM with a very wide distribution 
in the body; they are found beneath epithelial, mesothelial and endothelial cells and 
enclose muscle, fat and Schwann cells [1]. BM evolution started approximately 500 
million years ago [2] and have been studied since the late 1970s as highly specialized 
substrates for cellular differentiation and gene expression.  
BMs are known to play several fundamental roles. First, they are involved in the cell 
adhesion process by acting as anchoring devices between sheets of cells and 
connective tissue, via substrate-adhesion molecules (SAMs) [3]. Second, BMs are 
essential players in tissue and organ morphogenesis, as they support migration of 
cells during tissue remodelling; this also includes new cancer blood vessel growth, a 
process shown to be partially controlled by the BM beneath the tumour endothelium 
16 
 
[4]. Third, BMs are critical for maintaining mechanical barriers, preventing foreign 
bodies, bacteria or malignant cells from invading the underlying deeper tissues [5] 
and, under specific circumstances, BMs also have a role as diffusion barriers, e.g. in 
the lungs where they modulate O2 and CO2 diffusion between alveoli and capillaries 
[6], or as filters with selective permeability, e.g. in the kidney glomerulus [7]. 
Finally, BMs control cell differentiation by inducing tissue-specific gene expression 
[8] and can act as a reservoir for several types of growth factors (GFs) [9, 10].  
High-power transmission electron microscopy (TEM)-based studies show that BM 
thickness is around 100 nm on average, with the exception of the lens capsule, where 
it is over 10 µm [2]. BMs are composed of approximately 50 types of proteins, 
organised in a complex structure that changes with age and is, therefore, dynamic 
[2]. Normally, BMs are visible in TEM as two distinct layers: an electron-lucent 
layer close to the plasma membrane, named as lamina lucida, and an electron dense 
layer or lamina densa. The lamina lucida, in epithelial tissue, is 20-40 nm thick and 
is traversed by anchoring filaments (5-7 nm in diameter) rich in LM332 and 311, and 
which interact with the extracellular domain of α6β4 integrin [11]. The lamina densa 
has a thickness which varies with age (30-60 nm) and is mainly composed of 
collagen type IV, but contains also LM511 and 322, nidogens and heparan sulfate 
proteoglycans (HSPGs), such as perlecan (PLC) [11]. A third layer, known as lamina 
fibroreticularis, is only present in some tissues; it synthetized by fibroblasts and joins 
the BM to the underlying connective tissue [12].  
From immunostaining studies [12], BM principal components are collagen type IV in 
different variants, HSPGs including PLC and agrin, nidogens, also referred to as 
entactins, fibulins, fibronectin (FN) and LMs [13](Fig. 1.1). It is now accepted that 
these proteins are the major contributors to the self-assembly of BMs on competent 
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cell surfaces [14], primarily via cellular receptors such as integrins and dystroglycan 
[2, 15]. Mutations negatively influencing the folding and functions of the BM 
structural proteins have been shown to lead to either problems during development 
[16] or life-threatening diseases involving abnormal functions of muscles, nerves, 
brain, eyes, skin, vasculature and kidneys, highlighting the importance of BMs to the 
function of many tissues [8]. 
 
Fig. 1.1: BM simplified assembly process and structure.  
Schematic diagram of the BM assembly phases, adapted from LeBleu, MacDonald et 
al. 2007. 
 
 
1.1.1 Basement Membrane components 
 
The research described in this thesis is primarily related to LaNt 31, a LM related 
protein. LMs are not the only molecules present in the BM and, as LMs interact at 
different levels with the rest of the BM components, it is important to have a brief 
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vision of all the BM elements to fully understand their implications in the wider 
context of tissue functions.  
 
1.1.1.0 Collagens and Collagen type IV  
 
Collagens are the most abundant structural proteins in mammals [17], with 28 types 
identified and analysed [18]. The building blocks of collagen structure, termed 
tropocollagen, are right-handed triple helixes stabilized by many hydrogen bonds, 
made up by three parallel polypeptide strands twisted together with a left-handed 
helical conformation and a very specific amino acids arrangement. Tropocollagen is 
typically formed by two identical chains termed α1, and a third chain termed α2, 
which is slightly different in its chemical composition [19]. The binding of several 
tropocollagen molecules leads to the formation of a fibril, which interdigitates with 
neighbouring fibrils to form a fibre [20].  
Collagen type IV is the primary type of collagen found ubiquitously in all the BMs. 
Six individual chains have been identified, named as α1(IV) to α6(IV), each one 
consisting of three domains: an N-terminal 7S domain, a middle triple-helical 
domain and a C-terminal globular non-collagenous (NC1) domain [21]. The six α-
chains have been shown to self-assemble and form sets of triple-helical molecules 
that associate via their NC1 domains and their middle triple-helical regions to form 
spider web-like scaffolds [4]. This high order architecture forms an insoluble 
structure which is used by other BM components to interact and form the final BM 
scaffold [7].  
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With regards to the affinity and interplay between LM and Col type IV, it is known 
that their interaction plays an important role in defining the organisation and 
heterogeneity of the BM structure in tissues [22, 23]. It has been shown that 
LM/collagen type IV binding is enhanced by the presence of zinc [24] and can either 
be direct [25] or facilitated by nidogens [26, 27]. 
 
1.1.1.1 Heparan sulfate proteoglycans 
 
HSPGs are ubiquitous glycoproteins found in the BM, named after the presence of 
one or more covalently attached heparan sulfate (HS) chains, a type of 
glycosaminoglycan (GAG), in their molecular structure [28].  
In cells, HSPGs can be found either on the cell membrane, such as syndecans and 
glycosylphosphatidylinositol-anchored proteoglycans (glypicans), or in the secreted 
ECM, and this is the case of agrin, PLC and Col type XVIII [29]. HSPGs’ small size 
(40-160 nm) allows them to arrange self-assembling macromolecular structures and 
to play several different roles. These proteins have a crucial function in regulating 
key developmental signalling pathways [30], can regulate the formation of ligand-
receptor complexes by acting as co-receptors [31], can be involved in cell attachment 
and endocytosis [32], are used as indirect factors in ECM modulation of cell 
migration [33], show a protective barrier function [34] and control many of the 
signalling molecules involved in stem cell maintenance [35]. 
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1.1.1.1a Perlecan 
 
PLC or heparan sulfate proteoglycan 2 (HSPG2) is a protein encoded by the HSPG2 
gene [36]. It has a high molecular weight ( ̴ 470 kDa), is formed by five domains, 
termed I-V, and is synthesized by numerous cell types including vascular endothelial 
and smooth muscle cells, and corneal, limbal and skin epithelial cells [37, 38]. PLC 
has been demonstrated to be a strong inhibitor of smooth muscle cell proliferation 
and, on the other hand, a stimulator of endothelial growth and regeneration [39]; it is 
also involved in cell adhesion, GF binding and modulation of apoptosis [40]. 
Once assembled, PLC is secreted into the ECM, where it cross-links many ECM 
components and cell-surface molecules [41]. Among all the structural domains, the 
C-terminal Domain V, which has homology to the G domain of the long arm of LM, 
is responsible for PLC self-assembly and, therefore, for BM formation in vivo [42].  
PLC, via its domain IV [43], has been shown to bind to the LN-domain of LM α1 
chain [44], and a recent study demonstrated a strong correlation between PLC and 
the intact structure of corneal epithelium, as PLC-deficient mice are characterised by 
altered corneal epithelium architecture [45]. 
 
1.1.1.1b Agrin 
 
Agrin is a  ̴ 200 kDa,  ̴ 95nm long molecule produced by the growing end of 
motoneuron axons, named after its involvement in the aggregation of acetylcholine 
receptors during synaptogenesis [46]. In humans, agrin is encoded by the AGRN 
gene [47]. This protein is composed of a highly conserved N-terminal basal 
membrane-binding domain, nine follistatin-like repeats, and two laminin-B-like 
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modules, followed by three LG domains at the C terminus [48]. Agrin function can 
be post-translationally regulated, a process which allows this protein to have roles in 
different tissues of the body. Agrin is known to exert a key role in the formation, 
maintenance, and regeneration of the neuromuscular junction [49] as well as a 
regulator of postsynaptic differentiation and a modulator in the T-cell immunologic 
synapse [50]. In the skin, agrin and PLC show an anti-apoptotic function in dermal-
epidermal junctions [51] and downregulation of both these proteins by UV 
irradiation [52] can induce a higher level of apoptosis in keratinocytes. Agrin is also 
highly expressed in the eye, where it is found in the inner limiting membrane, the 
BM that separates the retina from the vitreous cavity [2], in the corneal epithelium 
[53] and in the stroma [54].This abundant expression, together with ocular 
phenotypes in mice and fish with mutated agrin protein [55, 56], suggest a function 
for agrin during eye development. 
Agrin is deposited from Xenopus Laevis cells cultured on LM containing-substrates 
[57] and it uses its N-terminal portion to bind to different LM isoforms, association 
which may play a role in the BM stabilization [58, 59]. The agrin-binding site has 
first been characterised in LM111 and it resides in a 20-residue long region of the γ1 
chain, in the LM LCC domain [60]. Agrin binds to LM211 and 221 too, with the link 
being strongest for LM221 [61]. Differential tissue distributions of LMs may 
regulate agrin binding [62] and it is, therefore, possible to speculate that the 
interaction between agrin and LMs drives the correct integration of agrin into the 
ECM scaffold. 
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1.1.1.2 Nidogens  
 
Nidogens, also known as entactins, are ubiquitous ECM components and belong to 
the sulfated monomeric glycoproteins family. To date, two nidogens have been 
described in humans: nidogen-1, of about 150 kDa and encoded by NID1 gene, and 
nidogen-2, of about 200 kDa and encoded by NID2 gene [63]. Each isoform is 
organised into three structural domains, an N-terminal globule linked to a smaller C-
terminal globule by a rigid stalk largely consisting of cysteine-rich EGF-like 
homology repeats and a cysteine-rich thyroglobulin homology repeat [63]. Structural 
analysis revealed that nidogen-1 is formed by a single 1200-residue polypeptide 
chain [22]; it contains binding sites for perlecan and collagen type IV at 
approximately 80 nm from its carboxyl non-collagenous end [64] and, most relevant 
for our studies, it can also bind to the LE repeats of LM γ1 and γ3 chains [65, 66]. By 
simultaneously binding different components, the nidogens act as bridging molecules 
in basement membranes. 
Nidogen-1-deficient mice show a mild deficit in nervous system function [56] and, 
interestingly, mouse animal models lacking either nidogen-1 or nidogen-2 show only 
minor effects [67, 68] pointing to a redundancy of function between the two 
isoforms. This is supported by the early lethality resulting from the deficiency of 
both isoforms, which affected integrity of lung and cardiac tissues because of 
modifications in the BM [69, 70]. Nidogens are able to bind calcium ions and 
support cell adhesion and are also known to be very sensitive to proteases, 
suggesting that they may be a target for proteolytic activity during tissue 
remodelling, metastasis and other events requiring the turnover of the BM [71]. 
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1.1.1.3 Fibulins 
 
A recent addition, in terms of discovery, to the ECM proteins is represented by the 
fibulin family, composed of six isoforms sharing calcium-binding consensus 
sequences with a broad range of interaction potentials [72]. Fibulins are composed by 
several epidermal growth factor (EGF)-like modules followed by a carboxy-terminal 
fibulin-type module; they can vary in size (367-1196 residues) and can undergo 
alternative splicing modifications [73].  
Fibulins are involved in elastic matrix fibre assembly [74, 75], they are highly 
expressed in blood vessels during development [76] and play a fundamental role in 
several types of eye disorders. For instance, the macular dystrophy named as 
Malattia Leventinese has been linked to a mutation (Arg345Trp) in the fibulin 3 
gene, and fibulins 1 and 4 have been indicated as candidate genes for retinopathies 
[77]. The expression of fibulins 3 and 1 is also elevated in a murine retinopathy 
model that primarily involves degeneration of rod photoreceptors [78].  
Fibulins can bind several protein ligands; with regards to this project, they bind to the 
LN-domain of LM γ2 chain and to the LE domains of LM α1 chain [79]. In addition, 
fibulin 2 has been reported to bridge LM111 and LM332 with other BM components, 
providing a linkage between the cell surface and the basement membrane [73, 79]. 
 
1.1.1.4 Fibronectin 
 
Fibronectin (FN) is a high-molecular weight (~440 kDa) adhesive glycoprotein 
present in the ECM, widely expressed by several cell types and fundamental during 
development, as demonstrated by the early embryonic lethality of knock-out mice 
24 
 
[80]. This protein is found as a dimer, formed by two nearly identical subunits with a 
molecular weight of 230-250 kDa, consisting of rod-like regions connected by 
disulfide bonds [81]; it is encoded by a single gene but, in humans, is present in 
almost 20 variants resulting from alternative splicing [82, 83].  
Fibronectin modules are arranged into several functional and protein-binding 
domains, allowing the protein to associate with other FN molecules [84]. Among the 
different domains, fundamental are the I1-5 domain, shown to be the "assembly 
domain" required for the initiation of FN matrix assembly, the III9 domain, known as 
the "cell-binding domain" and the III10 domain, site of cell attachment, via α5β1 and 
αVβ3 integrins, to the cell surface [84].  
Fibronectin is involved in numerous biological processes, such as cell adhesion, 
growth, migration, and differentiation [85]. It also plays a crucial role in wound 
healing [86] and embryogenesis [80]. Interestingly, fibronectin is present in the oral 
cavity, where it helps preventing the colonization by potentially pathogenic bacteria 
[87]. Related to our study is the FN-integrin binding, in particular the binding with 
α5β1 integrin receptor. In skin, the latter is involved in the re-epithelialisation 
process, when cells need to adapt their integrin receptors to be able to use the 
provisional FN-rich matrix, adhering and moving on top of it to close the wound 
[88]. LM332 is the ECM protein required for cell adhesion and, therefore, the one 
involved in the binding with integrins. Any change in the laminin conformation, 
assembly and/or interactions within the ECM may, therefore, affect fundamental 
processes like wound healing. 
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1.1.1.5 Laminins 
 
Among all the BM components, laminins are the first type of glycoproteins to be 
detected during embryogenesis, i.e. before collagen type IV, PLC, nidogens, etc. 
[13]. LMs are heterotrimeric proteins of high molecular weight (∼400 to ∼900 kDa), 
cross or T-shaped with three short arms and one long arm. Each LM consists of three 
chains; a α-chain, a β-chain, and a γ-chain, encoded in mouse and humans by  five α 
(LAMA1-5), three β (LAMB1-3), and three γ (LAMC1-3) encoding genes 
respectively [88, 89]. Additionally, via an alternate promoter, LAMA3 gene encodes 
for two isoforms, a short α3a form and a longer α3b form [90-92], therefore 
increasing the number of α chains to 6. Although this means that, potentially, the 
laminin chains could combine into more than 50 αβγ trimers, due to interaction 
forces and/or differential tissue distribution patterns, only 16 isoforms have been 
shown to exist in-vivo [93]. However, the structural and functional diversity between 
the different laminin heterotrimers means that differences between specific laminins 
within a BM have dramatic effects on cellular responses to that BM. 
As the LMs are the primary focus of this thesis, a deeper description of this protein 
family is presented in section 2. 
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Section 2. Laminins  
1.2.0 Nomenclature  
 
The chains of the first isolated laminin from Engelbreth-Holm-Swarm (EHS) tumour 
cells were named as A, B1 and B2 [94]. Following the discovery of related but non-
identical laminins from other cells and tissues, the three constitutive chains were 
renamed with the Greek letters α, β and γ. In 1994, the first unified LM family 
nomenclature was introduced, based on the use of one Arabic number per chain 
according to the order in which they were discovered, with no relationship to chain 
numbers [95]. For instance, LM5 is α3β3γ2. Given the high number of laminin 
isoforms discovered over time, the nomenclature has undergone a simplification in 
2005 [93]. According to the new system, each laminin trimer is named to describe 
which chains are present in each isoform; LM5 is now known as LM332. Table 1 
summarises the old and the new nomenclature. Throughout this thesis, the 2005 
nomenclature will be used. 
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Subunits New naming system, 2005 Old naming system, 1994 
α1β1γ1 LM111 1 
α2β1γ1 LM211 2 
α1β2γ1 LM121 3 
α2β2γ1 LM221 4 
α3Aβ3γ2 LM332, or LM3A32 5, or 5A 
α3Bβ3γ2 LM3B32 5B 
α3Aβ1γ1 LM311, or LM3A11 6, or 6A 
α3Aβ2γ1 LM321, or LM3A21 7, or 7A 
α4β1γ1 LM411 8 
α4β2γ1 LM421 9 
α5β1γ1 LM511 10 
α5β2γ1 LM521 11 
α2β1γ3 LM213 12 
α4β2γ3 LM423 14 
α5β2γ2 LM522 – 
α5β2γ3 LM523 15 
Table 1: LM nomenclature. 
 
 
1.2.1 Laminins in diseases  
 
LMs are very widely expressed in tissues, where they tightly connect the BM to the 
adjacent cell layer. As is now well known, the basement membrane provides 
stabilisation for cellular structures and serves as a physical barrier. Metastasizing 
solid tumours, for instance, must pass through basement membranes to reach the 
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vascular system, and various microbes and viruses enter the cells through direct 
interaction with BMs [96]. Due to the importance of LMs in basement membrane’s 
roles, dysfunctional LMs lead to many different types of diseases [97].  
 
1.2.1.1 Laminin-related autoimmune diseases 
 
Although published data reported the presence of antibodies against LMs in healthy 
individuals [98], several more recent studies revealed that different LM isoforms can 
act as antigens in autoimmune diseases [99-102]. Experimental models showed that 
tissue damage is due to antibody-mediated disruption of ligand-binding function of 
LMs, with a consequent activation of inflammatory pathways [99, 103].  Mucous 
membrane pemphigoid, caused by autoimmunity against LM332, is characterised by 
blisters and erosions of the mucous membranes [104] and has been shown to 
associate with solid cancers [105]. Furthermore, lupus erythematosus, graft-versus-
host disease, kidney rejection and linear IgA bullous dermatosis have been associated 
with reactivity against LM332 chains [106-110].  
Experimentally, the pathogenic potential of antibodies targeting LM332 has been 
characterised in mice and rabbits in which they have been passively transferred, 
leading to blistering [111, 112]. Furthermore, other studies indicate the presence of 
autoimmune diseases linked to antibodies against LM111, such as ANCA-associated 
vasculitis [113], systemic sclerosis, Raynaud phenomena, infertility and renal 
disorders [114-116]. 
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1.2.1.2 Laminin-related genetic diseases 
 
There are numerous examples of LM-related genetic diseases, three of which are 
specifically related to this research project; the junctional epidermolysis bullosa 
(JEB), the Pierson syndrome and the merosin-deficient congenital muscular 
dystrophy (MDC1A). Some, but not all, of the mutations causing the mentioned 
pathologic conditions reside in the LN domain of the involved laminin chain, which 
is the structural domain involved in the laminin polymerisation process, as described 
afterwards.  
JEB is a skin blistering disease due to defects in any of the subunits of LM332 [117, 
118] and is characterised by blisters and skin erosions forming in response to minor 
injuries or frictions, such as rubbing or scratching. JEB is classified into two main 
types, both inherited in an autosomal recessive manner [119]; a severe form called 
Herlitz JEB, which causes death during the first year of life [120, 121], and a milder 
form named non-Herlitz JEB, typically associated with a normal lifespan [122, 123]. 
Patients affected by Herlitz JEB present large skin regions with the presence of 
severe patches of granulation tissue, usually around nose, mouth, ears, tips of the 
fingers, toes and the back of the head. The condition becomes life-threatening as 
patients undergo extensive loss of blood, fluids and proteins, making the body 
susceptible to electrolyte imbalance and infections [124, 125]. In some cases, the 
granulation tissue may appear in the respiratory tract, leading to compression and 
obstruction of the airway [126], or in the urinary tract, leading to dysplastic or 
multicystic kidney, acute renal tubular necrosis, obstructive uropathy or duplicated 
renal collecting system  [127, 128]. Non-Herlitz JEB, on the other hand, appears with 
a milder phenotype characterised by skin blistering usually confined to hands, feet, 
knees and elbows [129]. 
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Analysis of skin biopsies by TEM revealed altered basement membrane in the 
epidermis, specifically the splitting of the lamina lucida, with hypoplastic and 
reduced in number hemidesmosomes and decreased or completely absent anchoring 
filaments [125, 130, 131]. Immunofluorescence staining of cells isolated from JEB 
patients highlighted the abnormal or absent staining of LM332 [132], resulting from 
pathogenic variants in LAMA3, LAMB3, or LAMC2 genes [133]. There is a strong 
genotype/phenotype correlation; mutations leading to loss of expression of any 
subunit give rise to more severe form, whereas most missense mutations give milder 
phenotypes [123]. 
Specifically relating to the studies described here is a relatively common LAMB3 
mutation leading to non-Herlitz JEB, which causes Glu210Lys substitution within a 
highly conserved region in the N-terminal domain of LM β3 [134], although it 
should be noted the mutation is near a splice site and could therefore have a broader 
effect on exon usage. Subsequently, knock-in mice were generated with this mutation 
and, whereas heterozygous mice were phenotypically normal, homozygous knock-in 
animals displayed blisters and died within 3 days of birth [135]. Moreover, staining 
for LM α3 and LM β3, but not Col type VII was diminished in skin sections of these 
animals. Together, these data suggest that the LM β3 N-terminal domain is 
functionally important in establishing an epithelial BM. 
The Pierson syndrome, a congenital syndrome caused by mutations in the LAMB2 
gene, gives a second example of laminin-related genetic disease [136-138]. Pierson 
syndrome is characterised by kidney failure and ocular abnormalities, symptoms 
leading to death in the first months of life [136]. Most affected infants display 
abnormally small pupils, a condition known as microcoria, but patients can also 
show other ocular alterations including cataracts, glaucoma, retinal detachments and 
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blindness [138]. Renal problems usually start just after birth and rapidly progress to 
end stage renal failure or, in the worst cases, are already noticeable in utero [136]. 
As for LAMB3, mutations in the N-terminal domain of LAMB2 have specifically 
been demonstrated to lead to Pierson syndrome [139]. Moreover, in-vitro functional 
studies have been performed, demonstrating how missense mutations within this 
region affect folding and interactions [140]. These will be described in the laminin 
polymerisation section. 
In addition to these pathologic conditions, LAMA2 mutations cause MDC1A [141]. 
LM α2 chain deficiency is characterised by congenital hypotonia, delayed or arrested 
motor abilities and feeding difficulties. Moreover, patients show respiratory 
insufficiency, orthopaedic complications, usually represented by joint contractures 
and spinal rigidity, ophthalmoplegia and brain signalling alterations [136, 142]. The 
MDC1A phenotype is related to the binding properties of LM α2, also called merosin 
[143]. LM α2 is a native ligand for dystroglycan and it is involved in the link 
between ECM and dystrophin, a basic component of the protein complex that 
connects the cytoskeleton of a muscle fibre to the surrounding ECM [141].  
Both the autoimmune and genetic laminin-related diseases show the importance of 
laminins for a correct tissue function. In particular, the existence of missense 
mutations in laminins’ LN domains points toward fundamental functional roles for 
the polymerisation process, as will be described afterwards.  
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1.2.2 Laminin Structure 
 
Laminins are comprised of three polypeptide chains, named as α, β and γ chains, 
each of which is folded into different structural domains and ultimately arranged in a 
typical cross-like shape (Fig. 1.2). The short arms of the cross are formed by the 
separately folded N-terminal regions of each chain, while all three chains form the 
stem of the long arm through assembly of a triple helical coiled coil. 
In the N-terminal short arms, the LM subunits contain three types of structural 
domains; a single N-terminal domain (LN), followed by tandem repeats of the LM-
type epidermal growth factor-like domains (LE) interspersed with globular LM IV 
(L4 or LF) domains [93]. In the long arm the LM coiled-coil domain (LCC domain) 
is found [144]. Lastly, the C-terminus of the LM α chains contains a tandem repeat 
of five LM G domains [145]. 
 
 
Fig. 1.2: LM structure representation.  
Diagram showing the cross-like shape of LM, including the three chains and all the 
structural domains.  
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1.2.2.1 Laminin N-terminal domain 
 
At the NH2 terminus of most LMs chains, excluding LM α3a, α4 and γ2 chains, 
there is a globular domain of 228-259 residues depending on the chain, known as the 
laminin N-terminal domain (LN domain). The published crystal structure of 
recombinant LN domain of the α5, β1 and γ1 chains shows that the respective 
polypeptides are similarly folded in a β-sandwich motif, with non-conserved 
elaborate loop regions [140, 146]. The LN domain is immediately followed by a 
stretch of LE repeats with the first LE repeat tightly associated with the LN domain 
itself, leading to a flower-like arrangement [147]. This association is important for 
laminin structural stability [148]. 
Numerous studies have demonstrated that LN domains play a fundamental role in 
LM self-polymerisation, a process required for the formation of LM scaffolding, and 
which contributes to overall BM assembly [148-151].   
In addition, the LN domain has been shown to be involved in other functions not 
related to its LM-LM interaction role, such as cell adhesion and neurite outgrowth 
[148]. The LN domain interacts with several cell surface receptors; α1, α2 and α5 LN 
domains have been shown to bind to integrins α1β1, α2β1 and α3β1, and some of the 
N-terminal globular domains have been reported to interact with sulfated glycolipids 
(SGLs) [8, 93]. In-vitro studies also reported LM111, 211 and 511 LN domains to 
interact with the HS-containing domains of PLC [148, 152]. 
Binding affinities for integrins and other receptors, analysis of conserved and chain-
specific active sequences and polymerisation features of LM α1 and α2 chains LN 
domains were previously published [150, 153, 154], as well as for LM α3b and α5 
chains LN-domains [148]. The alignment of the mouse sequences for α1, α2, α3b and 
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α5 LN domains revealed a 72% sequence identity between α1 and α2, 77% between 
α3b and α5 and 53-60% identity between both groups, with a strict conservation of 6 
cysteine residues, but non-conserved N-glycosylation sites [148].  
  
1.2.2.1a LN domain mediated polymerisation 
 
Experiments like equilibration gel filtration assays, analytical ultracentrifugation, 
LM gelation inhibition studies and rotary shadowing of polymerised molecules have 
shown that LN domains are crucial for laminin network formation [151]. Laminins 
have been demonstrated to self- and co-polymerise; self-polymerisation involves the 
binding of LN domains at each end of three full length short arms, leading to the 
formation of a ternary node (Fig. 1.3).  
 
 
Fig. 1.3: LM ternary node.  
Diagram showing a simplified LM ternary node assembly, with LM LN domains 
involved in the association colour-coded as indicated. 
 
α chain LN domain 
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β 
γ 
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Co-polymerisation, instead, is defined as the process through which more than one 
laminin associate in a network [153, 155]. Self- and co-polymerisation of laminins 
are key processes for the assembly of functional basement membranes, and are both 
mediated by the LN domains located on the short arms of each trimer.  
Co-polymerisation represents the first fundamental step for a correct basement 
membrane assembly [146, 156] and it occurs while the laminin molecule is bound to 
its receptors, such as integrins and dystroglycan, on the cell surface [157, 158]. 
Through co-polymerisation, laminins organise into complex polygonal arrays on the 
cell surface, an active process that requires remodelling of actin filaments and 
tyrosine kinase signalling and the reorganisation of LM receptors and elements of the 
cortical cytoskeleton, such as vinculin and dystrophin [158].  
LN domain-dependent self-assembly is considered to be crucial for the integrity of 
BMs, and, as introduced above, the presence of mutations in such domain can lead to 
different types of pathological conditions. For example, in Pierson syndrome, 
missense mutations clearly clustered in the LM β2 LN domain [139]; in particular, 
Arg246Trp and the rarer Arg246Gln affect LM β2 chain secretion by inducing an 
alteration of the glycosylation site, which takes part in the protein folding [140]. Due 
to the misfolding, mutated LM β2 chain may be retained in the endoplasmic 
reticulum (ER) and, therefore, not being able to reach the correct destination [159]. 
Leu139Pro is an additional missense mutation in the LM β2 LN domain [139] which 
alters a conserved serine located at the top of the LN domain resulting in a dramatic 
LM β2 chain misfolding [140]. 
MDC1A has also been linked with different point mutations; a Gly to Ala 
substitution in a splice site consensus sequence of LAMA2 gene induces abnormal 
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splicing of the gene, with the consequent translation of a truncated LM α2 chain 
carrying a deletion in the LN domain [160]. In addition, MDC1A is related to a point 
mutation in the murine LAMA2 gene, resulting in a substitution of Arg with Cys in 
the LN domain [161]. 
Together, this evidence suggests that the naturally occurring assembly model can be 
considered as a complex event, highly dependent on the laminin isoforms present in 
the tissues. 
 
1.2.2.1b Co-polymerisation conditions 
 
Laminin co-polymerisation has been shown to be temperature, time and 
concentration dependent in-vitro, to occur in solution at a critical concentration of 
70-140 nM and to be thermally reversible [153]. LM111 co-polymerisation is 
enhanced by calcium [13, 162], which induces conformational changes in the LN 
domains allowing them to interact [163]. The calcium-dependency has been 
confirmed by LM111 self-assembly blocking in-vitro using the chelating agent 
Ethylenediaminetetraacetic acid (EDTA) [148, 153, 163, 164].  
 
 
1.2.2.1c Laminin self-polymerisation in isoforms lacking one or more 
LN domain 
 
A study using purified EHS LM111 supported that laminin self-polymerisation 
requires the presence of all three short arms in an isoform, suggesting that only 
heterotrimers formed by three full-length subunits are able to self- and co-polymerise 
[164]. Nevertheless, the LM family consists of some truncated isoforms, which lack 
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the LN-domain, notably including two of the subunits of LM332, the major LM of 
most epithelial BMs (Fig. 1.4).  
 
 
Fig. 1.4: LM truncated isoforms.  
Schematic diagram showing the LM isoforms’ different structure in terms of 
presence of the LN domain.  
 
In 2004, Odenthal et al. used eight recombinant expressed LN and LE domains 
containing LM fragments, found in isoforms other than 111, to test homologous and 
heterologous interactions. The research demonstrated that α1, α2, α5, β2 and β3 LN 
domains are able to self-interact [151, 162], whereas the γ1 and γ3 LN domains 
showed affinity for β3 LN domain but a lower ability of self-binding [151]. The 
possibility of self-interaction between LN domains suggest that, probably, even the 
laminin isoforms lacking one or two LN modules could still self or co-polymerise 
[151]. Supporting the hypothesis of an association between truncated laminin 
isoforms to ensure a functional network assembly, LM332 has been isolated in a 
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complex together with LM311 and 321 from the human amnion basement membrane 
[165]. 
Interestingly, McKee et al. demonstrated that the inability to polymerise of mutated 
LM α1 subunits, lacking its LN domains, is rescued by the addition of a polypeptide 
containing the α1 LN-LE domains [166]. Therefore, an absent α LN domain could be 
replaced with a substitute protein resulting in the restoration of laminin self-
assembly.  
 
1.2.2.2 Laminin-type epidermal growth factor-like domains 
 
The LM-type epidermal growth factor-like domains (LE domains) are found in 
tandem repeats, separated into stretches by globular domains. Each stretch is named 
in order from the N terminus as LEa, LEb and LEc, in the short arms of ,  and  
LM chains. LE repeats are also found in netrins, agrin and perlecan [167]. LE 
domains consist of 41 to 70 residues each, with the α3a, α4, α5, β1, β2 and γ2 chains 
also having an additional truncated LE domain each (15 to 35 residues) [168]. LE 
domains contain eight cysteine residues; disulfide bonds between these cysteine 
residues determine the formation of loops, like in EGF [169]. The tandem arrays of 
LE repeats in laminins have been demonstrated to adopt a linear, extended 
arrangement [170] with a highly variable number of copies in the different laminin 
isoforms; from 3 up to 22 copies have been found [169].  
Concerning the functions in laminins, long consecutive arrays of LE domains form 
rod-like elements of limited flexibility, which determine the spacing in the formation 
of laminin networks in BMs [147]. LE domains can also bind to syndecans, which 
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regulates cell adhesion and motility [171, 172] and a high affinity-binding site for 
nidogens is located between residues 791 and 848 of the LE modules of LM γ1 chain 
[173]. The LE repeats, therefore, play a role in cross-linking the laminin network 
with collagen type IV network in basement membranes. 
Following proteolytic cleavage, LE domains can be released from LM γ2 chain and 
these fragments can play different roles; the fragment containing LEa1-3 + L4 
domains has been shown to promote cell adhesion via the syndecan-1 surface 
receptor, whereas the fragment containing LEa2-3 + L4 + LEb1-3 domains is 
involved in keratinocyte migration [174]. 
 
1.2.2.3 Laminin G like domains  
 
The C-terminus of the LM α chains is 865-900 residues longer than that of the β and 
γ chains and forms the large LG domain at the end of the long arm. LG domains are 
also present in some collagens, cell surface receptors and anticoagulant and 
hormone-binding proteins [145, 170]. This domain is folded into five subunits, 
named as LG1 to LG5, in a range of 160 to 200 residues each [175]. The LG1 to 
LG3 trio is separated from the LG4-LG5 pair by a short stretch of amino acids and 
this region is subject to proteolytic cleavage [170].  
From the crystal structure, is known that LG domains fold is based on 14 -strands 
arranged in two curved sheets with an extensively hydrophobic core, including a 
calcium binding site[145],  with a final diameter of approximately 3.5 nm [176]. 
Moreover, LG2 and LG3 contain between two and four cysteine molecules, which 
form disulphide bridges close to the C-terminus [177]. 
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The LG domains contain the major binding sites for different cell surface receptors. 
Specifically, the LG1-LG3 domains can interact with α3β1, α6β1, α6β4, α7β1 and α9β1 
integrins [178, 179], however, each integrin displays different affinities for different 
laminins. Specifically, α3β1 and α6β4 integrin show the highest affinity for LM332, 
511 and 521, whereas α6β1 binds preferentially to LM111, 332, 511 and 521 [180]. 
Two α7β1 integrin splice variants are also involved in LM binding; α7Xβ1 does not 
bind to LM332, while α7Xβ2 preferentially associates with LM111, 211 and 221 
[180]. 
In addition to integrin binding, the LG 4–5 pair contains the binding sites for           
α-dystroglycan and syndecans, fundamental interactions required for BM assembly 
as well as muscle and nerve cell function [176]. LG4 also contains a major heparin-
binding site [181] and binds to sulfatides [182], facilitating the laminin 
polymerisation into networks [183].  
 
1.2.2.4 Laminin Coiled Coil domain 
 
The LCC-domain is the long arm of the laminin and is formed by all the chains 
twisted with a -helical motif, stabilised by hydrophobic interactions and 
electrostatic interactions [147]. The LCC domain is composed of 90 heptads [170] 
and, in the  chain, is interrupted by a stretch of amino acids termed the LM  knob 
(L) [147]. The LCC-domain is important during the laminin heterotrimer assembly, 
where it is required for the formation of βγ dimers [184] and for the orientation of the 
LG domain [185]. Via binding to different proteins, such as integrins or syndecans, 
the LCC domain also facilitates cell binding to laminins [145]. Supporting this idea, 
data show that LCC domain is needed for the interaction between LM332 and α3β1 
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integrin [185], and that the central region of the coiled coil of LM111 contains a 
binding site for the N-terminal region of agrin, an interaction that is believed to be 
crucial for localisation of agrin to the basement membrane [186]. 
 
1.2.2.5 Laminin L4, LF and LFx domains 
 
Within the EGF-like repeats of the laminin short arms, other additional domains 
named as L4, LF and LFx are embedded. In particular, the L4 domains are formed by 
~250 amino acids and are found in central positions of the 1, 2, 3b, 5, 1 and 
3 LM chains; in addition, three L4 domains are found in perlecan [187]. As 
demonstrated using recombinant expressed mouse 1 L4 domain is capable of 
autonomous folding and of fibulin 1 binding [188]. Moreover, the LM α2 L4 domain 
appears to have a functional role in humans; it has been showed that a congenital 
muscular dystrophy is linked with an in-frame deletion within this domain [189]. 
Regarding the LF and the LFx domains, almost no data are available; their structures 
have not been determined, nor have they yet been assigned functions. One interesting 
study reported that the amino acid sequences of these domains are highly conserved, 
indicating that the domains have been maintained for physical or functional purposes 
throughout evolution [190]. Potentially, they could provide additional sources of 
binding and signalling activities. 
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1.2.2.6 Laminin heterotrimer assembly 
 
Laminins are structurally organised as heterotrimers, the assembly of which happens 
inside the cell. The first step of this process is the formation of disulphide linked βγ 
dimers [184]. Studies revealed that the β chain is also able to homodimerise whereas 
the γ chain is not but, when both chains are expressed, βγ dimers formation happens 
preferentially [184]. A 10-amino-acid region located in the LCC domain joins the β 
and γ chains together and stabilises the disulfide bonds between them [147, 191, 
192].  The laminin trimerisation process can be completed, and the protein secreted 
in the extracellular environment, only when the α-chain is incorporated in the 
structure [193]. Interestingly, however, it has been shown that the  chain can also 
be secreted independently as a monomer even if it is still unclear if this happens     
in-vivo [184, 194]. 
 
1.2.3 Laminin expression pattern in tissues 
1.2.3.0 Laminin expression during mammalian organogenesis 
 
LM expression starts at the very beginning of the pregnancy, when the uterus has to 
morphologically change; this process, and therefore the gestation progress, depends 
on the laminins for support [194]. After successful mating, the decidual cells of 
the blastocyst start to synthesize LM111, the first laminin deposited in the 
endometrial ECM [195]. Gradually, the laminin isoforms expressed will vary 
according to the organ being formed. 
The change in laminin isoforms expression during embryonic development has been 
characterised in several murine organs and tissues. For instance, during lung 
development, all LM α chains are present, except LM α4 [196],whereas a basement 
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membrane primarily formed by LM111 and LM411 is found during the 
mesenchyme-epithelium transition in kidney formation, as demonstrated by blocking 
antibody-based experiments targeting LM α1, which stopped such transition [197]. 
When kidneys are completely formed, a developmental transition in α and β chains 
deposition leads to the LM111 replacement with LM521 [198]. LM421/521 are 
found in peripheral nerves, whereas individual axons within the nerve are surrounded 
by myelinating Schwann cells synthesizing LM211 [199]. Studies of the placental 
BM revealed that it contains LM111, LM221, LM411 and LM521 [200], in addition 
to a truncated form of LM213, first purified from human placental chorionic villi 
[201]. A very interesting study, using laminin gene trap mice, showed no evidence of 
a laminin accumulation in the brain [202]. However, netrins, which are structurally 
very similar to LaNts as described ahead, have been shown to be expressed in the 
brain [203, 204]. 
 
1.2.3.1 Laminin expression in adult tissues 
 
In adult tissues, LM 1 chain expression is generally characteristic of newly forming 
epithelial cells, whereas 2 chain is predominantly found in mesoderm derived cells. 
LM 4 chain, instead, is mainly expressed by endothelial cells, with LM411 being 
predominant in smaller and dermal vessels [205, 206]. LM 3 and 5 chains 
expression is restricted to epithelial cells [207], with the α5 chain being widely 
expressed in the dermal vasculature and in the interfollicular epidermis of adult 
tissues [208]. 
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1.2.3.2 Laminins in wound repair 
 
During the wound healing process, re-epithelialisation and angiogenesis involve 
laminins in different ways and with different roles. During re-epithelialisation, the 
formation of new epithelial tissue as part of the restoration of structure and function 
of injured tissues, laminins are required to support epithelial keratinocyte migration 
[209, 210]. Laminins are deposited and provide a substrate over which the cells are 
able to move, leading to wound closure [211]. Indeed, LM332 deposition onto the 
wound bed appears to be one of the earliest events, occurring within hours of injury 
[92, 212]. Supporting these data, LM332 has been shown to be expressed at the 
leading edge of the motile keratinocytes and to be the only BM component deposited 
between the clot and the migrating tongue [211]. 
LMs are also key players in angiogenesis, defined as the new blood vessel growth 
and maturation; alterations in laminin deposition, particularly of LM511, result in 
delayed corneal epithelial wound closure associated with diabetes [213] and diabetic 
retinopathy [214]. In addition, in-vivo studies demonstrated the presence of vascular 
abnormalities and slightly altered vasculogenesis in LM α4 chain-deficient mice 
[215, 216], consistent with LM411 being the major component of capillary and 
larger vessel BMs [217]. 
 
1.2.3.3 Laminin expression in corneal epithelium 
 
The cornea is the clear, dome shaped surface that covers the eye outermost layer, 
playing a fundamental role in focusing the vision; it accounts for approximately two-
thirds of the eye's total optical power [218].  
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Although it may seem simple, the cornea is characterised by a highly organised 
structure; human cornea is composed of three thicker basic layers with two thinner 
membranes between them; starting from the outer layer, there are the epithelium, the 
Bowman’s membrane, the corneal stroma, the Descemet’s membrane and the 
endothelium [219, 220] (Fig. 1.5). The central corneal thickness is approximately 
520 µm, but increases towards the periphery, where it can reach 650 µm [221]. As 
opposed to conjunctiva, which is a highly vascularised and innervated mucous 
membrane, the cornea does not contain any blood vessels but rather receives 
nourishment and protection from infectious agents via a combination of tear film and 
aqueous humor [222]. 
 
Fig. 1.5: Human eye and cornea representation.  
Schematic diagram of the structures of the human eye and the cornea, including all 
the corneal layers.  Figure adapted from J-TEC company website (www.jpte.co.jp). 
 
The cornea, which is the portion of the eye we focused on during this project, is 
composed by keratocytes, endothelial and epithelial cells; corneal integrity is 
maintained by stem cells located within the basal layer of the limbus, the border 
separating the cornea from the conjunctiva and the sclera [223]. The limbus ensures a 
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cyclic corneal cell shedding and replacement, during either normal cell turnover or 
following injuries [224, 225]. 
Human corneal epithelial basement membranes significantly change in terms of 
components between the infant and adult phases [226]. In infants, stem cells are 
present in the central cornea, while in adults they are localised mainly in the limbus 
[227]. In addition, LM α2 and β2 chains are absent from the infant basement 
membrane, whereas they are both found in the adult’s limbal and conjunctival 
basement membrane. Nidogen-1, -2 and netrin 4 are found in stromal and endothelial 
sides of the Descemet’s Membrane in infants, but they remain only on the 
endothelial side of such membrane in adults [226]. 
Corneal epithelial cells are of fundamental importance for protecting the eye against 
foreign material and bacteria, and for providing a smooth surface to absorb O2 and 
nutrients from tears, which are then distributed to the other layers of the cornea 
[228]. The majority of our in-vitro functional work has been based on the use of 
hTCEpi, immortalised limbal-derived corneal epithelial cells [229]. These cells 
display the same characteristics as their in-vivo counterparts, the cells that form the 
corneal epithelium.  
Immunoprecipitation (IP) data revealed that cultured corneal epithelial cells produce 
a LM332-rich BM, found in-vitro as small plaques beneath the adhering cells first, 
and widely spread in co-localisation with β4 integrin subunit thereafter [230]. As 
LM332 and LM311/321 have the same α chain [95], it has been proposed that 
corneal epithelial cells also contain small amounts of these laminin isoforms [231]. 
Published studies on all these laminins have demonstrated their involvement in 
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regulating keratinocyte motile behaviour [89, 232, 233] and in contributing to wound 
repair [209, 212].  
 
1.2.3.4 LM332  
 
LM332 has a central role in the maintenance of epithelial-mesenchymal adherence in 
tissues exposed to external forces, in cell migration, in tissue development, in wound 
healing and in tumorigenesis [234, 235]. It is also the major laminin produced by 
corneal epithelial cells and, therefore, a major focus of the studies described in this 
thesis. As such, a deeper introduction to this specific laminin is required. 
 
1.2.3.4a LM332 processing 
 
Two of the LM332 chains, α3a and γ2, undergo extracellular proteolytic processing 
events to smaller forms [236]. LM332 is first synthesised as a precursor protein of 
460 kDa that is subsequently processed to a 440 kDa form, in low calcium 
concentrations, or to a 400 kDa form in high calcium concentrations [236]. These 
size changes are due to removal of the α3 chain C-terminal LG 4-5 domains, 
converting the 190kDa form to a 165 kDa mature form [237, 238], and to the 
cleavage of the N-terminal region of the γ2 chain, converting the 155 kDa form to a 
105 kDa mature form [236, 239]. There is no evidence of processing events 
regarding the β3 chain, therefore LM332 containing the 165 kDa 3 and the 105 kDa 
2 processed chains is considered the mature form. 
There are multiple in-vitro studies describing enzymes which are involved in LM332 
processing. It has been shown that the α3 chain processing happens after treatment 
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with plasmin or via the tissue plasminogen proteolytic cascade [240]. Furthermore 
matrix metalloproteinase-2 (MMP-2), membrane type-1 matrix metalloproteinase 
(MT1-MMP) and the C-proteinase family of enzymes, in particular the mammalian 
tolloid (mTLD) and the bone morphogenic protein 1 (BMP-1), have been 
demonstrated to take part in LM332 proteolytic cleavage [237, 241]. N-terminal 
amino acid sequencing of human LG4-5, purified from the conditioned medium of 
human skin cells or human gastric adenocarcinoma cells STKM-1, revealed that the 
α3 chain is cleaved between the residues Q1337 and D1338, suggesting that the 
cleavage site matches the minimal consensus sequence LLQD [242, 243]. In 
addition, thrombin was shown to be able to cleave α3 LG4-5 specifically at R1343 
and R1389, residues located in the LG3-4 linker sequence [244].  
Mature LM332 is involved in different cell functions; among them, LM332 allows a 
non-HD forming matrix to become competent for HD assembly [237]. Supporting 
this, an in-vivo study using an mTLD/BMP1 deficient mouse revealed the skin 2 
processing to be dramatically reduced and the hemidesmosomes to be altered, 
suggesting a fundamental role of LM332 correct processing for a functional HD 
formation and integrity [245]. 
Interestingly, the proteolytically released LG4-5 module has been shown to support 
cell adhesion when coated onto plates, but not to bind to 1 integrin [246]. 
Furthermore, purified LG4-5 was not able to stimulate cell scattering on rat liver 
epithelial cells until added to low concentration of LM332 [242]. LG4-5 has also 
been reported to bind to heparin [247] and to induce neurite outgrowth [247, 248], 
processes almost surely mediated by binding to syndecans 2 and 4 [247]. The 
proteolytic cleavage of the γ2 chain also leads to the release of a laminin fragment 
that increases cell migration [174, 245, 249]. 
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LM α3a chain also undergoes a signal peptide cleavage, which has been shown to 
occur between Gly26 and Tyr27, located in the N-terminal region of the 200 kDa 
form [241]. Further cleavage has been reported to occur in the N-terminal LE region 
of the α3 chain, releasing the short arm which might be important for LM332 
function [165, 241]. The importance of the N-terminal region in LM α3a chain is also 
demonstrated by the presence of a pathologic condition, named as Laryngo-onycho-
cutaneous (LOC) syndrome, precisely linked to a LM α3a mutation. LOC is 
characterised by cutaneous erosions, nail dystrophy and chronic overproduction of 
granulation tissue in some epithelia, especially conjunctiva and larynx, and is caused 
by a frameshift mutation leading to the LM α3a N-terminus deletion [91]. 
LM α3b chain also undergoes proteolytic cleavage with processing resulting in the 
release of a 190 kDa NH2-terminal fragment [232]. This released fragment 
demonstrated as being active in promoting cellular adhesion, migration, and 
proliferation through its association with integrin α3β1 [232]. Although this 
“fragment” is 3x larger than the LaNts, many of the domains are shared between it 
and the LaNt proteins (described below), which could suggest a similar role for 
LaNts too. 
 
1.2.3.4b LM332 deposition 
 
In-vitro studies have demonstrated that LM332 deposition depends on the LG 
domains and on the cleavage of the 2 N-terminus [244]. Vector-driven expression of 
LM 3, with or without the LG domains, revealed a decreased secretion of 
recombinant 3 protein in the culture medium associated with the reduced numbers 
of LG domains [185], while the absence of the entire region prevents secretion 
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entirely [250]. Consistent with this, the presence of the 3 LG4-5 region was found 
to be necessary for keratinocytes isolated from a LM 3-/- mouse model, to bind and 
deposit soluble LM332 [244]. Moreover, γ2 chain processing has been shown to be 
required for the LM332 incorporation in the skin’s basement membrane, possibly by 
facilitating collagen type VII interaction [251, 252].  
Supporting the important role of γ2 chain proteolytic cleavage for LM332 deposition 
is the study of patients affected from cylindromatosis, a condition involving multiple 
skin tumours that develop from structures associated with the skin [253]. This rare 
inherited disease is characterised by an incomplete laminin processing which leads to 
ultrastructural alterations of the basement membrane and altered 
expression/distribution of integrin receptors [252, 254]. Together, these data 
highlight the importance of post-translational processing for a correct laminin 
deposition and network formation.  
 
 
 
 
 
 
 
 
 
51 
 
Section 3. Cell to matrix adhesion devices 
 
Cell-matrix interactions are vital to enable cells to sense numerous extracellular 
signals and to regulate differentiation, cell cycle, migration and survival [255, 256]. 
These interactions are mediated by different proteins and adhesion receptors, leading 
to the formation of multi-component adhesive structures that link the actin 
cytoskeleton to the cell interior [257]. HDs and FAs complexes are the two main 
adhesive devices that connect the cells to the basement membrane and, in particular, 
to LM332.  
 
1.3.0 Hemidesmosomes 
 
Hemidesmosomes, originally called “bobbins” by Weiss and Ferris [258], can be 
defined as the major cell attachment site to the ECM and are known to be involved in 
tissue mechanical support and/or remodelling, cell differentiation, migration and 
wound healing[259-261].  The name “hemidesmosome” derives from their similarity 
to half a desmosome when observed under an electron microscope; however, the 
protein composition differs between the two structures although both play roles in 
intermediate filament association.  
Hemidesmosomes appear as electron dense spots, of about 0.5 µm in diameter, 
located in the plasma membrane [259]. At the ultrastructural level, HDs are 
characterised by a tripartite cytoplasmic plaque anchored to bundles of intermediate 
filaments (IFs) [262]. A sub-basal dense plate and several anchoring filaments 
represent the connection between hemidesmosomes and the lamina lucida and densa 
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respectively [263-265]. At the protein level, the stable junctional structure known as 
the hemidesmosomal adhesion complex [266] is composed of the following proteins: 
 - The intracellular plaque proteins bullous pemphigoid antigen 230 (BP230, also 
known as BPAG1e) and plectin [267, 268]; 
- The transmembrane proteins CD151, collagen type XVII, also known as bullous 
pemphigoid antigen 180 or BPAG2, and α6β4 integrin [262, 269, 270]; 
- LM332, found at the border between the lamina densa of hemidesmosomes and the 
lamina lucida at the base of anchoring filaments [271, 272]. 
This organisation is classed as a Type I HD (Fig. 1.6) and is present in basal 
keratinocytes of multi-layered squamous epithelia, including the cornea and the skin 
[262, 273]. Less mature hemidesmosomes, containing only α6β4 integrin and plectin, 
have also been described and classified as Type II HDs; these are generally found in 
cylindrical epithelia [274, 275]. 
 
Fig. 1.6: HD structure.  
Schematic outline of the HD structure, indicating all the components and their 
interactions in the hemidesmosomal adhesion complex. Electron micrograph adapted 
from “Cell and Molecular Biology”-Wiley & Sons, 2008. 
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1.3.0.1 HD components 
 
To form a functional HD complex, several components have to be assembled 
together in a specific order and with a specific spatial localisation. LM332 has a 
crucial role in both the nucleation of hemidesmosome assembly and in the 
maintenance of the hemidesmosome structural integrity; any alteration in LM332 or 
any modification of one or more HD components may be reflected on 
hemidesmosomal activity. It is, therefore, helpful to describe some of the 
characteristics of the hemidesmosome’s constituents. 
 
1.3.0.2 The cytoplasmic plaque proteins 
 
The cytoplasmic plaque of hemidesmosomes contains several proteins. The two 
major ones are plectin [276, 277] and BP230, named after being shown as a target 
antigen in the bullous pemphigoid, an autoimmune blistering disorder of the skin 
[278, 279]. In addition to these, the less studied protein P200 is also part of the 
cytoplasmic plaque. 
 
1.3.0.2a Plectin  
 
Plectin belongs to the plakin proteins family, involved in the organisation of the 
cytoskeleton [280]. Plectin acts as a multifunctional cytoskeletal linker [267] and 
undergoes alternative splicing to produce several isoforms [281]. These isoforms 
encode a protein of a 507-527 kDa size range, formed by a 200 nm central -helical 
rod flanked by two large globular domains [267]. The major function of the different 
plectin isoforms has been associated with IFs network architecture [282]. 
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Ligand binding analysis revealed that plectin-actin link occurs via an actin-binding 
site (ABD) located in the conserved N-terminal domain, which is also found in the 
actin binding proteins spectrin and dystrophin [273]; the same domain has been 
shown as able to bind to the cytoplasmic tail of integrin β4 [283]. On the other hand, 
the COOH-terminal domain of plectin binds to keratins, neurofilaments, and 
vimentin in-vitro [273]. Plectin’s interactions suggest it acts as a stabilising bridge 
between IFs and actin filaments and between IFs and HDs [267]. Supporting the 
latter role it has been demonstrated that loss of function mutations in the plectin 
encoding gene, PLEC1, are related to epidermolysis bullosa simplex associated 
with muscular dystrophy (EBS-MD), an autosomal recessive disorder [277, 284]. 
 
 
1.3.0.2b BP230 
 
BP230, also known as BPAG1e, belongs to the same protein family as plectin and 
was the first autoantibody identified in patients with the autoimmune skin blistering 
disease bullous pemphigoid (BP)[285]. BP230 interacts with keratins and IFs via its 
globular C-terminus and uses the NH2-terminus to bind collagen type XVII in the 
cytoplasm [286]. Moreover, BP230 can associate with the protein erbin, involved in 
the Ras signalling pathway, and also, directly with 4 integrin [287].  
The BP230 encoding gene, DST, undergoes alternative splicing, giving rise to a 
neuromuscular isoform called BPAG1n or dystonin, and BPAG1a, related to the 
dystonia musculorum neurodegeneration syndrome in mice, as reviewed by[287]. 
Studies using a BP230 knockout mice showed that this protein is involved in IFs -
cell surface anchorage, as HDs in the keratinocytes of these mice lack the inner 
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region of the hemidesmosomal plaque and exhibit very few associated intermediate 
filaments [288]. This evidence, therefore, suggests a similar role as plectin in linking 
the cytoskeleton to HDs, further supported by a recently identified form of EB 
caused by a homozygous nonsense mutation located in BPAG1e [289]. In contrast 
with the blistering affecting many patients who have autoantibodies against BP230, 
patients suffering from DST-e pathogenic mutations surprisingly show minor 
blistering, despite having the complete absence of the hemidesmosomal inner plaque 
[289].  
 
 
1.3.0.2c P200 
 
Very little is known about protein P200. From the available data, P200 is a 200 kDa 
protein recognised by the monoclonal antibody 6A5 and it is deposited at the 
epithelial-stromal interface [290]. P200 is likely to be involved in the linkage of 
intermediate filaments to the plasma membrane, also due to its localisation to the 
inner hemidesmosomal plaque [290].  
 
1.3.0.3 The membrane proteins 
 
Membrane proteins are responsible for several of the specific functions of 
membranes. This protein family includes integral membrane proteins, that are 
permanently anchored, or peripheral membrane proteins, that are only temporarily 
attached to the lipid bilayer or to other integral proteins. Accordingly, the amount 
and types of proteins in a membrane are highly variable. Hemidesmosome’s 
membrane proteins are α6β4 integrin and collagen type XVII. 
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1.3.0.3a Integrin α6β4 
 
Integrins are obligate heterodimeric matrix receptors, composed of non-covalently 
associated transmembrane glycoprotein subunits, named as α and β, which form 
bridges for cell-cell and cell-ECM interactions [291, 292]. Moreover, integrins can 
activate signal transduction pathways by triggering chemical pathways to the interior, 
playing a fundamental regulatory role in controlling the cell cycle, cell shape and/or 
motility [293]. Most integrins are connected to bundles of actin filaments [294], 
however the α6β4 integrin found in hemidesmosomes is an exception, as it is 
connected primarily to intermediate filaments [295].  
Structurally, α6 integrin is initially synthetized by the ITGA6 gene as a 150-kDa 
polypeptide, and then cleaved into “heavy” and “light” chains that dimerise via 
disulfide bonds [296]. α6 integrin (130 kDa) can pair with the β1 subunit but the 
association with the β4 subunit (250 kDa) has been shown to be happen preferentially 
[297]. Integrin β4 subunit, instead, is characterised by an unusually long (for 
integrins) C-terminus; this tail contains approximately 1000 amino acids and two 
pairs of FN type III repeats, separated by a connecting segment comprising 142 
amino acids [298]. It is within this tail region that the binding sites for plectin, 
BPAG1e and the intracellular site of collagen type XVII are located.  
Intracellularly, β4 interact with plectin and BP230, and therefore with the IF complex 
[299]. Extracellularly, the α6β4 integrin complex associates with processed LM332 
[273, 300]. The use of antibodies to block either subunits of α6β4 integrin revealed 
the importance of this trans-membrane receptor for the nucleation of HDs formation; 
804G cells with blocked α6β4 integrin do not show formed hemidesmosomes at the 
ultrastructural level [290]. In a wound healing model, integrin α6 blocking led to the 
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separation of the epithelial sheet from the underlying connective tissue, suggesting 
that α6 is fundamental for cell attachment [301].  
Further evidence on the major role of α6β4 integrin are given by patients who suffer 
from junctional epidermolysis bullosa associated with pyloric atresia (PA-JEB); due 
to mutations in the genes for α6 or β4 integrin subunits, they form rudimentary 
hemidesmosomes [302-304]. In addition to these data, it has been reported that mice 
lacking the α6 integrin chain die at birth, due to the HDs adhesion complexes not 
forming at all [305-307].  
 
1.3.0.3b CD151 
 
CD151 is a trans-membrane protein belonging to the tetraspanin superfamily. 
Structurally, CD151 contains two extracellular loops, one small and one large, and 
cytoplasmic COOH- and NH2-terminal domains [308]. Previous studies suggest that 
the large extracellular loop can bind to integrins α3β1, α6β1, α6β4 and α7β1 [309-312]. 
CD151 uses these interactions to take part in several cell biological processes, such 
as cell adhesion[313], motility [308, 310, 314] or the transport of integrins via 
vesicles [315].  
Regarding the role of CD151 in cell adhesion, data from Sterk et al. revealed that 
CD151, recruited into HDs via the integrin α6 subunit, is a major component of every 
pre-hemidesmosomal structure, with its expression decreasing on the basis of the 
HDs maturation stage [270]. The same group also showed that CD151 stabilises the 
HDs adhesion complex by facilitating the formation of a stable laminin-α6β4 integrin 
interaction [270]. However, the use of animal models to analyse the role of CD151 in 
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HDs has given controversial results. CD151-null mice appeared to be healthy and 
with normal HDs formation in a study published from Wright et al, but were 
described as having serious renal pathologies in a study published in 2006 by Sacks 
et al [316] [317]. These incongruous results suggest CD151 is still a relatively 
unstudied component of hemidesmosomes, and future research should be done to 
address open questions on its function. 
 
1.3.0.3c Collagen type XVII  
 
Collagen type XVII, previously named as bullous pemphigoid antigen 180 (BP180) 
or BPAG2, is a transmembrane protein encoded by the gene COL17A1 [318]. It is a 
homotrimeric molecule formed by three α1 chains (180 kDa), each characterised by 
an intracellular N-terminal domain (466 amino acids), a transmembrane stretch (23 
amino acids) and an extracellular C-terminal ectodomain of 1008 amino acids [319]. 
The C-terminal, in turn, contains 15 collagenous subdomains (COL1–COL15) 
flanked by 16 non-collagenous sequences (NC1–NC16A) [318]. The final structure 
is flexible, rod-like and triple-helical, with a significant thermal stability prevalently 
due to COL15, the largest collagenous subdomain of the C-terminal [320]. In its full-
length form, the cytosolic N-terminus is present at the HD plaque level, whereas the 
extracellular domain is located in the BM. A soluble form, LAD-1, also known as 
ectodomain, is generated by proteolytic cleavage of the full-length form [321].  
Collagen type XVII integrates into hemidesmosomes via α6 and β4 integrin chains 
binding, which occur respectively via amino acids 506-519 of the C-terminal 
ectodomain [269] and via the N-terminal region [322]. It can also interact with 
several other ligands, contributing to stabilise cell adhesion [322]. With regard to our 
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research, the ectodomain has been shown to co-localise with LM332 in the migration 
tracks of primary human keratinocytes, whereas LM332 deficient keratinocytes 
displayed a drastically reduced collagen type XVII deposition in the ECM [323].  
Genetic and acquired diseases, caused by mutations in the COL17A1 gene, indirectly 
demonstrate this key role; the loss of function of collagen type XVII leads to 
diminished epidermal adhesion and skin blistering (JEB) or angiogenic pathologies, 
such as the bullous systemic lupus erythematosous [285, 324]. 
 
1.3.0.4 Hemidesmosome assembly 
 
The first data describing HDs morphogenesis in-vitro were published by Krawczyk 
and Wilgram in 1973, who studied hemidesmosome’s formation in a mouse 
epidermal wound-healing model [325]. The proposed model had four sequential 
ultra-structural phases. The first stage was the extension of fine filaments between 
the plasma membrane and the lamina densa. These extracellular filaments became 
increasingly dense until a narrow electron-dense line, parallel to plasma membrane 
and the lamina densa, developed within them. Thereafter, an intracellular electron-
dense plate appeared in exact apposition to the extracellular filaments. The final 
stage was the insertion of intermediate filaments into the intracellular electron-dense 
plate [325].  
The concept of mature and immature hemidesmosomes was firstly used in 1983, 
when Gipson et al. used viable sheets of adult rabbit corneal epithelium to study the 
time requirements for HD formation and the relationship between HD formation and 
anchoring fibrils [326]. They found that the 83% of new hemidesmosomes developed 
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within the first 6h of culture and mostly appeared over pre-existing anchoring fibrils 
[327]. It is now well known that the interaction of integrin β4 with plectin is crucial 
for the formation of stable HDs [328, 329]. This is also supported by the defective 
assembly of HDs in patients affected by PA-JEB, caused by mutations in the ITGB4 
gene (Arg1281Trp or Arg1225His) that prevent the β4-plectin interaction [329] 
[330], and by plectin-deficient mice, which show dramatic epithelial detachment 
leading to death 2-3 days after birth [331]. 
HD assembly starts with CD151 and integrin α3β1 forming the so called pre-
hemidesmosomal clusters, hypothesised to serve as a ‘nucleation site’ for the process 
[270]. CD151 will, then, become a component of mature HDs, while α3β1 is recruited 
into FAs after HDs have been assembled [332]. The first association happens 
between the plectin ABD domain and the integrin β4, via the FNIII repeats and 
residues 1115-1355 of the β4 tail [283, 328, 333]. This interaction is followed by a 
second link between the plectin N-terminus and the C-terminal domain of the β4 
integrin [333, 334]. Following the β4-plectin association, collagen type XVII 
interacts with LM332 and with the plectin-α6β4 integrin complex. Lastly, BP230 is 
recruited through associations with collagen type XVII and CD151 [268, 333, 335]. 
The entire process is summarised in Fig. 1.7. 
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Fig. 1.7: HD assembly.  
Schematic diagram showing the four steps of HD assembly. Plectin-α6β4 integrin 
association triggers the binding of the other HD components and is facilitated by the 
presence of a pre-hemidesmosomal complex.  
 
 
1.3.0.5 Hemidesmosome disassembly 
 
HDs are highly dynamic structures that quickly disassemble during cell division, 
differentiation or migration [261]. When detachment from the basement membrane is 
needed, hemidesmosome’s components diffuse over the plasma membrane or in the 
cytoplasm and are translocated to lamellipodia [290, 336]. Transient and permanent 
disassembly of HDs can be distinguished. A transient dissolution occurs, for 
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instance, when skin keratinocytes migrate to close a wound or during carcinoma 
invasion [337-339].  
Due to the importance of the first of the HD assembly steps, it is believed that HD 
disassembly happens via disrupting the plectin-β4 association [340]. HD transient 
disassembly is primarily triggered and regulated by post-translational changes, such 
as the phosphorylation of HDs components in response to GFs stimulation [340].  
Although somewhat controversial, studies have revealed that EGF-induced tyrosine 
phosphorylation of Tyr1422 and Tyr1440 residues, located in the β4 tail, mediates 
HD disassembly [341, 342]. In contrast with this, different reports shown that the 
redistribution of HD components during disassembly is mediated by the activation of 
members of the protein kinase C (PKC) family, suggesting that PKCs induces the 
phosphorylation of specific sites present in the β4 tail and regulates HD disruption 
[343]. This was confirmed by other studies in carcinoma cells and normal 
keratinocytes, demonstrating the HDs undergo a disassembly process after the 
activation or the overexpression of PKC-family members [344-346].  
Despite being still unclear, it is possible that HD transient disassembly is 
differentially regulated in different cell types; tyrosine phosphorylation pathways 
might be involved in the migration and invasiveness of tumour cells, while serine 
phosphorylation-mediated HDs disassembly could be more relevant under more 
“normal” cellular conditions [340] .  
On the other hand, permanent dissolution of hemidesmosomes involves repression of 
gene transcription and proteolytic cleavage of the components [347]. Previously 
published data show that integrin α6β4 expression in proliferating or differentiating 
keratinocytes is mostly controlled at transcriptional level, with integrin α6 expression 
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repressed in presence of high levels of p63 [348, 349] and both integrin subunits 
expression repressed via the Notch signalling pathway, when cells undergo terminal 
differentiation [350, 351]. The involvement of the Notch pathway in the repression 
of integrin α6β4 gene transcription and, therefore, in hemidesmosome disassembly, 
has also been shown by Ambler and Watt, who developed mice with hyperactivated 
Notch signalling in basal keratinocytes and observed a focal epidermal detachment 
[352]. 
 
1.3.0.6 Hemidesmosomes in keratinocytes migration 
 
To move from one location to another, an essential process for normal development 
or tissue remodelling, cells must first disrupt, or at least loosen, their connection with 
the BM; HD components are highly involved in this mechanism.  
There are data showing that keratinocytes derived from β4 integrin-null mice display 
aberrant motility and do not move in linear tracks but in circles [307, 353, 354]. 
Interestingly, this defect can be rescued if the cells are plated onto a WT cell-derived 
matrix, where the migration goes back to linear fashion [353]. These data implicate 
integrin 4 in regulating the deposition pattern of LM332, pointing to a regulatory 
role on cell motility for LM332 matrix organisation [353]. The same group indicated 
that α6β4 integrin interacts with the Rac1 signalling pathway, a small G protein that 
regulates lamellipodia formation at the leading edge during migration and is required 
for an efficient establishment of cell front-rear polarity and processivity [353]. This 
interaction places Rac1 mediated pathways in the control of LM332 matrix 
organisation and in support of this idea, expression of dominant negative Rac1 leads 
to defective motility in keratinocytes [353].  In addition to α6β4 integrin, Rac1 
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activity is also influenced by collagen type XVII; when the latter is absent, 
lamellipodial dynamics and keratinocytes migration are decreased [355].  
When it comes to tissue remodelling in response to wounded epidermis, 
keratinocytes at the leading edge of the wound have to migrate to close it. This 
implies a so-called processive migration, during which skin cells are stably polarized 
and migrate linearly without a chemotactic gradient [356]. As described above, 
LM332 is known to be highly involved in cell motility. When containing an 
unprocessed α3 chain (190 kDa), LM332 supports keratinocyte motility [237]; 
instead, when α3 chain is cleaved within its G domain, LM332 induces HD assembly 
and a sequential decreased cell migration  [209, 237, 357].  
Moreover, in addition to the individual HD proteins roles, support for keratin-HD 
interaction being fundamental for cell-matrix adhesion and migration was generated 
by Seltmann et al, who recently showed that keratinocytes in which the entire keratin 
cytoskeleton was depleted are characterised by loss of plectin, dispersion of the HDs 
transmembrane core along the BM and faster adhesion/motility properties [358].  
 
1.3.1 Focal Adhesions 
 
Focal Adhesions (FAs) are defined as mechanical linkages between intracellular 
actin bundles and the ECM, acting as biochemical signalling hubs to direct and 
mediate the regulatory effects of a cell in response to ECM adhesion [359, 360]. FAs 
are the earliest and best-characterised cell-ECM adhesion structures; therefore, 
localisation to focal adhesions is often considered a good indication for the 
functionality of a protein in cell-ECM adhesion [360]. It is important to consider that 
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FAs are highly dynamic protein complexes, in a state of constant flux: proteins 
associate and dissociate with FAs continually as signals are transmitted to other parts 
of the cell. A large number of specific proteins are known to be present in FAs; these 
are usually structural and cytoskeletal proteins but many are also signalling 
molecules [361].  
 
1.3.2 Focal Adhesions components 
 
As part of adhesive devices, focal adhesion components are tightly modulated in 
terms of assembly, disassembly and, therefore, interactions with different ligands. 
Hundreds of proteins have been associated with focal adhesions in different contexts. 
Here, I will just deal with some of the main components that are either always 
present or are used to indicate different levels of FA maturity. 
 
1.3.2.1 Talin 
 
Talin is a high molecular weight (∼270 kDa), elongated (approx. 60 nm) and flexible 
anti-parallel dimer, which appears as a series of “beads on a string” under the 
electron microscope [362]. Structurally, talin is characterised by a globular N-
terminal domain followed by a flexible rod region [363]. The N-terminal head 
contains a FERM domain, named after its component proteins; 4.1, ezrin, radixin and 
moesin. The FERM domain is a widespread protein module, involved in localising 
proteins to the plasma membrane, which has binding sites for the cytoplasmic 
domains of β1 and β3 integrins and filamentous actin (F-actin) [364].  
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Via its N-terminus, talin also interacts with focal adhesion kinase (FAK), a crucial 
signalling molecule activated by numerous stimuli that takes part in controlling cell 
motility [365], with phosphatidylinositol phosphate kinase type Iγ (PIPK1γ), 
phosphatidylinositol (4,5) bis-phosphate (PI(4,5)P2) and with layilin, C-type lectin 
found in membrane ruffles [366]. In addition to such binding partners, the talin 
flexible rod contains further integrin-binding sites, two actin-binding sites and 
several binding sites for vinculin [367]. Finally, talin has a highly conserved, large 
C-terminal rod domain that contains bundles of α helices involved in actin-binding 
integrin-binding [368] and vinculin- binding [369].  
Several studies have demonstrated that talin plays a key role in integrin-mediated 
adhesion; for instance, microinjection of talin antibodies in cultured cells disrupted 
FAs [370]. Moreover, FAs assembly and cell spreading decreased when talin 
expression was down-regulated using antisense RNA [371], as well as when the talin 
encoding gene TNL1 was silenced [372]. Further support to this concept is given by 
an in-vivo study, where mice with a targeted disruption of the talin gene survived 
only for 8.5-9.5 days post coitum, proving that talin is necessary for embryogenesis 
[373].  
 
1.3.2.2 Vinculin 
 
Vinculin is a 117 kDa cytoskeletal protein composed of 1066 amino acids. It 
contains an acidic N-terminal domain, which includes binding sites for talin and α-
actinin as well as a tyrosine phosphorylation site, and a basic C-terminal tail region, 
containing binding sites for F-actin, paxillin and lipids [374]. These two domains are 
separated by a proline-rich middle segment. Vinculin is crucial for regulation of 
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cytoskeletal mechanics, cell spreading and lamellipodia formation [375]. Supporting 
this role,  loss of vinculin prevents cell adhesion and spreading, leads to a decreased 
number of stress fibres and FAs, and stops lamellipodia extension [374], although 
vinculin overexpression studies demonstrated that these defects could be restored 
[376]. Moreover, a study using vinculin deficient mice showed that embryos are 
smaller than controls and die at embryonic day 10.5 (E10.5), due to major defects 
during brain and heart development [377].  
When localising to focal adhesions, vinculin undergoes conformational changes 
[378] and, therefore, there is an intracellular equilibrium between vinculin’s active 
and inactive state [379]. Such a conformational change allows vinculin to be 
accessible to its 19 binding partners [379] including; talin [380], α-actinin [381], 
VASP (VAsodilator-Stimulated Phosphoprotein) [382], Arp2/3 [383], paxillin [384], 
F-actin [385], synemin [386], calpain [387], polycystin-1 [388] and PIP2 [389]. 
Binding with vinculin can activate or link to other proteins, triggering different 
signalling cascades [390]. 
 
1.3.2.3 Paxillin 
 
Paxillin is a phosphotyrosine-containing FA component of about 68-70 kDa [391]. 
Structural analysis revealed that the paxillin N-terminal region is characterised by a 
proline-rich portion, numerous tyrosine residues and, additionally, five copies of a 
peptide sequence, named as LD motif, which are now known to function as binding 
sites for other proteins [392]. Furthermore, paxillin is formed by a C-terminal 
domain, which comprises four LIM domains, zinc-binding structures named after 
their similarity to double zinc finger domain, which act as mediators for protein-
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protein interactions [393]. The FA targeting sequence of paxillin is located in the C-
terminal half of the protein, within the LIM domains 2 and 3 [394].  
Several paxillin-associated proteins have been identified, among which there are 
vinculin, FAK enzyme and the cytoplasmic domain of the β1, β3 and β4 integrins 
[395].  Regarding the latter, paxillin has been shown to regulate cell spreading and 
motility through its binding to the α4 integrin subunit [395]. Giving further support to 
the importance of paxillin for fundamental cell behaviours, paxillin -/- mice die at 
E9.5, highlighting the key role that paxillin plays during embryonic development 
[396].  
 
1.3.2.4 Focal Adhesion Kinase 
 
Encoded by the PTK2 gene, Focal Adhesion Kinase (FAK) is 125 kDa cytoplasmic 
tyrosine kinase associated with FAs that participates in cell attachment, spreading 
and motility [397]. Structurally, four α helices arranged in a bundle form the C-
terminal region, composed of 1059 amino acids, in which the FAK targeting domain 
(FAT), used for linking within the focal adhesions, is located [398]. The N-terminal 
domain has been demonstrated to interact with the integrin β1 subunit in-vitro [399] 
and to directly bind the N-terminal domain of protein p53, leading to p53-mediated 
apoptosis suppression [400]. Moreover, FAK N-terminal domain interacts with the 
tumor suppressor protein neurofibromin, playing an important role in the intracellular 
signalling and carcinogenesis [401]. Between the N- and the C- regions lies the 
catalytic or regulatory domain, important for the kinase activation of FAK as it 
contains the so-called activation loop, involved in protein phosphorylation [402].  
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FAK displays different functions within FAs. It binds directly to talin and paxillin 
and is able to induce the activation of Rho-family GTPases by modulating various 
upstream regulators [403, 404]. Moreover, FAK is involved in the regulation of cell 
migration. In cultured cells, FAK deficiency negatively affects cell spreading on 
ECM proteins and cell movement in response to chemotactic and haptotactic signals 
[405, 406], defects rescued after the reconstitution of FAK-deficient cells with wild-
type FAK [407]. FAK-deficient cells also appear to respond slowly to forces and to, 
therefore, have a decreased movement reorientation [408]. A study on FAK 
overexpression in Chinese hamster ovary (CHO) cells support this regulatory role in 
cell motility; FAK overexpressing CHO cells display an enhanced cell migration 
[409]. Not surprisingly, oncological studies on human tumour samples revealed 
elevated expression of FAK [410], which has been correlated with increased cancer 
cell motility, invasiveness and proliferation [410-412]. 
 
1.3.2.5 Integrin α3β1 
 
In FAs, α3β1 integrin acts as a mediator for cell adhesion to the ECM, as shown in 
cultured human keratinocytes [413]. The intracellular tail of β1 subunit binds to talin 
and FAK [414], whereas, extracellularly, integrin α3β1 has been shown to mediate 
cell adhesion to LM332, 511 and 521 [415, 416]. In particular, the interaction 
between integrin α3β1 and LM332 has been demonstrated to be fundamental for LM 
deposition, since α3 and β1 integrin subunits have been reported to co-localise with 
LM332 [417] and wound closure studies showed a decreased healing process after 
the treatment with antibodies against α3 or β1 integrin [209]. Supporting the 
interaction between LM332 and integrin α3β1, in-vitro studies with α3 null mouse 
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skin cells showed that LM332 pattern changes from diffuse arcs to spikes and 
arrowhead, affecting the cell adhesion strength [417]. This suggests that α3 integrin is 
crucial for a correct LM332 organisation in a similar but distinct way to that of 64 
integrin described above [353].  
Further support to the role of α3β1 integrin in cell-ECM interactions is given by in-
vivo studies using α3β1 integrin knockout mice; the α3 integrin gene is expressed 
during the development of many epithelial organs, including kidneys [418], lungs 
[419] and skin [420], and homozygous offspring born from integrin α3β1 mutant mice 
survived to birth, but died during the neonatal period due to BM defects [421].  
α3β1 integrin-LM332 interaction is also important in other circumstances. It has been 
demonstrated to be involved in gap junction communication, as keratinocytes 
cultured on LM332 promoted gap junction communication to a greater extent than 
when plated on collagen or fibronectin [422], indicating that, perhaps, gap junction 
formation is dependent on α3β1 integrin-LM332 synergy. These data, considered 
together, highlight the central role of α3β1 integrin in the adhesive interactions of 
epithelial cells with underlying basement membranes.  
 
1.3.2.6 α-actinin 
 
α-actinin is an actin filament crosslinking and bundling protein, part of the spectrin 
gene superfamily [423]. On the basis of its location, α-actinin plays different roles; in 
non-muscle cells, it is calcium sensitive and involved in binding actin to the cell 
membrane, whereas in skeletal, cardiac, and smooth muscle cells, α-actinin is 
calcium insensitive and helps in anchoring the myofibrillar actin filaments [424]. 
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Four isoforms of α-actinin have been identified; α-actinin 1 is located primarily in 
FAs, 2 and 3 are muscle specific actin crosslinkers and 4 is present in membrane 
ruffles [425]. With regards to the structural features, α-actinin is composed of two 
identical anti-parallel peptides, with the actin binding domain close to the N-terminal 
region, followed by four spectrin-like repeats and two calcium binding motifs [426].  
Studies of the α-actinin binding properties demonstrated that it is able to interact with 
vinculin [381, 427], syndecan-4 [428], collagen type XVII  [429] and integrin β1 
cytoplasmic tail [430] [431], particularly important to maintain integrin-actin 
linkages at FAs [432]. As for many other actin-binding proteins, α-actinin function is 
regulated by polyphosphoinositides, particularly phosphatidylinositol 4,5 bis-
phosphate (PIP2) [433]. Additionally, previous studies showed that actin binding to 
α-actinin protein can be modulated by FAK-dependent phosphorylation of the N-
terminal domain [366]. 
 
1.3.3 Focal adhesion assembly and disassembly 
 
Focal adhesion’s components assemble and disassemble to maintain the balance of 
cell-ECM attachment, required for continuous migration. The assembly of FAs is a 
highly regulated mechanism, with protein recruitment occurring in a sequential 
manner. The first step of FAs assembly is an integrin clustering, the binding of 
adhesion receptors to ECM ligands, at the protruding edge of a cell [434]. In 
particular, β1 integrin have been reported to act as a force-bearing molecule, due to 
its catch bond properties [435], the ability to create non-covalent bonds whose 
lifetime, instead of decreasing, increases when tensile force is applied [436].  
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At this point, several signal transduction cascades are activated, leading to the 
consequent recruitment of talin, which, in turn, binds the actin cytoskeleton and 
stabilizes the integrin-ECM linkage [437]. Then, the actin-talin-integrin cluster 
recruits, among the others, FAK [438] [439], and induces the contraction of myosin 
II, another f component. This contraction has been shown to stretch talin [440], 
revealing binding sites for vinculin [441]. After such a step, signal transduction 
molecules (e.g. Rap1 GTPase or VASP) are activated and α-actinin is recruited, to 
complete the FA maturation with the actin polymerisation and the recruitment of 
paxillin [442] plus several other components, such as zyxin or tensin[443]. Fig. 1.8 
shows a schematic diagram of mature FA.  
 
  
Fig. 1.8: FA structure.  
Schematic outline of the mature FA structure, indicating the components and their 
interactions in the complex.  
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It is interesting to notice that, during growth and early maturation, the focal adhesion 
size correlates with traction stress [444], however, probably due to the altered 
chemical state of focal adhesion signalling components, upon maturation FAs 
effectively become passive anchorage devices, only involved in the maintenance of a 
spread cell morphology [445]. Normally, FAs disassembly occurs within 10-20 min 
from the maturation; this process is controlled by tyrosine phosphorylation events 
and changes in cytoskeletal tension [446], regulated, in turn, by molecules such as 
calpain or microtubules [447, 448]. At the rear of the cell, FAs protein aggregates 
leave the adhesion complex and disperse away from the adhesion site [449], moving 
centripetally; they, then, coalesce over 30 min before disintegrating [450]. Integrins 
are, instead, recycled for ligand binding [451].  
The extracellular ligand for FAs also plays a role in their assembly and organisation. 
LM332 has been shown to play a role in regulating the activation of distinct sets of 
integrins and the induction of different molecular assemblies within the cell adhesion 
signalling complexes. In human skin fibroblasts, for example, integrin subunits, 
vinculin, talin and paxillin were recruited into thick and short aggregates at the end 
of actin stress fibres when cultured on LM111, while on LM332 they appeared as 
dots or streaks clustered on a long portion of actin microfilaments [452]. Using α3β1 
function-blocking antibodies on cells cultured on LM111, the same group 
demonstrated that focal adhesions have a similar distribution as if the substrate was 
LM332, pointing to a cross-talk between α3β1 and α6β1 integrin in FAs, resulting in 
the activation of α6β1 integrin when α3β1 is blocked [452]. 
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Section 4. Laminin N-terminus proteins (LaNts) 
 
The Laminin N-terminus proteins (LaNts) were identified in 2009 and they owe their 
name to their structural similarity with laminins, being products of alternative 
splicing from the 5’ end of the LM α3 and α5 encoding genes, LAMA3 and LAMA5 
[453]. To date, two LaNts transcripts generated from each gene have been identified 
and only one study has been published on their characteristics and possible roles in 
skin [453]. 
 
1.4.0 LaNt α31 alternative splicing mechanism  
 
Alternative splicing in eukaryotic gene expression is a key process that increases the 
coding capacity of the human genome, resulting in a single gene coding for more 
than one protein; in humans, more than 95% of the genes undergo alternative 
splicing [454, 455]. ECM, due to its constant remodelling and context specific 
functional requirements, needs an appropriate balance between many different 
proteins and is, therefore, characterised by several alternative splicing events. With 
regards to the LM family, protein isoforms derived from alternative splicing have 
been identified in LAMA4 [456], LAMB3 [457], LAMA2 [458], LAMC2 [459] and 
LAMA5 [453], but LAMA3 gene is the one undergoing the most dramatic 
differential splicing.  
LAMA3 gives rise to two major transcripts: LAMA3A, starting from a promoter 
within intron 38 and containing exons 39–76, which encodes for a N-terminally 
truncated protein named as LM α3a [90, 92], and LAMA3B, instead formed by exons 
1–38 and 40–76, which generates the full-length LM α3b [91]. In addition to these 
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products, which are generated by use of different promoters, the LaNts are generated 
via a process of intron retention and alternative polyadenylation, a rarer form of 
splicing where an intronic region is retained in the final sequence [460].  
LaNt α31 is generated from an mRNA termed LAMA3LN1, produced by read-
through of the exon 9/intron 9 splice boundary and, therefore, carries an extension to 
the LAMA3 exon 9, known as exon 9e. This extended sequence contains a stop 
codon, a polyadenylation signal and the isolated expressed sequence tag (EST), 
through which it was initially identified to carry a polyA tail [461]. LAMA3LN1, 
therefore, is composed of exons 1-9 from LAMA3 gene +9e, and encodes for a 
protein of 488 amino acids. It is important to highlight that exon 9e encodes for 54 
amino acids unique to the LaNt α31 protein generated [461], and this sequence was 
used to produce antibodies against LaNt α31 [461] (Fig. 1.9A). 
 
1.4.1 LAMA3LN1 transcript localisation 
 
sqRT-PCR analysis of the LAMA3LN1 expression pattern revealed a relatively strong 
expression in heart, placenta, prostate, testis, small intestine, leukocytes and 
keratinocytes, with lower expression levels in pancreas, brain, ovary and fibroblasts 
[461]. Studies using in site hybridisation on skin sections demonstrated that 
LAMA3LN1 transcript is localised in the same tissues where LAMA3 gene has been 
shown to express, therefore epidermis and interfollicular epidermis, sebaceous 
glands, sweat glands and hair follicles, in which LAMA3LN1 distribution is evident 
in the outer and inner root sheaths [461, 462]. 
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1.4.2 LaNt α31 protein structure 
 
The protein encoded by LAMA3LN1 transcript has been named Laminin N-terminus 
α31 on the base of its structural characteristics [461]. LaNt α31 consists of LM 
globular LN domain, which is followed by a short stretch of LE repeats (Fig. 1.9B). 
Apart from the missing C-terminal domain, LaNts structure is highly similar to the 
structure of the netrin family of LM-related proteins (Fig. 1.9C) [156].   
 
1.4.2.1 Netrins 
 
All netrins are structurally composed of a LN domain followed by 2-3 LE repeats 
and a basic C-terminal domain. In terms of sequence similarity, netrins LN domains 
more closely resemble either LM γ chains (netrins 1, 3) or LM β chains (netrins 4, 
G1 and G2) and it is believed that these two subtypes of netrins evolved 
independently. 
The netrins are best known for their roles as neuronal guidance cues [463]; however, 
they have been demonstrated to play significant roles in cell migration, cell-cell 
interactions and cell-ECM adhesion, processes that are important in wound repair 
[464]. The primary role of netrins in axonal guidance is based on modulating the 
activity of three groups of receptors; deleted in colorectal cancer (DCC), neogenin 
and UNC5A-D. The netrins’ C-terminal-domain has capability to bind HS [465] and, 
in addition, a highly basic region of the netrin 1 C-terminus has been shown to 
contain a 25-amino acid region involved in the netrin 1 association with integrins 
α3β1 and α6β4, describing a role for netrin-integrin interactions in epithelial cell 
adhesion and migration [466].  
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The cellular responses to netrin exposure are determined both by the local netrin 
concentration and by the precise combinations of receptors expressed by the cell. 
Intriguingly, signalling via DCC and UNC5a in response to netrin has been 
demonstrated to induce dramatic rearrangement of the actin cytoskeleton, by 
modulating the activity of the small Rho GTPases Rac1 and Cdc42 [467, 468]. 
Netrin 4 is also involved in the regulation of glioblastoma multiforme cells’ 
migration and proliferation, via interacting with β4 integrin and triggering the 
downstream Akt and mTOR signalling [469].  
In addition to direct binding of cell surface receptors, it has been suggested that 
netrins localise and multimerise in the ECM [465, 470]. Particularly interesting is a 
study showing that netrin 4 can be incorporated into the BM via interaction of its N-
terminal domain with the LM LN domain [471]; this is supported by other studies 
showing that netrin 4 inhibits BM assembly by interfering with the LM 
polymerisation process [471-473]. Moreover, the high-resolution structure of netrin 4 
has been elucidated, revealing unique behavioural characteristics belonging to netrin 
4 only [474]. It has a high binding affinity for the LM γ1 chain LN domain, and has 
been shown to inhibit LM polymerisation process; very interesting is the ability of 
netrin 4 to also disrupt any pre-existing LM network, resulting in the alteration of the 
entire BM [474]. Netrin 4 binding to LM γ1 affects, in turn, processes like 
angiogenesis and vessel maturation, as it induces the collapse of the entire capillary 
network by disrupting the BM underlying the vasculature [474], an effect which may 
be helpful to reduce cancer progression. Netrin 4 association to LM γ1 chain is also 
important for the regulation of the mitogen-activated protein kinase pathway; this 
pathway occurs via ligating α6β1 integrin, a process triggered by interaction with LM 
γ1 chain [475].  
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Specifically looking at the cornea, netrin 1 has been shown to reduce corneal 
inflammation and to suppress and reverse corneal neovascularization when topically 
applied in a corneal alkali burn rat model, a well-established severe ocular surface 
disease model [476]. Similarly, netrin 4 studied on the same animal model acts as an 
anti-angiogenic factor, leading to a decreased corneal neovascularization [477], 
increased wound healing and reduced inflammation when topically applied [477]. A 
very recent study supports netrin 4 anti-angiogenic functions in the cornea, showing 
that netrin 4 absence leads to increased corneal hemangiogenesis in suture-induced 
neovascularization mouse model [478]. 
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1.4.3 LaNt α31 functional data 
 
In the skin, LaNt α31 has been shown to partially co-distribute with LM332 in the 
BM. In cultured human keratinocytes, LaNt α31 is found beneath the edges of either 
individual or clustered cells, with a distinctive punctate pattern [461]. HaCaT cells 
do not retain the protein intracellularly though, but deposit it into the ECM and 
western blotting data indicate that upon secretion LaNt α31 possibly undergoes 
proteolytic cleavage [461].  
LaNt α31 has been demonstrated to affect skin cell attachment, as keratinocytes in 
which LaNt α31 expression was knocked down, using siRNAs, displayed a 
decreased attachment rate [461]. However, the difference in adhesion rate between 
controls and knockdown cells was not significant anymore after 60 min, suggesting 
that the LaNt α31 knockdown primarily affects the initial stages of attachment [461].  
LaNt α31 has also been implicated in playing a role in the wound healing process. In 
cultured epidermal keratinocytes, LaNt α31 expression increases following 
wounding, with the expression peak reached around 6h post-wounding [461]. Further 
support is given by the impairment in wound closure observed in LaNt α31 
knockdown keratinocytes [461]. 
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Aim of the thesis 
 
The aim of my PhD project was to characterise, and then establish, the role of LaNt 
α31 protein in corneal epithelium. Specifically, we wanted to investigate LaNt α31 
effects on hTCEpi cell behaviour in relation to ECM components. The study 
produced very interesting and novel results, highlighting a strong and specific 
interaction between LaNt α31 and LMs. The data collected from the in-vitro 
experiments inspired the creation of an animal model, the first one of this type, 
which gave preliminary yet extremely promising results.  
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2.1.0 Cell Culture  
 
Telomerase-immortalised human corneal epithelial cells, hTCEpi cells [229], were 
cultured at 37°C with 5% CO₂ in Keratinocyte-Serum Free Medium (KSFM) 
supplemented with bovine pituitary extract (0.05 mg/ml), human recombinant 
Epidermal Growth Factor 1-53 (5 ng/ml) (Life Technologies, Carlsbad, CA) and 0.15 
mM CaCl₂ (Sigma-Aldrich, St Louis, MO). hTCEpi cells were characterised using 
the corneal marker Keratin 12 (Appendix, Fig. 1). 
HaCaTs, spontaneously transformed human epidermal keratinocytes [479], were 
cultured using Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) 
supplemented with 10% Foetal Calf Serum (LabTech, East Sussex, UK) and 2 mM 
L-glutamine (Sigma-Aldrich).  
KERA-308, Murine Keratinocyte cells [480], were purchased from CLS (Cell Lines 
Service GmbH, Eppelheim, Germany) and cultured in high glucose (4.5 g/L) DMEM 
(Sigma-Aldrich) supplemented with 10% Foetal Calf Serum (LabTech, East Sussex, 
UK) and 2 mM L-glutamine (Sigma-Aldrich). 
Tenons fibroblasts [481] were isolated from the Tenon’s capsule, beneath the 
conjunctiva, by Mrs Neeru Vallabh in the Department of Eye and Vision Science 
(University of Liverpool), and cultured in DMEM (Sigma-Aldrich) supplemented 
with 10 % foetal Calf Serum (Life Technologies), 100 units/mL penicillin (Sigma-
Aldrich), and 100 μg/mL streptomycin (Sigma-Aldrich) at 37 °C with 5 % CO2.  
Human Retinal Pericyte Cells (HRP) were purchased from Cell Systems Corporation 
(Kirkland, WA) and cultured in DMEM supplemented with 5.5 mM D-glucose, 10% 
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Foetal Calf Serum, 1X Penicillin-streptomycin solution (Sigma-Aldrich) and 1X 
sodium pyruvate (Thermo Fisher Scientific, Waltham, Massachussets, USA). 
 
2.1.1 Antibodies and reagents  
 
Rabbit polyclonal antibodies against paxillin and lamin A/C, and mouse monoclonal 
antibodies against β4 integrin (clone M126), GAPDH (clone 9484) and 6X-His Tag 
(clone HIS.H8) were purchased from Abcam (Cambridge, UK). Rabbit polyclonal 
antibodies against LM β3 and mouse monoclonal antibodies against GFP (a mixture 
of clones 7.1 and 13.1) were from Thermo Scientific (Loughborough, UK). J17, 
rabbit polyclonal antibodies against Col type XVII [482] was a kind gift from 
Professor Jonathan Jones, Washington State University, WA. Rabbit polyclonal 
antibodies against LAMA3exon9e were previously described [461]. 
Fluorescein isothiocyanate, rhodamine and Cy5 conjugated goat anti-mouse and goat 
anti-rabbit secondary antibodies were obtained from Jackson Immunoresearch (West 
Grove, PA). Goat anti-mouse and goat anti-rabbit IRDye 800CW and/or IRDye 
680CW were obtained from LiCor BioSciences (Rugby, UK).  
Mouse monoclonal antibody clone 3E11 was raised against the synthetic peptide 
VLPQRSHQANFGSV (GenWay Biotech, San Diego, CA), corresponding to human 
LaNt α31 residues 437-451, conjugated to keyhole limpet haemocyanin following 
the procedure described in [483], with help from the recombinant protein production 
core, Northwestern University, Chicago IL. Five days following the final boost, 
spleens were removed and isolated splenocytes were fused with the myeloma cell 
line Sp2 for the production of hybridomas using standard techniques [484]. 
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Hybridoma cells producing antibodies against the LaNt α31-derived peptide were 
selected based on their ELISA reactivity to the unconjugated peptide and 
immunoblotting reactivity against HaCaTs’ protein extract. Selected hybridoma cells 
were cloned twice by limited cell dilution. 
RG13, mouse monoclonal antibodies against LM α3 [485] was purified in our lab 
starting from conditioned media, dialyzed for 24h at 4°C ,with constant shaking in 
PBS, using SnakeSkin® Dialysis Tubing (10K MWCO, 16mm DRY) sealed with the 
SnakeSkin® Dialysis Tubing Clips  (Thermo Scientific, MA). IgG were purified 
using the NAb Protein G Spin Kit 1ml (Thermo Scientific). The IgG in PBS were 
diluted 1:1 in binding buffer (100 mM phosphate, 150 mM sodium chloride , pH 7.2) 
and applied to columns containing 1ml resin bed of protein G cross-linked 6% 
beaded agarose in 0.02% sodium azide. Columns were then washed using binding 
buffer and bound IgG eluted in 5x1ml fractions using elution buffer (2 M glycine), 
with pH 2.8. Eluted IgG were neutralised in 1M Tris-HCl (pH 8.5). The RG13 
containing eluted solution was concentrated through ammonium sulphate 
precipitation. Eluted fractions were pooled and mixed with 100% saturated 
ammonium sulphate solution (Sigma-Aldrich) and precipitates allowed to form over 
a period of 4h at 4°C , with constant shaking. Precipitates were pelleted by 35 min 
centrifugation at 5850g; the pellet was washed twice with cold 33% saturated 
ammonium sulphate solution, dissolved in coupling buffer  (0.1 M NaHCO3 buffer 
containing 0.5 M NaCl, pH 8.3-8.5) and dialyzed in PBS for 48h at 4°C with 
constant shaking. Silver stain and indirect immunofluorescence staining of hTCEpi 
cells (Appendix fig. 2) tested RG13 mAb activity and purity; protein concentration 
was determined by Bradford assay. 
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2.1.2 Bradford Assay 
 
RG13 mAb concentration was determined using a Bradford spectroscopic procedure, 
using the Quick Start Bradford kit from BioRad. Samples were mixed 1:1 with 
Bradford reagent, in a final volume of 200 µl in a 96 well-plate (NUNC™, NY). 
After 5 min incubation at room temperature, the absorbance was read at 595nm. A 
standard curve was generated using seven serial dilutions of commercially bought 
mouse IgG solution (Sigma-Aldrich) or bovine serum albumin supplied with the kit 
for proteins other than immunoglobulins, and the mAbs concentration (600 μg/ml) 
was extrapolated from the graph equation.  
 
2.1.3 Adenovirus production and cell transduction  
 
Full length LAMA3LN1 was PCR amplified from cDNA generated from cultured 
human keratinocytes, cloned into pCR2.1 (Life Technologies) and sequence verified 
by DNA sequencing (DNA Sequencing and Services, University of Dundee). The 
native translational stop codon was converted to an AgeI restriction enzyme site by 
site-directed mutagenesis, following the manufacturer’s directions of QuikChange II 
XL mutagenesis kit (Agilent, Santa Clara, CA). The mutated LAMA3LN1 was then 
subcloned using KpnI and AgeI (New England Biolabs, Hitchin, UK) into pENTR4 
(Life Technologies), with eGFP inserted into the BglII and KpnI sites of the multiple 
cloning site (a kind gift from Professor Jonathan Jones, Washington State University, 
WA).  
LR recombination was used to transfer the LAMA3LN1-eGFP construct from pENTR 
to pAD-CMV/V5-DEST (Life Technologies) and adenoviral particles produced 
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following the standard gateway-adapted ViralPower adenoviral expression protocol 
(Life Technologies). Adenoviruses inducing CMV-driven expression of LM β3-
mCherry [486] and eGFP were kind gifts from Professor Jonathan Jones, 
Washington State University, WA. 
For cell transduction, 3x105 hTCEpi cells were seeded in 60mm dishes (Greiner-
BioOne) and transduced 24h after seeding with recombinant adenoviruses harbouring 
eGFP protein, LaNt α31-GFP protein and/or LM β3-mCherry protein, 10 μl each in 
4ml of hTCEpi culture medium. All analyses of LaNt α31-GFP (+LaNt α31), LM 
β3-mCherry (+LMβ3), GFP (+GFP) or untreated cells were conducted 48-72h 
following transduction. 
 
 
2.1.4 Short hairpin RNA (shRNA) and knockdown clone generation 
  
shRNA sequences, targeting the unique portion of the LAMA3LN1 transcript, were 
designed using the BROAD institute design algorithm 
(http://www.broadinstitute.org/rnai/public/seq/search). A gblock (Integrated DNA 
Technologies, Coraville, IA) containing the shRNA sequence 
(CCCTCTCTCTTCAGAGTATT) or validated non-silencing sequence 
(TCTCGCTTGGGCGAGAGTAAG), as well as stem loop sequence with BamHI 
and XhoI restriction enzyme compatible overhangs, was cloned into the miRNA 
adapted pGIPz plasmid (Open Biosystems, GE Healthcare Little Chalfont, 
Buckinghamshire, England). Lentiviral particles were generated as previously 
described [487] by the DNA/RNA Delivery Core, Northwestern University, Chicago, 
IL, using 293T packaging cells (Gene Hunter Corporation, Nashville, TN).  
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To generate stable clones, hTCEpi cells were seeded at 2x105 cells/well in 6 well 
plates and transduced with lentiviral particles at final MOI of 0.5 with 8 μg/ml 
polybrene (Sigma-Aldrich). Transduced cells were selected in puromycin (10 μg/ml 
Gibco, LifeTech) for 7 days and resistant cells plated a 1 cell/well in 96 well plates. 
Clones were expanded and screened by western immunoblotting (WB). 
 
2.1.5 Immunofluorescence microscopy 
  
1x105 cells were seeded either for 5h or overnight on uncoated glass coverslips, then 
fixed and extracted in ice cold methanol or ethanol for 4 min. They were, then, air-
dried or fixed in 3.7% formaldehyde (Sigma-Aldrich) for 5 min and extracted in 
0.05% Triton X-100 in PBS for 7 min (Sigma-Aldrich).  
For ECM analysis, cellular material was removed through exposure to 0.18% 
ammonium  hydroxide (NH4OH) for 5 min followed by extensive PBS washes [483] 
prior to fixation. Primary antibodies were diluted in PBS with 20% normal goat 
serum (Jackson Immunoresearch) and incubated at 37°C for 2h; coverslips were then 
washed extensively with PBS prior to probing for 1h at 37°C with FITC, Rhodamine 
or Cy5 conjugated secondary antibodies diluted in PBS. After being washed in PBS, 
coverslips were mounted with polyvinyl alcohol mounting medium with DABCO 
(Sigma-Aldrich). 
Images were obtained using Zeiss LSM510 confocal microscope or Zeiss 
ApoTome.2 fluorescence microscope (Zeiss, Cambridge, UK).  
LM α3 staining area was measured for 50 regions of staining per cell treatment, 
using the freehand selection tool on Fiji32-ImageJ software (National Institutes of 
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Health, Bethesda, MA). Pearson’s correlation coefficients were calculated using the 
Coloc-2 plugin on Fiji32-ImageJ software (NIH) for all pixels above channel 
thresholds in both acquired channels. 
 
2.1.6 Tissue processing and immunohistochemistry 
 
Human donor eyes, obtained from the Liverpool Research Eye Bank (Liverpool, UK) 
were fixed in formalin, embedded in paraffin wax and processed as previous 
described [488]. The study was approved by local Research Ethics Committees and 
was performed in accordance with the Declaration of Helsinki.  
Eyes were sectioned anteroposteriorly through the pupil and the anterior segment 
analysed separately. 4 μm sections were cut using a rotary microtome RM2235 
(Leica, Wokingham, UK), adhered to coated microscope slides (Dako, Cambridge, 
UK) and allowed to dry overnight at 37°C. Sections were then de-waxed and 
rehydrated through a series of decreasing ethanol concentrations. Antigen retrieval 
was performed by microwaving sections in preheated 0.01M citrate buffer (pH6, 
Sigma-Aldrich) for 5 min at 95-100°C. Endogenous peroxidases and non-specific 
binding were blocked by treatment with 0.3% v/v hydrogen peroxide (15 min; Dako) 
and 20% v/v goat serum (Sigma-Aldrich) respectively. Sections were then incubated 
with anti-LaNt α31 antibodies at a final concentration of 7.2 μg/ml, in 5% v/v goat 
serum, or isotype matched controls overnight at 4°C.  
Immunostaining was performed using the EnVisionTM+ System-HRP (Dako) kit 
following manufacturers’ recommendations. Sections were counterstained with 
haematoxylin, dehydrated and mounted in pertex mounting media (HistoLab, 
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Gothenburg, Sweden). Images were captured with an Olympus BX60 system 
microscope equipped with an Olympus DP71 digital camera and cell imaging 
software (Olympus, Southend-on-Sea,UK). 
 
2.1.7 SDS PAGE and immunoblotting  
 
Cells were plated at 1x106 in 100mm dishes (Greiner-BioOne, Stonehouse, 
Gloucestershire, UK) and lysed after 24h using Urea/SDS buffer (10 mM Tris-HCl 
pH=6.8, 6.7 M Urea, 35 mM SDS, 10% Glycerol and 7.4 μM bromophenol blue) 
containing 50 μM PMSF and 50 μM N-methylmaleimide.  
Prior to use, lysates were sonicated and 15% β-mercaptoethanol (final volume, 
Sigma-Aldrich) added. Proteins were separated by SDS PAGE using a 10% 
polyacrylamide gel (Biorad, Hercules, CA), transferred to a nitrocellulose membrane 
using a Biorad TurboBlot system (Biorad) and blocked at room temperature in 
Odyssey®TBS-Blocking Buffer (Li-Cor BioSciences, Nebraska, USA) for 1h. The 
blocked membranes were probed for 2h at 37°C with primary antibodies diluted in 
blocking buffer, washed 3 x 5 min in TBS/0.1% Tween and probed for 2h at 37°C 
with IRDye® 800CW and/or IRDye® 680CW conjugated secondary antibodies (Li-
Cor) diluted in blocking buffer (1:13.000). Membranes were then washed for 3 x 5 
min in TBS/0.1% Tween and imaged using an Odyssey® CLx 9120 Infrared 
Imaging System. 
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2.1.8 Cell morphology analysis, low-density motility and  
cross-matrix assays  
 
For cell morphology analyses and low-density migration assays, cells were seeded at 
2.5x104 cells/well onto uncoated 24 well plates (Greiner-BioOne). Where cell-
derived preformed matrixes were required, non-transduced hTCEpi or +LaNt α31 
hTCEpi were plated at 1.8x105/well overnight on a 24 well plate, after which cellular 
material was removed through exposure to NH₄OH, as previously described. Fresh 
untreated or +LaNt α31 hTCEpi were then seeded on top of the prepared matrixes for 
2h prior to analysis.  
For morphology, 20X phase contrast images were acquired on a Nikon TiE 
epifluorescence microscope (Nikon, Surrey, UK). Images of individual cells were 
analysed using Fiji32 software (NIH). Cell perimeters were manually traced to define 
cell area; cell length was measured as the longest linear axis, with width measured at 
widest point at right angles to length measurement. Aspect ratio was defined as the 
ratio of width to length.  
For low-density migration assays, cells were imaged every 2 min over a 2h period of 
time, using a 20X objective on a Nikon TiE fluorescent microscope, then individual 
cells tracked using the MTrackJ plugin of the Fiji32-ImageJ software (NIH). Speed 
(total distance travelled/time) and processivity (total distance/linear distance) were 
calculated for each cell. 
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2.1.9 Scratch closure assay 
 
For scratch closure assays, hTCEpi, scrambled shRNA or LaNt α31 shRNA clones 
were seeded at 2x105 cells/well in a 24 well plate (Greiner-BioOne). For 
overexpression studies, 16h after seeding hTCEpi were adenovirally transduced. 24h 
later a scratch was introduced into the confluent monolayers using a 200 μl tip. Cell 
debris was removed with several PBS washes. Scratch closure was imaged using a 
Nikon TiE epifluorescence microscope with a 4X objective for 16h. Scratch closure 
rates were determined by measuring scratch area after 0, 4, 8, 12 and 16h using the 
freehand image tool in Fiji32-ImageJ software (NIH). 
 
 
2.1.10 Attachment Assay 
 
Coatings were prepared using LM111 from EHS, Col type IV or FN (Sigma-
Aldrich). Each protein was initially tested at the following range of concentrations; 
LM111 1, 2 3 or 4 μg/ml, Col type IV 0.025, 0.05, 0.1, 0.25 μg/ml, FN 0.1, 0.25, 0.5, 
1 μg/ml. This range was selected to allow us to identify a mid-point of attachment 
rate so that we would be able to detect increases or decreases induced by LaNt α31 
overexpression or exogenous addition. Based on the obtained attachment rate (Fig. 
2.1), an appropriate starting concentration was chosen for each protein: LM111 was 
used at 2 µg/ml, Col type IV at 0.1 µg/ml and FN at 1 µg/ml.  
ECM proteins were mixed with either 0.02 µg/ml or 0.1 µg/ml LaNt α31 (produced 
by Northwestern University protein production core) and TBS (50 mM Tris and 150 
mM NaCl, pH 7.6, Sigma-Aldrich), or 0.02 µg/ml or 0.1 µg/ml netrin 1 or 4 (R&D 
Systems, Minneapolis, MN) and TBS. LM111 coating solutions also included 1 mM 
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CaCl₂ or 1 mM EDTA (Sigma-Aldrich). Coatings were prepared in a 96 well plate 
(Greiner-BioOne) with each well coated with 100 µl of solution for 2h at 37°C, 
followed by blocking of unoccupied binding sites with 100 µl of 1% Bovine Serum 
Albumin (Sigma-Aldrich) in PBS (phosphate buffered saline Tablets, Oxoid-Thermo 
Scientific) for 1h at 37°C.  
1x105 cells in a final volume of 100 µl were plated in each coated well and incubated 
at 37°C for 1h. Attached cells were fixed with 100 µl of 3.7% formaldehyde (Sigma-
Aldrich) in PBS for 15 min at room temperature. Fixed cells were washed three times 
with PBS and stained with 100 µl per well of 20% Crystal Violet solution (Sigma-
Aldrich) in methanol (Chemistry Department, University of Liverpool) for 15 min at 
room temperature. Excess staining was removed with ddH₂0. To permeabilise the 
cells, 100 µl of 1% SDS (Sigma-Aldrich) in PBS were added to each well and the 
plate was shaken at room temperature for 1h. The absorbance was measured at 570 
nm, using the microplate reader LUMIstar Omega (BMG labtech). To evaluate 
hTCEpi cell attachment in different cell treatments or coating conditions, absorbance 
readings were normalized to the value obtained from FN 10 μg/ml coated well.  
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2.1.11 Polymerisation Assay  
 
25 μl of LM111 from EHS (1 mg/ml, Sigma-Aldrich) were mixed with 75 μl of a 
0.01% Triton X-100/1X TBS solution to a final concentration of 0.25 mg/ml and 
centrifuged for 15 min at 11,000 rpm. Supernatants were transferred into two fresh 
tubes, 50 μl each, and mixed with 1 mM CaCl2 or 10 mM EDTA [164]. 15 μl of 
LaNt α31 solution, either cloned into pSecTag plasmid (pSec) or V5 plasmid (V5), 
and purified by affinity chromatography (AC) or gel filtration (GF), were also added 
to some of the samples, with a final pure LaNt α31 mass of 0.4 μg. Prepared samples 
were incubated at 37°C for 3h and then centrifuged for 15 min at 11,000 rpm; 
supernatants were transferred to fresh tubes and pellets incubated overnight at 4°C 
with 1 mM EDTA (50 μl final volume). After 24h, supernatant and pellet from both 
the samples were separated via SDS PAGE on a 7.5% polyacrylamide gel, for 3h at 
200 V. Silver stain (Pierce™ Silver Stain Kit, Thermo Fisher Scientific) was 
performed according to manufacturer’s instructions.  
 
2.1.12 Immunoprecipitation 
 
hTCEpi cells were plated at 1x106/plate in 100 mm plates and 24h later transduced 
with GFP or LaNt α31-GFP adenovirus. 48h later cells were extracted in 0.1% SDS, 
0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 1 mM CaCl2 in 50 
mM Tris-HCl, pH 7.5 containing a mixture of protease and phosphatase inhibitors 
(Sigma-Aldrich). Cell extracts were clarified by centrifugation and 50% slurry of 
sepharose beads covalently conjugated with rabbit anti-GFP polyclonal antibodies 
(Abcam) was added to the supernatant. The bead/supernatant mixture was incubated 
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overnight at 4°C; the beads were then washed in lysis buffer, collected by 
centrifugation and boiled in SDS-PAGE sample buffer prior to immunoblotting.  
 
 
2.1.13 Live protein imaging  
 
1x105 hTCEpi cells, doubly transduced with LaNt α31-GFP and LM β3-mCherry 
adenoviruses, were seeded either directly or within a cloning ring on a 35 mm glass 
bottomed dish (MatTek Corporation, Ashland, MA). For preformed matrix studies, 
5x105 singly transduced LM β3-mCherry hTCEpi were seeded for 24h, then ECM 
extracts prepared as above, fresh LaNt α31-GFP expressing cells were then plated 
onto the preformed matrix for 2h prior to imaging.  
Dishes were placed in the holder of a Zeiss 510 Multiphoton 2 confocal microscope 
at 37°C for 1h, to stabilise. Images were acquired at 63X objective every 20 min over 
16h.  Images were processed using Fiji32-ImageJ (NIH).  
 
2.1.14 Proximity Ligation Assay (PLA) 
 
8x104 hTCEpi cells were seeded onto glass coverslips. Cells were fixed after 24h, as 
described in the immunofluorescence microscopy section, and non-specific binding 
blocked for 30 min at room temperature using 5% normal goat serum in PBS 
(Sigma-Aldrich). Primary antibodies against LM γ2, LaNt α31, integrin β4 and 
actinin α4 were diluted 1:100 in the Odyssey®TBS-Blocking Buffer blocking 
solution (LiCor BioSciences) to a final volume of 30 μl and each probed coverslip 
was incubated at 37°C for 2h. After 3x5 min washes with PBS, coverslips were 
incubated at 37°C for 1h with Duolink® Orange secondary probes (emission at 579 
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nm), 1:5 diluted  in the Odyssey®TBS-Blocking Buffer to a final volume of 30 μl,  
following PLA® Technology  kit instructions (Sigma-Aldrich). Secondary probes 
were removed with 2x5 min washes in 1X Wash Buffer A (Duolink® using PLA® 
Technology kit), under gentle agitation; ligation was performed for 30 min at 37°C 
probing the samples with the supplied ligation mix and ligase enzyme, respectively 
1:5 and 1:40 diluted in ddH2O. Coverslips were washed 3x5 min in TBS + 0.5% 
Tween-20 before being incubated, for 100 min at 37°C, with the supplied 
amplification mix and the polymerase enzyme (Sigma-Aldrich), 1:5 and 1:80 
respectively diluted in ddH2O . Final coverslips washes were performed 2x10 min in 
1X TBS; Duolink® In Situ Mounting Medium with DAPI was used to mount the 
samples on slides and signal was detected using a Zeiss ApoTome.2 fluorescence 
microscope (Zeiss). 
 
2.1.15 Limbal Explants Culture 
 
Human rims were received as a waste product from St Pauls ‘eye theatre and stored 
in organ culture media. Track record of the identification numbers was taken.  
Limbal rims were put into a 100 mm petri dish (Greiner-BioOne), with some of the 
storage medium to prevent dryness. The endothelium was gently rubbed off using 
sterile forceps and some of the sclera was cut out, leaving a ring of about 3 mm in 
diameter. Every ring was put into PBS mixed with 2.5 μg/ml Amphotericin B 
(Fungizone) and 2% Penicillin/Streptomycin solution (Sigma-Aldrich) to prevent 
contamination, and chopped into 12 portions. After 15 min, each explant portion was 
placed in the centre of a 12 well plate (Greiner-BioOne) in 500 μl of limbal media 
consisting of; 3 parts DMEM low glucose medium (1000 mg/l) containing pyruvate 
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and GlutaMAX (Sigma-Aldrich), 1 part DMEM Ham/F12 (Sigma-Aldrich), 10% 
foetal calf serum (Labtech), 1% penicillin/streptomycin solution (Sigma-Aldrich), 
1% Amphotericin B (Sigma-Aldrich), 20 mM HEPES (Thermo Fisher Scientific), 26 
mM NaHCO3 (Sigma-Aldrich). 
Aliquots of 50 ml of media were made, and supplemented with 5 μg/ml Transferrin, 
5 μg/ml Insulin, 1.4 ng/ml Triiodothyronine, 12 μg/ml Adenine, 0.4 μg/ml 
Hydrocortisone and 10 ng/ml EGF (Sigma-Aldrich). To prevent dryness, plates were 
placed into a larger box with a 60 ml pot of ddH2O. Explants were fed three times a 
week, leaving 150 μl of old medium behind to maintain secreted components. 
Primary corneal epithelial cells (pCEC) grew after 10-14 days in culture, and were 
detached from the tissue culture plastic using TrypLETM Express Enzyme, 1X 
without phenol red (Thermo Fisher Scientific). 
 
2.1.16 Statistical analysis 
 
Quantification of experiments was derived from a minimum of 3 biological 
replicates. One-way ANOVA and Tukey’s post hoc analysis were used to analyse 
and interpret the data generated from cell morphology, LM cluster area, adhesion and 
scratch assays. Instead, one-way ANOVA and Bonferroni post hoc analysis were 
used to analyse and interpret the cell motility assay data. All the statistical analyses 
were performed using SPSS software (IBM, Hampshire, UK); differences were 
deemed significant where p<0.05.  
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2.2.0 LaNt α31 mouse model preparation 
2.2.0.1 Restriction Digests 
 
Unless otherwise stated, restriction digests were set up with 1 µg of plasmid DNA, 
20 U of each enzyme (New England Biolabs) and CutSmart buffer (50 mM 
Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, 100 μg/ml 
BSA) and incubated at 37°C for 2h. Where necessary, digested DNA products were 
treated with 5 U of the DNA Polymerase I, Large (Klenow) Fragment (New England 
Biolabs) [489] and 33 µM dNTPs mix (Qiagen, Hilden, Germany) at 37°C for 30 
min, to create blunt ends by filling in of 5´overhangs [490]. To prevent cloning 
vector recirculation, the removal of the 5´ phosphates in linearised DNA was 
achieved by treatment with 5 U of the Antarctic Phosphatase enzyme (New England 
Biolabs) and 1X of reaction buffer (50 mM Bis-Tris-Propane-HCl, 1 mM MgCl2, 0.1 
mM ZnCl2, New England Biolabs) at 37°C for 30 min. Enzymatic activity was 
subsequently inactivated by a 10 min incubation period at 65°C. Digested products 
were gel-purified using the QIAquick gel extraction kit (Qiagen), following 
manufacturer’s instructions, and successful purification confirmed by gel 
electrophoresis. 
 
2.2.0.2 Agarose gel electrophoresis 
 
Agarose gels were prepared by dissolving 1% agarose powder (Sigma-Aldrich) and 
35 µg Ethidium Bromide solution (Sigma-Aldrich) in 1X TAE buffer (40 mM Tris 
pH 7.6, 20 mM acetic acid, 1 mM EDTA). A voltage of 85V was applied for 95 min 
and the DNA products were visualised using the UV transilluminator ChemiDoc™ 
MP System (BioRad).  
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2.2.0.3 Plasmid Ligation, bacterial transformation and plasmid 
preparation 
 
Purified inserts were ligated overnight into cloning vector at 3:1 molar ratios, chosen 
as a mass of insert to backbone ratio, using 400 U of the T4 DNA ligase (New 
England Biolabs) and 1X reaction buffer (50 mM Tris-HCl,10 mM MgCl2,1 mM 
ATP,10 mM DTT, New England Biolabs) at 16°C. Ligated DNA was heat shock 
transformed into One-Shot TOP10 Chemically Competent E.Coli cells (Life 
Technologies), following the procedural steps suggested by the manufacturer, and 
plated onto ampicillin (100 µg/ml, Sigma-Aldrich) LB plates.  
Amplified DNA from selected bacterial colonies was purified using the GenElute™ 
Plasmid Miniprep Kit (Sigma-Aldrich). For maxiprep DNA, DNA from verified 
bacterial colonies was expanded in 300 ml LB Broth (Sigma-Aldrich) with ampicillin 
(100 μg/ml, Sigma-Aldrich) and purified using the Qiagen Plasmid Maxi Kit 
(Qiagen). 
 
2.2.0.4 PCR amplification of the hK14 promoter 
 
Modified primers to amplify the hK14 promoter (table 2) were designed using the 
NCBI Primer Blast designing tool, on the base of the published DNA sequence 
(GenBank accession No. Ul1076) [491]. 5’ end of the forward primer was modified 
with MluI restriction enzyme site; Reverse Primer 3’ end with NdeI, NsiI and KpnI 
restriction sites. 
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OLIGO  Tm° GC% SEQUENCE 5’- 3’ 
hK14 
promoter 
213F+ 
MluI 
66.4 °C 47.8 TATACGCGTGGAGGAAGGAGTTTCTTTTGGGT 
hK14 
promoter 
256R+               
NdeI      
NsiI   
KpnI 
66.6 °C 57.1 ATGGTACCATGCATCATATGTATACTCATGGGTAGGGGGCG 
Table 2: Modified PCR primer sequences to amplify hK14 promoter. 
 
The hK14 promoter was amplified by PCR in a reaction containing 1 µg of human 
genomic DNA template (1 µg/µl, Bioline, London, UK), 2.5 µM forward and reverse 
primers, 1 mM MgCl₂, 1X reaction buffer, 2.50 U Taq polymerase, 400 μM dNTPs 
and the thermocycler T100™ Thermal Cycler (BioRad) set as follows: 
 
STEP TIME TEMPERATURE 
Initial activation step 3 minutes 95°C 
Denaturation 30 seconds 95°C 
Annealing 1 second 60°C 
Extension 3 minutes 72°C 
End of PCR cycling Indefinite 4°C 
Table 3: Thermocycler programme for hK14 promoter amplification. 
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The samples were separated by gel electrophoresis technique and amplified DNA 
bands gel-purified using the QIAquick gel extraction kit (Qiagen). 
 
2.2.0.5 Cell transfection 
 
1x10⁶ KERA-308 or HaCaT cells were seeded in 6 well plates (Greiner-BioOne) the 
day before transfection. Lipofectamine® 2000 Reagent and OptiMEM® Medium 
(Life Technologies) were used to set up the transfection, following the procedural 
steps suggested by the manufacturer, with a 3:1 (μl:μg) Lipofectamine to DNA ratio 
for KERA-308 cells, and 0.8:2 (μl:μg) Lipofectamine to DNA ratio for HaCaT cells. 
One well was left untransfected as a negative control. Transfected cells were 
visualised with 10X and 40X objectives 24h post transfection, using a Nikon TiE 
epifluorescence microscope. LaNt α31 protein expression levels were analysed by 
WB. 
 
2.2.1 LaNt α31 overexpressing mice generation and genotyping 
 
All animal procedures were approved by local ethical review and licensed by the UK 
Home Office under the Animal (Scientific Procedures) Act 1986, project licence 
number (PPL) 70/7288. 
 
2.2.1.1 DNA embryonic injection 
 
To generate the transgenic model, Dr. Ke Liu (Prof. George Bou-Gharios’ 
laboratory, University of Liverpool) injected DNA in the mouse oocyte [492]. The 
103 
 
DNA was diluted to 2 ng/μL in embryo water (Sigma-Aldrich) and filter-purified 
using Durapore®-PVDF 0.22 μM centrifuge filters (Merck Millipore LtD).  
 
2.2.1.2 Superovulation of egg donors  
 
Superovulation was performed on F1 females aged between 4-6 weeks. 5 IU of 
follicle stimulating hormone was injected intraperitoneally, followed by 5 IU of 
luteinising hormone 46h later. Treated females were mated with F1 males overnight. 
Mated females, identified via copulation plugs checking, were anaesthetised and 
oviducts removed and dissected in M2 media (Millipore, Specialty Media, 
EmbryoMax®). Eggs were transferred to clean media via mouth pipetting. Cumulus 
cells were removed by hyaluronidase (300 μg/mL) treatment in M2 media with 
gentle shaking until visibly detached from the egg surface. Eggs were then rinsed and 
transferred to M16 media (Millipore, Specialty Media, EmbryoMax®) ready for 
injection.  
 
2.2.1.3 Pseudopregnant females’ generation  
 
Pseudopregnant females were generated by mating vasectomised F1 males overnight. 
Copulation plugs were checked and females were used 1 day post-coitum. Females 
were anaesthetised with 50 μL hypnorm and 50 μL hypnoval by intraperitoneal 
injection.  
 
 
 
104 
 
2.2.1.4 Injection of fertilised eggs 
  
Injection pipettes were used to pierce the outer layers of the oocyte, avoiding the 
nucleus, and to inject DNA. Undamaged eggs were transferred to clean M16 media 
and incubated until transfer into pseudopregnant F1 females. Eggs were 
microinjected at the 1 cell stage and transferred to the oviducts using the 
infundibulum. In the first session (November 2015), 90 embryos were collected from 
8 F1 females and 60 of them were injected. 50 embryos survived after the injection 
and were transferred into 2 recipient mothers. In the second session (December 
2015), 110 embryos were collected from 8 F1 females and 100 of them were 
injected. 90 embryos survived after the injection and were transferred into 3 recipient 
mothers. Surprisingly, the number of offspring obtained was very low, compared to 
what normally expected [493]; two pregnancies were aborted, one pregnant female 
gave birth to a litter of five animals and the remaining two gave birth to one animal 
each. 
 
2.2.1.5 DNA extraction 
 
4 weeks after birth, ear punches from the few born mice were collected from the 
Technical Staff of the Biomedical Services Unit (BSU, University of Liverpool). Ear 
tissue was digested using 100 μl of lysis buffer (50 mM Tris-HCL pH 8, 0.1 M NaCl, 
1% SDS, 20 mM EDTA) and 10 μl of proteinase K (10 mg/ml) overnight, at 55°C. 
The day after, samples were allowed to cool down at room temperature and vortexed 
until tissues were disintegrated. Solutions were incubated with 3.75 M NH4OAc on 
ice for 5 min and centrifuged at 14,000 rpm for 10 min. 100 μl of absolute 
Chloroform were added and samples spun again. Once centrifugation was completed, 
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supernatants were transferred to new tubes, mixed with 500 μl absolute Ethanol and 
incubated at -20°C for 2h. Samples were centrifuged at 14,000 rpm for 10 min and 
Ethanol removed. Equal volumes of cold (-20°C) 70% Ethanol were used to wash the 
pellets, which were then allowed to air dry for 10 min and reconstituted in 100 μl of 
TE buffer. 
 
2.2.1.6 PCR 
 
100 ng of the extracted DNA were mixed with 12.5 μl of REDtaq ® ReadyMix PCR 
Reaction Mix (20 mM Tris-HCl pH 8.3,100 mM KCl, 3 mM MgCl2, 0.002 % 
gelatin, 0.4 mM dNTP mix, 0.06 unit/mL of Taq DNA Polymerase, Sigma-Aldrich) 
and 0.5 μM of each primer; volume was then brought up to 25 μl with PCR-grade 
H2O (Sigma-Aldrich). Each sample was amplified using two sets of DNA primers, as 
summarised in table 4. 
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OLIGO  Tm° SEQUENCE 5’- 3’ 
MUS LaNtα31 
For3428 into 
mCherry 
69.5 °C CAGATGTTGAGCGGCAGCAG 
MUS mCherry 
Rev4426 
into LaNt α31 
70.3°C CGAAGTTCATCACGCGCTCC 
llc016 mCherry F 65°C ATGGTGAGCAAGGGCGAGGAGGATAAC 
llc017 mCherry R 65°C CTTGTACAGCTCGTCCATGCCGCC 
Table 4: DNA primer sets, used for mice genotyping after DNA extraction from ear 
notches.  
 
PCRs were run according to the following protocol (table 5) and the samples 
separated by gel electrophoresis technique and imaged using BioRad Gel Doc™ 
XR+ System. 
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STEP TIME TEMPERATURE 
Initial activation step 5 minutes 95°C 
Denaturation 30 seconds 94°C 
Annealing 30 second 61°C 
Extension 1 minutes 72°C 
End of PCR cycling Indefinite 4°C 
Table 5: thermocycler protocol applied to amplify DNA for mice genotyping. 
 
2.2.1.7 F1 generation  
 
Transgene-positive males 1.2 and 1.3 were time-mated with two and three females 
respectively, to produce the first filial generation (F1). Mouse 1.2 mating generated 
two litters composed of 5 newborn each, whereas mouse 1.3 generated three litters 
composed of 4, 3 and 4 newborns each. F1 genotyping was performed as previously 
described. 
 
2.2.1.7a Tissue samples processing 
 
Transgene-positive mice 4.1 and 6.3, respectively born from males 1.2 and 1.3, were 
sacrificed and skin and kidneys collected. Both the organs were positioned on labeled 
cork pieces and covered in optimum cutting temperature (O.C.T.) formulation 
(Tissue-Tek; Sakura Finetek, USA) for few minutes. Without fully submerge them, 
samples were snap-frozen in isopentane (Merck Millipore, Darmstadt, Germany) and 
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then covered in aluminium foil to be stored at -80°C. Part of the frozen samples were 
cut in 10 μm sections, using the CM1850 Cryostat (Leica, Wetzlar, Germany), 
whereas the remaining specimens were homogenised in preparation for WB.  
Tissues were grinded into powder in liquid nitrogen, dissolved in UREA/SDS lysis 
buffer (10 mM Tris-HCl pH=6.8, 6.7 M Urea, 35 mM SDS, 10% Glycerol and 7.4 
μM bromophenol blue) containing 50 μM PMSF and 50 μM N-methylmaleimide, 
and incubated with agitation for 1h at 4°C. Samples were then clarified by 
centrifugation at 13,000 rpm for 10 min and supernatant transferred to fresh 
Eppendorf tubes. 1:200 diluted tissue solutions were used for WB and probed with 
antibodies against 6X-His tag (Abcam).   
 
2.2.1.7b E15.5 embryo analysis 
 
Transgene-positive males 1.2 and 1.3 were time-mated for a second time, to start 
pregnancies planned to be prematurely stopped in order to collect embryos and 
analyse LaNt α31 and mCherry expression during development. The two pregnant 
females were sacrificed at E15.5; notably, as for the previous pregnancies, offspring 
number was very low; only one foetus was collected from mouse 1.2 timed-mating 
and genotyped as described before.   
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                                                                                 Chapter 3 
                                                                     In-Vitro RESULTS 
 
LANT α31 DISPLAYS DIFFERENTIAL DISTRIBUTION 
ACCROSS THE ANTERIOR SURFACE EPITHELIUM, 
AND IT REGULATES CELL MIGRATION VIA 
MODIFYING CELL-LM INTERACTIONS DURING 
MATRIX ASSEMBLY 
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Introduction 
  
To date, there has been only one study looking at LaNt α31 biology and that was 
restricted to the skin [461]. As previously established, LaNt α31 encoding gene 
LAMA3 is also expressed in the anterior segment; we decided, therefore, to further 
analyse LaNt α31 distribution and functions in the eye, and, on the base of the 
differential localisation in the anterior segment layers, specifically in the corneal 
epithelium.  
This chapter includes the data obtained from in-vitro studies, using LaNt α31 
overexpressing hTCEpi cells. Starting from the LaNt α31 protein expression in the 
anterior segment and in hTCEpi cells, the results will describe the effects of LaNt 
α31 overexpression on the main cell behaviours, such as cell adhesion, migration, 
wound closure and protein deposition.  
 
3.0 Anti-human LaNt α31 antibody generation 
 
Human LaNt α31 shares the majority of its sequence with the amino terminus of LM 
α3b; however, the final 54 amino acids, encoded by exon 9e, are unique to LaNt α31 
(Fig. 3.1A). Mouse monoclonal antibodies were raised against the 14-mer peptide 
VLPQRSHQANFGSV within this unique region. Clones were screened by ELISA 
against the unconjugated peptide and then by WB against protein extracts from 
HaCaT cells, which have previously been shown to express LaNt α31 protein toward 
the edge of either single or clustered cells, partially co-distributing with LM332 
[461]. We also probed hTCEpi cells extracts and confirmed that a similarly sized 
protein product (~58 kDa) is recognised by the antibodies in both HaCaT and 
hTCEpi cells (Fig. 3.1B).  
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To confirm the specificity of our antibodies, we used lentiviral transduction of 
shRNAs targeting the LAMA3LN1 sequence to generate stable knockdown clones in 
hTCEpi cells, followed by WB of whole cell extracts from knockdown clones 
relative to non-transduced hTCEpi or hTCEpi cells expressing a non-silencing 
shRNA (scrambled shRNA) (Fig. 3.2).  
Processing hTCEpi and HaCaT cells for indirect immunofluorescence microscopy 
with the mouse anti-LaNt α31 antibodies revealed diffuse staining throughout the 
cell body, with clustered puncta or short stretches of linear staining toward cell 
peripheries in both cell types (Fig. 3.3A). A similar protein distribution was observed 
in hTCEpi when probed with the previously characterised rabbit polyclonal anti-
LaNt α31 antibodies (Appendix Fig. 3); staining confirmed the presence of discrete 
intracellular puncta, with protein enrichment at the cell peripheries. Consistent with 
knockdown, fewer and less extensive regions of organised staining were observed in 
LaNt α31 knockdown clones compared to scrambled shRNA cells (Fig. 3.3B). 
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3.1 LaNt α31 distribution differs between the corneal, limbal and 
conjunctival epithelium 
 
Next, we sought to determine the distribution of LaNt α31 in the anterior segment 
using immunohistochemistry. Interestingly, this revealed differential distribution of 
LaNt α31 across the surface of the eye.  
In the central cornea, LaNt α31 staining was observed throughout all layers of the 
epithelia (Fig. 3.4A), whereas in the peripheral cornea, limbus and conjunctiva, the 
epithelial LaNt α31 distribution was restricted to the basal and first suprabasal layers 
(Fig. 3.4B; for higher magnification, compare central cornea 3.4C with limbus 3.4D 
and conjunctiva 3.4E). Positive immunoreactivity for LaNt α31 was also observed in 
blood vessels within the limbal stroma (Fig. 3.4F). Despite high similarity between 
the human and pig (Sus scrofa domesticus) LaNt α31 sequence, the precise peptide 
used to generate our new monoclonal antibody is not conserved between species 
(Fig. 3.4I). Therefore, in addition to using isotype-matched control staining, we also 
stained porcine anterior segments as an additional control (Fig. 3.4L).  
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3.2 LaNt α31 knockdown does not affect corneal epithelial cell 
migration characteristics 
 
As a first analysis of LaNt α31 function in corneal epithelial cells, Mr. Lee 
Troughton from our lab performed a simple scratch closure assay, comparing shRNA 
knockdown clones to scrambled shRNA and control hTCEpi (Fig. 3.5A). This 
revealed no significant difference in closure rates in hTCEpi LaNt α31 knockdown 
cells relative to controls (Fig. 3.5B; 85±16% closure in 16h for hTCEpi, 88%±18% 
for scrambled shRNA, 81±17% for LaNt α31 shRNA clone #1, 74±15% for clone 
#2, 82±16% for clone #3).  
In addition, low-density migration assays, where the movement of individual cells 
were tracked over a 2h period (Fig. 3.5C), revealed that the migration speed (Fig. 
3.5D) and the ratio of the linear distance migrated to total distance (processivity,  
Fig. 3.5E) of knockdown clones was not significantly different from controls 
(hTCEpi speed 0.92±0.25 μm/min; processivity 0.39±0.11; scrambled shRNA speed 
0.92±0.34 μm/min, processivity 0.51±0.19; LaNt α31 shRNA clone #1 speed 
1.25±0.35 μm/min, processivity 0.51±0.19; clone #2 speed 0.84±0.34 μm/min, 
processivity 0.41±0.15; clone #3 speed 1.22±0.35 μm/min, processivity 0.45±0.17). 
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3.3 LaNt α31 is not incorporated into the ECM deposited by hTCEpi 
cells 
 
Similar studies using HaCaTs cells were published in 2009, reporting keratinocytes 
as unable to close a wound in-vitro in the presence of LaNt α31 knockdown [461]. 
As the effect of LaNt α31 knockdown in hTCEpi cells does not match that published 
in HaCaTs, we were prompted to investigate more closely the differences in LaNt 
α31 distribution between HaCaTs and hTCEpi cells.  
Staining coverslips where the cells were removed by NH4OH treatment, to leave 
ECM extracts only, revealed that, in HaCaTs cells, LaNt α31 puncta were decorating 
regions of LM β3 (Fig. 3.6, lower panel). However, similar staining was not 
observed when hTCEpi were treated in the same manner, despite a similarly 
extensive LM β3 matrix (Fig. 3.6, upper panel), indicating differences between the 
way the two cell types organise their LaNt 31 protein. This diversity is consistent 
with the distribution of LaNt 31 in the central cornea, where it is expressed 
throughout all corneal layers. 
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3.4 LaNt α31 overexpression leads to an extracellular protein 
deposition 
 
The difference in LaNt α31 distribution between hTCEpi and HaCaTs cells may be 
due either to the possibility that LaNt α31 expressed by hTCEpi cells is not secreted, 
or to an absence of association of the secreted protein with matrix.  
To analyse these aspects, and to mimic in hTCEpi cells a similar LaNt α31 
deposition as in HaCaTs cells, we induced the overexpression of a full-length LaNt 
α31 construct containing the human cytomegalovirus (CMV) promoter, which drives 
high level of constitutive protein expression [494], and a C-terminal eGFP tag (Fig. 
3.7A). The overexpression was induced using an adenoviral expression system [486]. 
hTCEpi overexpressing LaNt α31 will be indicated as +LaNt α31; hTCEpi 
overexpressing GFP (+GFP) or LM β3-mCherry (+LMβ3) were used as controls. 
Transduction efficiency was confirmed by WB of total cell lysates from +LaNt α31 
and controls +GFP or +LM β3 hTCEpi. Anti-GFP mAbs gave a band at the predicted 
molecular weight of ~76 kDa, together with a smaller species at around ~72 kDa, 
likely indicative of removal of the N-terminal secretion signal sequence (Fig. 3.7B). 
Interestingly, imaging of GFP fluorescence indicated that, while the distribution of 
the intracellular LaNt α31-GFP protein resembles the one of the antibody derived 
staining of untreated hTCEpi, LaNt α31-GFP signal was also present in the ECM 
preparations (Fig. 3.7C). This signal also appears to be very similar, though not as 
extensive, to the LM β3-mCherry signal observed in the ECM preparations of doubly 
transduced hTCEpi cells (Fig. 3.7D). 
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3.5 Corneal epithelial cells overexpressing LaNt α31-GFP  
display decreased motility and scratch wound closure rates 
 
LaNt α31 overexpression in hTCEpi led to a protein deposition in the ECM, 
therefore, we decided to exploit the opportunity to use the hTCEpi cell line and 
overexpression system as a tool to investigate the impact of increased LaNt α31 
expression and extracellular accumulation on corneal cell behaviour. As LaNt α31 
has previously been shown to influence cell migration [461], we first investigated 
this using a conventional scratch closure assay.  
In scratch closure assays, +LaNt α31 cells displayed a dramatically reduced ability to 
close wound compared to controls (Fig. 3.8A,B; in 16h, 50±15% closure for +LaNt 
α31 compared to 98±22% closure for hTCEpi, 92±26% for +GFP and 99±36% for 
+LM β3, p<0.01).  
Scratch closure assays, while useful for gaining an overall impression of motility 
behaviour, are unable to identify where the problem leading to delayed closure lies. 
We, therefore, followed up these studies with low-density motility assays, where the 
movement of individual cells was tracked over a 2h period of time (Fig. 3.9A,B). 
Assays of this type are able to distinguish fundamental differences in movement 
versus a failure to establish and maintain polarity. Using this assay, +LaNt α31 
hTCEpi again displayed large reduction in total cell migration speed, significantly 
slower than controls (Fig. 3.9C, +LaNt α31 0.74±0.20 μm/min vs 1.31±0.22 μm/min 
for hTCEpi, 1.20±0.13 μm/min for +GFP and 1.24±0.23 μm/min for +LM β3 
hTCEpi controls, p <0.05). However, there was no difference in processivity, 
measured as the maximum linear distance travelled divided by the total difference 
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travelled (Fig. 3.9D), indicating that the cell polarity is not specifically influenced by 
overexpression of LaNt α31. 
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3.6 Cell-derived preformed ECM rescues the migration impairment 
in hTCEpi cells 
 
To determine whether the cell motility defect of LaNt 31 overexpressing cells was 
caused by a cell fault or by an inadequate matrix assembly, we next investigated 
whether a preformed cell-derived matrix could rescue the defective phenotype 
observed. 
Cell-derived ECMs from either hTCEpi or +LaNt α31 hTCEpi were generated 24h 
after plating at high density on tissue culture plastic. Onto these prepared matrixes, 
fresh hTCEpi or +LaNt α31 cells were plated, allowed to attach for 2h and then 
single cell motility behaviour analysed as above. These analyses revealed that the 
migration speed defect of the +LaNt α31 is rescued by provision of an extensive cell-
derived matrix indicating, therefore, that +LaNt α31 cells abnormal migration is not 
inherent to the cells themselves (Fig. 3.10; in (B), hTCEpi on hTCEpi ECM 
1.15±0.21 μm/min, +LaNt α31 on hTCEpi ECM 1.20±0.28 μm/min). Moreover, 
these studies revealed that the matrix deposited by +LaNt α31 cells plated at high 
density was indistinguishable from non-transduced hTCEpi ECM in terms of 
supporting cell movement (Fig. 3.10; in (B) hTCEpi on +LaNt α31 ECM 1.26±0.20 
μm/min, +LaNt α31 on +LaNt α31 ECM 1.14±0.29 μm/min). 
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3.7 LaNt α31 overexpressing cells show an increase in cell spread 
area 
 
During routine work with the +LaNt α31 cells, we noted an apparent increase in cell 
spread area, potentially indicative of a change in the way the cells interact with their 
matrix (Fig. 3.11A). To analyse this further, the 2D cell area of live individual cells, 
plated at low density on uncoated tissue culture plastic, was analysed using Fiji32-
ImageJ software (NIH). +LaNt α31 cells displayed significantly increased area 
compared to controls (Fig. 3.11B, +LaNt α31 2249±206 µm² vs hTCEpi 839±150 
µm², +GFP 942±185 µm², +LM β3 868±200 µm², p < 0.05). No significant 
differences were observed in length/width aspect ratio, suggesting the absence of any 
polarity defect and consistent with motility data (Fig. 3.11C).  
To determine if the spreading phenotype was a reflection of the changes in the matrix 
organisation induced by the LaNt α31 overexpression, we generated cell-derived 
ECMs from either hTCEpi or +LaNt α31 hTCEpi, 24h after being plated at high 
density on tissue culture plastic. Onto these prepared matrixes, fresh hTCEpi or 
+LaNt α31 cells were plated and cell spread area measured after 2h (Fig 3.12A).  
These analyses revealed that the increased cell spread area of LaNt α31 
overexpressing hTCEpi is not a direct defect of the cells themselves, but rather 
related to cell-matrix interactions, as it can be rescued by provision of a preformed 
matrix (Fig. 3.12B, +LaNt α31 on hTCEpi ECM 1303±282 µm² vs 1180±278 µm² 
hTCEpi on hTCEpi ECM; +LaNt α31 on +LaNt α31 ECM 1194±298 µm² vs 
1266±230 µm² hTCEpi on +LaNt α31 ECM). Furthermore, LaNt α31 overexpressing 
hTCEpi cell polarity was not affected (Fig. 3.12C).   
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3.8 hTCEpi overexpressing LaNt α31 show a decreased attachment 
to LM111 
 
Having observed a change in cell motility and morphology when LaNt α31 is 
overexpressed in hTCEpi, we also used a rapid adhesion assay to determine if the 
protein LaNt α31 has an effect on the cell attachment to different ECM components 
[251, 495]. We performed rapid adhesion assays using hTCEpi, +LaNt α31, +GFP or 
+LM β3 hTCEpi attaching to plates coated with LM111, FN or Col type IV. A 
significant decrease in the hTCEpi cell attachment rate to the LM111 coating was 
observed in +LaNt α31 cells (Fig. 3.13A, 40% less attachment compared to hTCEpi, 
+GFP and +LM β3 cells, p <0.05). Attachment to Col type IV (Fig. 3.13B) and to FN 
(Fig. 3.13C) was not significantly affected by the overexpression of LaNt α31, 
suggesting that LaNt α31 affects hTCEpi cell attachment with a LM-specific 
interaction. 
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3.9 Overexpressed LaNt α31 interacts with and modifies LM332 
organisation in hTCEpi cells 
 
The observed altered cell properties also suggested the possibility that LaNt α31 
overexpression influences the organisational status of LM332 deposited by hTCEpi 
cells. If true, this process could in part explain the increased cell area coupled with 
defective cell motility and adhesion characteristics. To study this aspect, hTCEpi, 
+LaNt α31 or +GFP hTCEpi cells were stained for the LM α3 subunit to compare the 
LM matrix deposited.  
When fixed 5h after seeding onto glass coverslips, control cells deposited arcs and 
contiguous lines of LM β3, whereas +LaNt α31 cells deposited LM β3 in tight and 
small clusters (Fig. 3.14A; average LM β3 cluster area for hTCEpi 236±24 pixel2, for 
+GFP 234±24 pixel2 and for +LaNt α31 79±18 pixel2). However, when cells were 
plated at higher density and allowed 24h to form their matrix, there was no 
significant difference in LM β3 organisational status (Fig. 3.14B right panel, hTCEpi 
274±44 pixel2, +GFP 180±53 pixel2, +LaNt α31 254±47 pixel2). 
These data point to a role for LaNt α31 at times when new matrix is being deposited; 
moreover, they support our cross-matrix motility findings, as they indicate that 
ultimately the matrix assembled by +LaNt α31 is indistinguishable from controls, at 
least as far as LM332 is concerned. 
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3.10 LaNt α31 overexpressing cells display mislocalised focal 
contacts 
 
As described, high levels of LaNt α31 in hTCEpi cells lead to defects in cell 
morphology, motility and adhesion and interfere with LM organisation. A potential 
explanation for the observed results is the presence of differences in the cell-to-
matrix attachment complexes assembled by the +LaNt α31 cells compared to 
controls. Epithelial cells assemble two major integrin-based cell to LM adhesive 
complexes; FAs and HDs [413, 496]. 
To analyse the effect of induced LaNt α31 expression on FAs and HDs, we first 
performed indirect immunofluorescence for the FA protein paxillin and the HD core 
component β4 integrin, 5h after cell seeding [265, 391]. Immunostaining revealed 
that, while paxillin formed discrete puncta in control hTCEpi, in +LaNt α31 cells 
paxillin was assembled into regions of linear staining around cell margins (Fig. 3.15). 
The distribution of β4 integrin revealed swirls and arcs in control cells compared to 
tight clusters in the +LaNt α31 cells (Fig. 3.15). These tight clusters are more 
reminiscent of the “cat paw” staining pattern obtained from tightly adhered cell lines, 
such as the 804G rat bladder epithelial line [483].  
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3.11 LaNt α31 overexpressing cells display early HD maturation 
 
The HD-like structures assembled by cultured epithelial cells develop over time, 
from an initial α6β4 integrin/plectin containing complex to more mature complexes, 
through recruitment of Col type XVII and BPAG1e [497]. We, therefore, 
investigated about the presence of changes in the maturation of HD complexes 
assembled by +LaNt α31 cells when cultured for a short time in a low density, 
conditions where differences in LM organisation had previously been observed.  
Immunofluorescence analysis of the distribution of Col type XVII in relation to β4 
integrin revealed good co-localisation in +LaNt α31 cells, compared with a general 
lack of co-distribution in non-transduced hTCEpi or +GFP hTCEpi (Fig. 3.16, 
Pearson’s co-localisation coefficient for hTCEpi 0.13, for +GFP 0.12, for +LaNt α31 
0.57), suggesting that the HD-like complexes are more mature in +LaNt α31 cells 
than controls. 
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3.12 LaNt α31 co-distributes with LM β3 during matrix deposition 
 
Following the data obtained from the functional assays in the presence of LaNt α31 
overexpression, which point toward a role for LaNt α31 during the initial stages of 
matrix assembly, we next wanted to investigate LaNt α31 dynamics in relation to 
LMs during this period, both when new matrix is required and when cells move on a 
cell-derived matrix.  
First, LaNt α31-GFP and LM β3-mCherry co-expressing hTCEpi cells were seeded 
in a cloning cylinder and imaged shortly after seeding (Fig. 3.17A, movie 1). Over 
the first 3h of this experiment, LM β3 and LaNt α31 were deposited in clusters 
toward cell peripheries (maximum intensity projection shown in Fig. 3.17B). The 
two proteins displayed near identical patterns and we were unable to discern any 
difference in timing of deposition. 
Second, doubly transduced hTCEpi expressing LaNt α31-GFP and LM β3-mCherry 
were plated overnight at low density on uncoated glass-bottomed dishes, then imaged 
using confocal microscopy every 20 min over 12h. Consistent with the motility assay 
data, the movement patterns of individual cells was extremely restricted and did not 
extend beyond the extent of the LM β3 deposits already present at the start of the 
assay. Interestingly, throughout the time course of this experiment, rather than stable 
association with LM β3, the LaNt α31-GFP rapidly formed and dissociated clusters 
at sites of LM β3 deposits (Fig. 3.18A-movie 2, Fig. 3.19A and 3.20A). Although 
individually transient, the LaNt α31 and LM β3 co-distribution is strongly apparent 
when a maximum intensity projection of each frame of the movies is generated (Fig. 
3.18B, 3.19B, 3.20B). 
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3.13 Proximity Ligation Assay reports that LaNt α31 is spatially 
close to LM γ2 chain 
 
To provide finer resolution regarding the potential co-distribution data and the LaNt 
α31-LM specific interaction, we next performed a Proximity Ligation Assay (PLA). 
PLA is a relatively recent technique with the power of detecting single protein 
events, such as protein-protein interactions and/or modifications in tissue and cell 
samples prepared for microscopy [498], with the signal visualised as an individual 
fluorescent dot.  
hTCEpi were, first, processed for indirect immunofluorescence and probed with 
antibodies against LM γ2, β4 integrin or solely the secondary rabbit-Rho or mouse-
FITC conjugated secondary antibodies as controls. This analysis showed that LaNt 
α31 appears to co-localise with LM332 and β4 integrin at the cell periphery (Fig. 
3.21A).  
hTCEpi were, then, processed for in-situ PLA and probed with antibodies against 
LM γ2, β4 integrin or solely the Duolink® secondary probes as controls. The PLA 
showed that LaNt α31 protein is in close proximity to LM γ2 chain (Fig. 3.21B) at 
physiological expression levels. As the theoretical maximum distance between two 
target proteins for the PLA signal to be produced is 40 nm [498], this assay also 
gives us an idea of the LaNt α31 and LM spatial localisation in hTCEpi cells.  
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3.14 LaNt α31 is also spatially close to actinin α4 
Actinin α4 regulates skin cell migration rate via modulation of the main cell-matrix 
adhesion devices [499, 500]. Moreover, Col type XVII may form a complex with 
actinin α4 in keratinocytes, modulating actin dynamics and, therefore, cell movement 
[499]. Having observed an alteration in HDs and FAs when LaNt α31 is 
overexpressed, we decided to analyse the localisation of actinin α4 in relation to 
LaNt α31. Immunofluorescence showed that actinin α4 and LaNt α31 co-localise at 
edge of the cells (Fig. 3.22A) and PLA results revealed a close proximity between 
these two proteins in the same position (Fig. 3.22B). Even if these results are quite 
preliminary, actinin α4 co-localisation with LaNt α31 may suggest, for the latter, the 
function of scaffold for Col type XVII during lamellipodial formation. 
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3.15 LM β3 precipitates along with LaNt α31 
 
In the ECM derived from hTCEpi doubly transduced with the LaNt α31-GFP and 
LM β3-mCherry constructs, the GFP and mCherry signals were largely co-
distributed (Fig. 3.7D), while PLA suggested co-localisation with LM 2 (Fig 
3.21B). To determine whether LaNt α31 and LM β3 associate together into a 
complex, we performed an IP experiment using covalently conjugated anti-GFP 
beads and lysates derived from +LaNt α31 and +GFP hTCEpi. We, then, blotted the 
immunoprecipitated proteins with antibodies against LM β3 and GFP (Fig. 3.23A), 
revealing that LM β3 precipitates along with LaNt α31 only, as it is not pulled down 
with GFP. These data indicate that LM β3 (therefore LM332) and LaNt α31 form a 
complex, either directly or indirectly. 
 
3.16 LaNt α31 is observed in the LM111 polymer fraction in LM 
polymerisation assays 
 
All the described data are consistent with a specific interaction between LaNt α31 
and LM, possibly during early matrix assembly. As the latter starts with a LM 
polymerisation process, and the role of LN domains in the LM matrix assembly is 
well-established [151, 162, 501], we hypothesised a potential for involvement of the 
LaNt α31 α-LN domain during the LM polymerisation. To investigate this 
possibility, we used the well-established LM polymerisation assay [164] that 
involved incubating for 3h at 37C LM111 from EHS tumour, along with CaCl2 or 
EDTA as a negative control. In these experiments, polymerised LM is then pelleted 
by centrifugation and comparison between pellet and supernatant fractions indicates 
level of polymer formed. In our experiment, we added purified recombinant LaNt 
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α31 generated either from pSecTag plasmid (pSec) or V5 plasmid (V5) and purified 
by either affinity chromatography (AC) or gel filtration (GF). 
Silver stain of the insoluble and polymer fractions, separated by SDS PAGE, 
revealed a proportion of LM111 in the pellet fraction in positive control reactions 
(CaCl2, Fig. 3.23B). LM111 polymerisation is reported as being dependent on 
calcium ions [162] and, consistent with this, no band was observed in the EDTA 
pellet (EDTA, Fig 3.23B). Moreover, the polymer fraction appeared increased if 
compared to the insoluble fraction in the presence of LaNt α31, as if LaNt α31 
induces higher proportion of polymer to be formed. Since the polymerisation assay 
was not fully optimised, we cannot assume this hypothesis to be true; nevertheless, 
what was very clear is the presence, within the LM polymer fraction of the +LaNt 
31 lanes, of a band of ~50-60 kDa, consistent with molecular weight of LaNt α31, 
suggesting the latter to associate with the LM111 polymer (Fig. 3.23B).  
  
152 
 
  
 
153 
 
3.17 Exogenously added LaNt α31 influences the ability of hTCEpi 
to attach to LM111 
 
According to the polymerisation assay results, LaNt α31 protein may interact with 
laminin during the polymer formation steps. Laminin polymerisation is an essential 
process for the formation of a functional BM [502]; therefore, we wanted to 
determine whether hTCEpi cell adhesion to LM111 or FN was compromised in the 
presence of exogenously added LaNt α31. To do so, we used the rapid cell 
attachment assay described in section 2.1.10. LaNt α31 was added to the LM111 or 
collagen type IV coating solutions at either 0.02 μg/ml or 0.1 μg/ml, together with 1 
mM CaCl2 or EDTA, and FN was used as a positive control at a concentration of 10 
μg/ml. A significant decrease in the hTCEpi cell attachment to LM111 + CaCl₂ 
coating was observed with the exogenous addition of LaNt α31 0.1 µg/ml (Fig. 
3.24A, 30% less attachment, p <0.05, compared to LM111 in absence of LaNt α31). 
Moreover, cell attachment to LM111 was reduced in the presence of EDTA (Fig. 
3.24B, 20% less attachment, p <0.05, compared to the presence of CaCl2) but not 
when exogenous LaNt α31 was added to the coating solution (Fig. 3.24B). 
Attachment rate of cells to collagen type IV was not affected (Fig. 3.24C). These 
data indicate a laminin and calcium specific inhibition of cell adhesion. 
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3.18 Exogenously added netrin 1 or 4 do not affect hTCEpi 
attachment to LM111  
 
The LaNt structure, characterised by a LM N-terminal domain followed by a short 
stretch of LM-EGF repeats, resembles that of the netrins, proteins involved in the 
axonal guidance cues [503]. Previously shown rapid attachment assays revealed a 
decrease in hTCEpi adhesion to LM111 in the presence of exogenous LaNt α31, 0.1 
μg/ml.  As LaNts and netrins are structurally related, we also wanted to study any 
possible effect on cell attachment due to interactions between ECM proteins and key 
netrins 1 and 4. Rapid adhesion assays were set up as previously described and  
revealed that hTCEpi cell attachment to LM111 is not affected by the presence of 
exogenously added netrin 1 or netrin 4, either 0.02 μg/ml or 0.1 μg/ml (Fig. 3.25), 
strengthening the already hypothesised LaNt α31-laminin specific interaction. 
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3.19 LaNt α31 overexpression effects on pCEC cells behaviour 
mirror those observed in hTCEpi 
 
The results described so far highlight a very interesting modulatory role for LaNt α31 
in corneal epithelial cell behaviour. However, all the data were obtained using an 
immortalised cell line. We, therefore, wanted to confirm some of our key findings in 
directly isolated primary corneal keratinocytes (pCEC) isolated from human limbal 
explants according to a slightly modified version of a previously published protocol 
[504]. 
First, isolated pCEC cells were characterised using the corneal marker Keratin 12 
(Appendix, fig.4), to exclude contamination with fibroblasts or other cell types 
derived from the human explants [227, 505]. Next, we analysed the morphology of 
wild type compared to adenovirally transduced to overexpress LaNt α31 (+LaNt α31) 
or GFP (+GFP) pCEC cells (Fig. 3.26A). As for hTCEpi, +LaNt α31 pCECs 
displayed significantly increased 2D area compared to controls (Fig. 3.26B, +LaNt 
α31 2716±720 µm² vs pCEC 1232±377 µm² and +GFP 1277±283 µm², p < 0.05), 
whereas no difference was observed in cell aspect ratio (Fig. 3.26C).  
pCEC cells were also used to perform low-density motility assays (Fig. 3.27A,B). 
Again, these assays showed that +LaNt α31 pCECs are characterised by a decreased 
migration speed compared to controls (Fig. 3.27C, +LaNt α31 0.46 ±0.14 μm/min vs 
pCEC 0.91±0.14 μm/min and +GFP 0.77±0.04 μm/min, average values for all the 
donors, p< 0.05) whereas no difference was observed in cell processivity (Fig. 
3.27D).  
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Laminin organisational studies confirmed the presence of an alteration in laminin 
pattern deposition when cells are seeded at low density for a short period of time 
(Fig. 3.28A). pCEC, +LaNt α31 and +GFP pCEC cells, seeded at low density for 5h, 
displayed a tighter LM β3 cluster area (Fig. 3.28B, +LaNt α31 101±32 μm/min vs 
pCEC 233±86 μm/min and +GFP 238±133 μm/min) than when seeded at high 
density for 24h (Fig. 3.28B, +LaNt α31 352±132 μm/min vs pCEC 357±158 μm/min 
and +GFP 358±145 μm/min). Results showed no differences in pCEC cells 
characteristics and behaviour compared to the hTCEpi cell line. Together, these data 
support the reliability of our findings in hTCEpi cells as being truly reflective of 
limbal-derived corneal cell behaviour.  
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DISCUSSION 
3a.0 hTCEpi functional assays data summary 
 
The results presented in this chapter support a regulatory role for the laminin-derived 
protein LaNt α31 on corneal epithelial cell behaviour. Specifically, these data 
demonstrate that hTCEpi or pCEC cells overexpressing LaNt α31 show impairment 
in cell motility, spreading and attachment to LM111 compared to controls. 
Furthermore, LaNt α31 overexpressing hTCEpi are characterised by mislocalisation 
of focal adhesion’s proteins, an early maturation of hemidesmosomes and by forming 
a matrix with laminin organisational changes. Live analysis of protein deposition 
indicate that LaNt α31 is deposited alongside LM β3; PLA results give further 
support to this idea, showing that they are in close proximity, and IP studies 
demonstrate that LaNt α31 and LM β3 are capable of associating into a complex.  
There could be several interpretations of the described results, and I will address 
them in turn. 
 
Interpretation 1. LaNt α31 influences LM network assembly 
 
The major structural feature of the LaNt α31 protein, in terms of conserved domains, 
is the LN domain, a region well-established as being the structural domain involved 
in LM-to-LM interaction and LM polymerisation [162]. Our data support a model 
where LaNt α31 binding to LMs influences the assembly and interactions of the LMs 
themselves in the corneal epithelial ECM, resulting in the observed functional effects 
[153, 162, 164, 506].  
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LM polymerisation happens in a two-step process: first β and γ LN domains interact 
to form a relatively short-lived and unstable βγ dimer, second the α LN domain is 
incorporated in a slower, calcium-dependent manner to form a more stable αβγ 
ternary node of three LN domains [146, 507]. The presence of an α-chain LN domain 
in LaNt α31 could either stabilise transient βγ LN interactions or compete for binding 
sites where αβγ interactions are occurring, depending on when the LaNt α31 was 
added, which other LN domains were present and how they were assembled at that 
time. Therefore, LaNt α31 effects would depend on the interaction status of LMs in 
the matrix and on which LMs are present, in terms of how many LN domains they 
have.  
Taking the adhesion assays to LM111 first, our data show that, when hTCEpi cells 
overexpressing LaNt α31 are exposed to a LM111 coating, their adhesion decreases 
compared to controls. In these assays, the LM111 coating was prepared in conditions 
that support LM polymerisation, so this result suggests that competition could exist 
between LaNt α31 α-LN domain and the α1 chain-LN domain in the assembled 
network, which would cause disruption of the formed ECM. The hypothesis of LM 
network status influencing cell behaviour is supported by studies using polyLM, a 
biomimetic polymerised LM assembled on pH acidification; rat retinal cells exhibit 
normal spreading and neurite outgrowth when cultured on polyLM as opposed to 
non-polymerised LM, which instead induced cell clustering [508].  
The assays where LaNt α31 was exogenously added also displayed LM specific 
effects. In this case, taking the in-vitro polymerisation and adhesion data together, 
there may be a slightly different interpretation.  Our data show that, when LM111 is 
incubated with LaNt α31, the LaNt is observed in the LM111 polymer fraction, 
suggesting LaNt α31 as part of the LM polymer. It should be noted that this assay is 
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quite crude, in that the “polymer” fraction may actually be an unstructured aggregate 
rather than a true polymer. Our adhesion data show decreased adhesion to the 
LM111 in the presence of LaNt α31, suggesting that the “polymer” formed is inferior 
as a substrate; again, this is in keeping with the data showing LM network assembly 
status influences cell behaviour.  
Our data showing LaNt α31 incorporation into the LM111 polymer fraction was, 
actually, somewhat surprising. Previous data analysing netrin 4 in a similar 
experiment, demonstrated that rather than be incorporated into the polymer, the 
netrin 4 addition led to inhibition of LM111 polymerisation [471]. Moreover, netrin 
4, due to its nanomolar binding to the LM γ1 chain, not only blocks LM 
polymerisation but also disrupts pre-existing LM network [474]. As LaNt α31 and 
netrin 4 are characterised by a very similar structure (LN domain followed by LE 
repeats), we might expect LaNt α31 to have the same effect as netrin 4. Beside our 
polymerisation assay data, the presence of exogenously added netrin 1 or 4 does not 
affect hTCEpi attachment to LM111, suggesting that LaNt α31 and netrins act 
differently.  
Most of the cell work within this chapter has been carried out using hTCEpi, a 
limbal-derived corneal epithelial cell line. The corneal BM is characterised by a 
LM332-rich matrix, with small amounts of LM511 [53, 226, 231, 509, 510]. Unlike 
LM111, LM332 only contains a single LN domain on the β3 chain and 
polymerisation assay data show that LM332 does not self-polymerise or co-
aggregate with LM111 [164]. Nevertheless, LM332-rich BMs function properly; 
perhaps, the presence of small amounts of LM α5, β1, and γ1 chains in corneal 
epithelia is sufficient to establish a weak interaction [226, 231] which could be, then, 
either stabilised or strengthened by the LaNt α31 α LN domain. It would be, at this 
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point, particularly interesting to study the interaction between LaNt α31 and LMs 
other than LM332, to better understand weather the LaNt α LN domain specifically 
interacts with LM332 only or can associate with different LM isoforms.  
Numerous studies support the hypothesis that structural alterations of LM332 in the 
BM lead to defective cell adhesion and migration. It has been reported that primary 
keratinocytes, isolated from Herlitz JEB patients, show a significantly reduced cell-
substrate adhesion and impaired migratory efficiency due to LM332 mutations [511] 
and a targeted disruption of LM332 in mouse keratinocytes blocks cell adhesion and 
inhibits migration of keratinocytes in response to EGF [512]. As with our data 
demonstrating rescue of the LaNt overexpressing cell phenotype by preformed 
matrix, it has been described that Herlitz JEB keratinocytes, which do not produce 
LM332, are able to adhere and migrate normally on exogenously supplied LM332 
[513]. Moreover, our data demonstrate no major issues within the cellular motility 
machinery in overexpressing cells, supporting the premise that it is in the matrix 
assembly steps where the problem lies, rather than either in the cells or the matrix (at 
least in terms of heavily plated cells) themselves. 
Specifically looking at the matrix deposited by LaNt α31 overexpressing cells, our 
data show that, 5h after seeding, hTCEpi cells deposit LM332 in tight clusters. 
Numerous studies indicate that LM deposition is modulated by cell-surface receptors, 
including integrins α3β1 [417, 514] and α6β4 [353]; the potential roles for these 
interactions in the observed phenotype will be described below.  
Questions remain as to why the cell motility and LM organisation defects are rescued 
on a fully formed matrix. The answer may simply be that the relatively increased LM 
coverage, derived from the increased cell density, masks any organisational 
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difference and provides a suitably extensive network to support normal migration. 
Consistent with a masking effect, it has been shown in epidermal keratinocytes with 
different colour tagged-LMs, that when cells are presented with a preformed, cell-
derived matrix they adhere to and use that matrix rather than elaborate their own 
[486]. The masking of organisational differences may be exacerbated by our 
experiments being performed on glass or tissue culture plastic, where the LM is 
directly adsorbed onto the substrate and, therefore, any influence on preformed LM 
networks is minimised. Future in-vivo studies and use of 3D tissue equivalent models 
will help to address these questions. 
Interpretation 1 is summarised in the following schematic diagram: 
 
 
 
 
 
 
 
Interpretation 2. LaNt α31-cell surface receptor interactions affect 
matrix assembly  
 
An alternate hypothesis that can be supported by the data is that, rather than the LaNt 
α31 directly competing for or stabilising LN-LN domain interactions, it instead 
indirectly influences these interactions by competing for LM receptor binding sites. 
This hypothesis is based on a number of studies that demonstrated binding to cell 
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surface receptors is a necessary first step for LM111 polymerisation and matrix 
formation in breast epithelial and ES cells, and for LM211 deposition and assembly 
in Schwann cells [157, 158, 515-519].  
The strongest receptor binding sites in LMs are located in the LG domains [520], 
however cell surface receptor binding capabilities have been described for some LN 
domains as well, including LM α3b [148, 149, 521, 522]. In this model, when 
initially deposited and, therefore, at low concentration, LMs are orientated parallel to 
the bottom of the cell, with both the LN and LG domains interacting with surface 
receptors. As the LM concentration increases over time, the LG domains’ superior 
receptor affinities outcompete the LN domains, in turn driving reorientation of the 
LM and tighter clustering of the receptors (Fig. 3.29), which ultimately support 
activities such as HD assembly. Moreover, the reorientation of the LMs would 
position the LN domains into close proximity, and at sufficiently high local 
concentration, to allow LN-LN interactions to begin.  
 
 
Fig. 3.29: LM LG and LN domains may compete for receptor binding sites on 
the base of the LM density in the ECM. 
Schematic diagram showing the possible competition between LM LG domain and 
LM LN domain for integrin binding.  
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Within this model, when overexpressed in hTCEpi cells, LaNt α31 would compete 
with LN domain interactions for receptor binding, meaning earlier reorientation of 
the LM332, potentially earlier receptor and LM cluster formation and, therefore, 
earlier HD assembly/maturation, all of which fit our observations.  
In addition, as LM332 density increases, the LG domains would outcompete the 
LaNt α LN domain-receptor interactions. On this basis, once sufficiently high 
LM332 density is reached, there would be no appreciable difference between the 
matrixes assembled by normal and LaNt overexpressing cells, as summarised in the 
following schematic diagram. 
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This is exactly what we observed in the high cell density, longer attachment 
experiments and it is consistent with the motility defects’ rescue observed after 
supplying hTCEpi with a preformed cell-derived ECM. 
It is possible that both interpretations 1 and 2 are contributing. Our live experiments 
demonstrate that LaNt α31 and LM β3, as far as we can resolve, are deposited 
together, both spatially and temporally, suggesting their initial assembly points are 
close together rather than the two proteins being independently secreted and 
subsequently organised. Moreover, the in-vitro polymerisation data support a direct 
influence of LaNt 31 on LM111 polymerisation that is not dependent on surface 
receptors. Determining whether LaNt α31 is exerting its effect through LN network 
nucleation, via a more general stabilisation of LN interactions or a combination of 
both mechanisms are complex questions, which will form an interesting future 
research direction. Specifically, it would be novel to induce the overexpression of the 
two proteins using a photo-switchable fluorescent probe, enabling the use of super-
resolution microscopy imaging to clarify the proteins deposition time, proximity and 
at which point the LaNt α31 binds to and stabilises nascent LN-LN interactions.  
If the LaNts bind to cell surface receptors, an important next step is to identify which 
receptors are involved and their relative binding affinities. Of course, if LaNt do bind 
to receptors, the observed phenotypic effects could be directly due to these 
interactions and this will be discussed in the interpretation 3. 
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Interpretation 3. Cell phenotypes are dependent on LaNt α31 
affecting FAs and HDs assembly  
 
We have described that hTCEpi overexpressing LaNt α31 present with 
mislocalisation of FAs and premature HDs maturation, in the form of early Col type 
XVII recruitment. Changes to FAs and HDs are intimately associated with the other 
aspects of the observed cellular phenotype, adhesion and migration; therefore, it is 
tempting to speculate that the observed cell behaviour is due to LaNt α31 effects on 
these two critical cell-matrix adhesive devices. These effects could be indirect, via 
the matrix changes described above, or direct, on components of either complexes. I 
will consider each of these scenarios in turn. 
 
LaNt α31 indirect effect on HDs / FAs  
 
The LM organisational changes, observed in the LaNt α31 overexpressing cells, 
could explain the differences observed in HDs maturation and FAs localisation. 
Previously, it has been shown that the human epidermal carcinoma line SCC12, 
which normally does not assemble HDs in vitro, assemble mature HDs when 
cultured on 804G cell-derived matrix [483]. It has also been reported that the 
recruitment of different FA components changes according to how cells adhere to 
LM111 or LM332 [452]. A very interesting study revealed that disruption, removal 
or inhibition of LM332 disrupts the LM332-integrin-CD151-FAK network, affecting 
the human ErbB2+ breast cancer cells’ drug sensitivity [523]. Therefore, it would not 
be surprising for the altered LM pattern observed in LaNt 31 overexpressing cells 
to be the driving force behind both the FAs and HDs changes; put simply, if you 
change the LMs, you change the LM-receptor complexes. 
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LaNt α31 direct effect on HDs  
 
To have a direct effect on HD assembly/localisation and maturation, LaNt α31 would 
need to be capable of directly binding one or more of the HD components. Although 
we have not extensively tested this hypothesis in the course of these studies, some of 
our data combined with published work suggest this could be a possibility. 
As already mentioned before, it is predicted that LaNts resemble netrin proteins 
[461] and this similarity could lead one to believe that, in some circumstances, they 
also share some roles. Previously published studies revealed that netrin 1 is able to 
interact with α6β4 integrin in developing pancreatic epithelium, regulating pancreatic 
epithelial cell adhesion and migration [466], and that netrin 4 can bind directly to β4 
integrin [469]. α6β4 integrin is one of the core components of HDs and play a critical 
role for HD assembly [524]. Indeed, α6β4 integrin-LM332 association triggers HD 
assembly, as has been demonstrated in several published studies [290, 302, 303, 305-
307, 524, 525]. Our live imaging data of LaNt α31 distribution, which identified 
clustering that resembles HD-like complexes, may support this hypothesis. 
Considering these data, LaNt α31 may also directly bind α6β4 integrin and nucleate 
HD assembly, hypothesis supported by peptides studies demonstrating that specific 
regions of LM 3b LN domain can support cell adhesion directly. 
How could LaNt α31/β4 integrin binding lead to early recruitment of Col type XVII? 
A hypothesis may be that LaNt α31, by binding to α6β4 integrin, induces a 
conformational change of the latter, which, then, allows association with other HD 
components. In simple terms, this could purely be receptor occupancy/ligand density; 
the Col type XVII recruitment is early rather than impaired. The cytoplasmic domain 
of Col type XVII interacts, among other ligands, with plectin, β4 [323, 335, 526] and 
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α6 integrins [355, 486]; the early recruitment of Col type XVII observed in our study 
may therefore reflect the alteration of the HD assembly timing and, potentially, of the 
HD components localisation. It would be interesting to use live imaging to analyse 
HD maturation in real time. 
The observed changes to HDs could explain most of the other phenotypic 
observations, with the exception of the cross-matrix motility assays. In cultured 
epithelial cells, HD maturation leads to a decrease in cell motility [237]. This study 
has elucidated the ability, for epithelial cells, to regulate their own behaviour via 
inducing changes in their own ECM; by activating an enzymatic pathway, LM332 
proteolysis is triggered [237], which then causes HD nucleation and maturation 
[527].    
Col type XVII has also been shown to regulate keratinocyte lamellipodial formation 
by promoting association between BPAG1e and α6β4 integrin [355], inducing actin 
remodelling via Rac regulation [355, 500]. However, cells with defects in HD 
proteins show motility defects related to steering rather than speed, which suggest 
that the defects observed here are not purely down to HD-related problems.  
Despite the apparently solid rationale behind this interpretation of our data one piece 
of evidence suggests it is unlikely to hold the answer; our PLA experiments suggest 
that very little, if any, LaNt 31 is close to β4 integrin. It should be noted that these 
data represent a snapshot; the PLA is only effectively measured at the time point 
when we processed the images and our live experiments suggest that interactions, if 
they occur, are transient. It would, therefore, be interesting to generate a 
Fluorescence Resonance Energy Transfer (FRET) donor/acceptor pair and perform 
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live imaging to determine proximity in real time, at different stages of the HD 
assembly process.  
 
LaNt α31 direct effect on FAs  
 
In addition to HDs, FAs complexes provide additional cell to LM interaction points 
and are usually the first matrix attachment points to assemble. Again, the structural 
similarity between LaNts and netrins may be important to explain the decreased 
hTCEpi cell motility and the mislocalised FAs observed in our study. Netrin 1 has 
been shown to bind α3β1 integrin, a key FA component on cells attached to LM332 
[466], therefore LaNt α31 may be involved in defining FAs localisation/assembly 
through similar mechanisms as outlined for the HDs. 
Many FAs and HDs components share binding sites or localisation; plectin, for 
instance, may mediate communication between FAs and HDs [528]. It has been 
shown that HD perturbation affects FA size and movement during re-epithelialisation 
[529], and it is now known that HDs and FAs’ functions can couple and/or interfere, 
as shown in different types of skin diseases[260]. This means that a FAs and HDs 
crosstalk may be happening, masking the LaNt α31 to LM direct binding. 
 
LaNt α31 indirect effect on FAs and HDs via actinin α4 interaction 
 
Our PLA data indicate that LaNt α31 is in close proximity (theoretical maximum 
distance between epitopes = 40nm, [498]) with actinin α4, one of the four actin 
cross-linking protein isoforms belonging to the spectrin superfamily [425]. It has 
been presented that actinin α4 localises throughout the lamellipodium [447] and 
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regulates epithelial cell motility [499]. Furthermore, in cell-cell contacts, actinin α4 
interacts with the cytoplasmic domain of Col type XVII [429] and is part of the FAs, 
where it interacts with β1 integrin [530]. At FAs, actinin α4 links integrin β1 to actin 
[430], but it also interacts with several FA proteins, playing a central role in both FA 
organisation and signalling [531-533]. If LaNt α31 interacts with actinin α4 or 
actinin α4 normal function is disrupted by LaNt α31 binding to integrin β1, the FA 
complex or the lamellipodia assembly will be impaired, explaining the 
mislocalisation observed in our study and, potentially, the LM organisation and cell 
phenotypes.  
It has been reported that, in response to binding interactions with actin-associated 
cytoskeletal proteins, such as α actinin or paxillin, different integrins cluster and 
become immobilised within FA complexes [534]. When such a clustered binding 
between ECM, integrins and actin happens, cell adhesion becomes locally stable 
[535] [536]; this may explain why, in LaNt α31 overexpressing hTCEpi cells, LM 
appears to be aggregated and enriched in little clumps. Further analyses on the 
interaction between LaNt α31 and actinin α4, perhaps using IP, label transfer or 
biophysical approaches like Surface Plasmon Resonance (SPR) or FRET will be 
extremely useful to explore this aspect. 
Interpretation 3 is summarised in the following schematic diagram; 
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Interpretation 4. LaNt α31 overexpression induces GF release in the 
extracellular environment 
 
In addition to other functions, the ECM also serves as a reservoir for GFs [537]; the 
matrix disruption induced by LaNt α31 overexpression could impact the “store and 
release” dynamics of the GFs reservoir, by altering either the ways in which GFs are 
stored, the amount of GFs sequestered or their release rate from the ECM. This is 
highly speculative, but could explain the phenotypes observed and would be a very 
interesting aspect to be investigated in the future. 
Many GFs interact directly with ECM components, which, in turn, dictate cellular 
responses. For instance, GFs–ECM binding is required for FGF-2 signalling and 
happens via interaction with HSPGs [538]. In the lens epithelial cells, FGF-2 has 
been reported to bind to PLC [539, 540]; as PLC binds to LMs in the BM, a LaNt 
α31-induced LM network disruption could cause FGF-2 to be released. It has also 
been shown that lens epithelial cell proliferation and differentiation are FGF-
concentration dependent processes [541], which, therefore, suggest the cell functions 
to be altered if GF release is not controlled.  
LM disruption could also induce the release of GFs such as morphogens [542], 
which modulates cell adhesion via enabling traction forces between the cells and the 
matrix [543]. Furthermore, when these traction-activating adhesion morphogens are 
released in the extracellular environment, they induce a change in the stiffness and 
elastic properties of the matrix itself, changes that will affect cell phenotypes, well-
established as influenced by the stiffness of the cell substrate [544].  
Among the ECM-bound GFs, very important in our scenario is EGF and its 
interaction with the EGF receptor (EGFR). EGFR, in theory, could be directly bound 
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to LMs via their EGF-like domains, as shown for the LE domains in the γ2 LM 
[249]. When activated, EGFR stimulates the activation of several downstream 
signalling pathways, which regulate cell migration, adhesion and proliferation [545, 
546]. If LaNt α31 is disrupting the LM network, more EGF may be released and, 
therefore, there will be less of it stored by the matrix, leading to changes in cell 
behaviour. Up to now, we have largely ignored the other structural feature of the 
LaNts, the LE repeats. This is because data from the Sasaki and Hohenester groups 
have shown that these regions are required to stabilise the fold of the LN domain, 
rather than being functional as signalling entities [146, 148]. Unpublished data from 
our lab show that EGFR distribution across the anterior segment almost precisely 
mirrors that of LaNt α31, therefore the proteins are in the appropriate location to 
interact and it may be possible, for the EGFR activity, to be modulated by the 
presence of LaNt α31 in the ECM. Again, at this point, this is only a speculation; 
additional experiments, such as IPs or direct binding assays as well as activity assays, 
are needed to further investigate the possibility of an interaction between EGFR and 
LaNt α31. 
An additional aspect to be considered is the potential crosstalk between integrins and 
GF released from the ECM when LaNt α31 is overexpressed. Many of the signalling 
pathways activated by integrins may also be activated after GF stimulation and these 
molecules could, synergically, coordinate biochemical responses in multiple cell 
types [293, 547]. In human breast carcinoma cells [548], the association of α6β4 and 
α6β1 integrins with ErbB-2 receptor, which belongs to the EGFR family and has 
tyrosine kinase activity, represents one example of GF receptor - integrin crosstalk, 
particularly interesting for our findings.  
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Interpretation 4 is summarised in the following schematic diagram; 
 
 
 
 
 
 
 
 
My opinion  
 
Despite the description of multiple potential hypotheses, I believe the most likely 
interpretation for our data is that the observed effects are due to a LaNt α31 direct 
effect on LMs, which is then reflected by changes to HD and FA organisation. 
Supporting this interpretation, our live imaging data show that the LaNt α31 
containing clusters are more transient than what described for HDs [261, 355, 495, 
499]. Furthermore, we were able to rescue the LaNt α31 overexpressing hTCEpi 
phenotype through provision of a preformed cell-derived matrix, suggesting the 
increased LaNt α31 levels do not directly negatively influence cell-matrix 
interactions. Last but not least, the HD-like complexes assembled by LaNt α31 
overexpressing cells appear more mature in terms of recruitment of collagen type 
XVII, suggesting assembly occurs more effectively rather than being impaired [497]. 
The organisational state of LM332 specifies cellular migration patterns[353, 461]; 
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indeed, WT skin keratinocytes deposit LM332 in linear tracks and migrate normally, 
while JEB patient cells deposit LM332 in small circular arrays, which reflect their 
defective BM assembly and restricted migration [353]. This phenotype is markedly 
different from the tight clusters we observe in LaNt 31 overexpressing corneal 
cells. Overall, I think the weight of evidence in this “chicken or egg” scenario is 
leaning toward the matrix changes being the driving force behind all the other 
observed differences. 
 
 
 
Open Questions 
 
The functional data, although the major focus of this work, still leaves an open 
question; why is LaNt 31 deposited from HaCaT cells into the BM of the skin, but 
retained within cultured corneal epithelial cells and in tissue sections? This was 
interesting and surprising to discover. It is possibly that, in hTCEpi cultured cells, 
LaNt α31 is secreted but does not efficiently associate with the ECM, due to the 
lower calcium concentration in their media compared to HaCaTs (0.15 mM vs 2 
mM), as calcium concentration mediates LN domain interactions. It would be 
interesting to deepen this aspect, perhaps by comparing hTCEpi conditioned media 
to that from HaCaTs and blotting for LaNt α31 to determine if secretion rates are 
similar. We could perform calcium switch experiments to determine if we culturing 
hTCEpi in high calcium conditions will increase the LaNt α31-ECM association. 
It should also be noted that some proteins can localise both intracellular and 
extracellular, and can function in different ways on the base of their position [549]. A 
possible reason behind this is that the protein can coordinate the organisation and 
179 
 
maintenance of a global tissue function. There are data supporting the independent 
secretion of LM  chains only, whereas the β and γ chains cannot be secreted as 
monomers and remain intracellular [184]. This may, therefore, indicate ECM 
coordination exerted by LMs. Other examples are given by HMGB1 [550] and TTG 
proteins, both of which act in a different way if secreted in the cytoplasm or retained 
inside the cell [551]. May, therefore, be that LaNt α31 can be secreted or not secreted 
on the base of the function it has to play? These are open questions and will be 
interesting subjects for future investigations. 
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                                                                       In-vivo RESULTS 
 
      LaNt α31 OVEREXPRESSION INDUCES A LOW 
OFFSPRING NUMBER IN-VIVO 
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Introduction 
 
The data obtained from our in-vitro work suggested a very novel and interesting role 
for LaNt α31 in corneal epithelium, and highlighted a specific interaction between 
LaNt α31 and LMs. We, therefore, decided to create a LaNt α31 overexpressing 
animal model to evaluate any LaNt α31-induced effect in-vivo. 
This chapter describes the characteristics of the DNA construct injected in the mouse 
embryos and contains the preliminary data obtained from LaNt α31 overexpression 
analyses, using tissue samples collected from our animal model.  
 
4.0 Construct features 
4.0.1 Human keratin 14 and its promoter 
 
Human Keratin 14 (hK14), encoded by the KRT14 gene, belongs to the type I acidic 
keratins [552] and is one of the major proteins expressed in mitotically active basal 
layer cells of skin, together with Keratin 5 (K5) [553]. Early studies revealed that 
hK14 mRNA is restricted to proliferative cells [554]; as basal cells [555] 
differentiate, they downregulate transcription of both K5 and K14, inducing new sets 
of differentiation-specific keratins [553].  
The tissue specificity of hK14 is made possible by a 2.2 kb promoter segment [491], 
previously used to engineer mice for conditional inducible-knockout technology, 
driving transgene expression in the skin [556], or to gain insights into hair growth 
regulation [557] as hK14 promoter maintains its activity in adult skin, in-vitro and 
in-vivo, and is strongly active in cultured cells [558]. In addition to being highly 
expressed in skin, hK14 promoter has also been shown to be present in the epithelia 
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of tongue, mouth, forestomach, trachea, thymus and respiratory and urinary tracts 
[557].   
During development in mouse, K14 promoter drives protein expression as early as 
E10 in the skin [559], with an optimal expression observed at E14 in the ocular 
surface epithelium [560, 561]. With regards to the eye, in the developing human 
cornea, hK14 promoter is highly expressed in the superficial epithelia between 8 and 
10 weeks of gestation; at about 12 weeks of gestation it is extensively present in 
suprabasal and superficial cells [562].  At 20 weeks of gestation, the limbal 
epithelium was shown to express K14, which then progressively faded to be finally 
restricted to basal epithelia in the neonatal cornea [562].    
In our study, the choice of using hK14 promoter to drive LaNt α31 overexpression 
in-vivo was based on the broad expression of this promoter in different epithelial 
types and, therefore, on the possibility to maximise LaNt α31 overexpression in the 
animal models whilst at the same time not globally expressing the transgene as this 
could be problematic in terms of animal viability and interpretation of obtained data.  
 
4.0.2 Thosea asigna virus-derived 2A peptide sequence (T2A) 
 
The Thosea Asigna virus-derived 2A peptide (T2A), with the sequence 
EGRGSLLTCGDVEENPGP [563], has also been included in our DNA construct. 
Linking a protein to T2A, or T2A-like peptide sequences, means a cellular 
expression of multiple proteins (in essentially equimolar quantities) derived from the 
same promoter [564], with a continuous translation of  the proteins ensured by a 
ribosomal “skipping” mechanism, an alternate type of translation which prevents the 
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ribosome from forming a peptide bond between the C-terminal Gly of the 2A 
sequence and the N-terminal Pro of the downstream peptide, allowing it to 
continuously translate [565] [566].   
 
4.0.3 Murine Immonoglobulin (Ig) kappa (κ) chain secretory leader 
sequence (IgK leader sequence) 
 
The efficiency of protein secretion is known to be strongly affected by the signal 
peptide [567, 568]. In our DNA construct, we decided to include the murine IgK 
light-chain sequence METDTLLLWVLLLWVPGSTGDJ [569],  because it is known 
to direct the protein fused to its N-terminus to the secretory pathway [570] allowing 
secretion. Therefore, the presence of the IgK leader sequence gave us a maximised 
chance of LaNt α31 secretion. In this model, we wanted to study the effect of LaNt 
α31 overexpression on BM assembly, so limiting the likelihood of having a large 
build-up of the overexpressed protein within expressing cells was highly desirable.  
 
4.0.4 Myc and 6xHis tags 
 
LaNt α31 encoding transcript cloned into the final vector used for embryonic 
injection was fused to different protein tags, peptide sequences usually attached to 
recombinant proteins to allow expression analysis or purification of the protein 
themselves [571].  We included the Myc tag, derived from the c-myc gene, and the 
6xHis tag, consisting of six His residues. Both these protein sequences can be used to 
study the characteristics of the protein they are linked to, as they can be targeted 
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using well characterised antibodies. We included these tags to ease detection of the 
transgene in mouse tissue and provide flexibility for downstream applications. 
 
4.0.5 mCherry fluorophore 
 
mCherry is a monomeric fluorescent protein with a peak of absorption and emission 
at 587 nm and 610 nm respectively, used as a marker when tagged to proteins and 
which derives from a protein isolated from Discosoma sp. [572]. In our study, we 
decided to include mCherry in the DNA construct to ensure the possibility of protein 
expression analysis on embryos and tissues, as well as in live animals. Moreover, 
mCherry is resistant to photobleaching, is very stable and it matures quickly, 
allowing the signal visualisation soon after translation [573]. Here, the mCherry was 
added downstream of the T2A sequence, therefore the mCherry expression would 
indicate cells where the construct is active rather than directly tagging the protein.
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4.1 LaNt α31 overexpressing mouse model construct generation 
Different sequential cloning steps were performed to prepare a hK14 promoter-
driven LaNt α31 overexpression DNA construct. The following table and Fig. 4.1 
summarise each step. 
 
Cloning experiment name Plasmid obtained 
Cloning Step 1 pGEM®-5Zf(+) - LaNt α31 plasmid 
Cloning Step 2 pUBCmCherry-hK14 promoter 
plasmid 
Cloning Step 3 pUBCmCherry-hK14 promoter- 
LaNt α31 plasmid 
 
Table 6: Summary of the DNA cloning steps performed to prepare the hK14 
promoter driven-LaNt α31 overexpressing construct.  
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4.1.0 Cloning Step 1 
 
Full-length LaNt α31 was cloned into pSecTag (Thermo Fisher Scientific) by Dr. 
Kevin Hamill (unpublished). This plasmid introduces sequences encoding the IgK-
chain leader at the 5’ end, and Myc and 6xHis epitopes at the 3’ end (Fig. 4.2A). The 
complete construct, including 5’ and 3’ tags was excised with NheI high fidelity and 
PmeI (New England Biolabs) and cloned into pGEM®-5Zf(+) cloning vector 
(3000bp, Promega, Wisconsin, USA) linearised with SacI high fidelity (New 
England Biolabs) (Fig. 4.2B). Correct orientation of LaNt α31 was verified by 
restriction analysis of the purified DNA with ClaI and NdeI or SalI and NotI; panels 
C, D, E in Fig. 4.2 indicate the test and the circular map of the final plasmid. 
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4.1.1 Cloning Step 2 
 
The UBCTimp3-mCherry plasmid, encoding Timp3 followed by a T2A ribosomal 
entry site, was a kind gift from Prof. George Bou-Gharios. The Timp3 sequence was 
removed by enzymatic digestion with MluI and KpnI (Fig. 4.3A). 
The sequence encoding the hK14 promoter was amplified from human genomic 
DNA using modified primers to incorporate one MluI site at the 5’ end and NdeI, 
NsiI and KpnI sites at the 3’ end (Fig. 4.3B,C). This PCR product was then digested 
with MluI and KpnI, gel-purified and ligated into the linearised UBCTimp3-mCherry 
(Fig. 4.3D). The presence and correct orientation of hK14 promoter insert into the 
plasmid vector was verified by restriction analysis of the purified plasmid with MluI 
and KpnI, NdeI and NsiI or EcoRV restriction enzymes (Fig. 4.3E,F). In figure 4.3G, 
the circular map of the final plasmid is shown. 
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4.1.2 Cloning Step 3 
 
The pGEM®-5Zf (+)-LaNt α31 and pUBC-mCherry-hK14 promoter plasmids were 
enzymatically digested with NdeI and NsiI (New England Biolabs) (Fig. 4.4A), gel-
purified, ligated and heat shock transformed into One-Shot TOP10 Chemically 
Competent E.Coli cells (Life Technologies). Successful integration was confirmed 
by digestion with NdeI and NsiI or EcoRV and NotI restriction enzymes (Fig. 4.4 
B,C,D). 
The final construct (Fig. 4.4E) was linearised, and ampicillin resistance encoding 
sequence removed by digestion with ZraI and FspI restriction enzymes (New 
England Biolabs) (Fig. 4.4 F,G). 
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4.1.3 In-vitro tests of construct 
 
Complete plasmids were tested by transfection into KERA-308 and HaCaT cells as 
follows: 
Table 7: DNA transfection set up to test the functionality of the hK14 promoter 
driven-LaNt α31 overexpressing construct in-vitro. 
 
Visualisation of the T2A-driven mCherry sequence was confirmed by visualisation 
of the mCherry signal by fluorescence microscopy (Fig. 4.5A,B,C). Expression of 
hK14-driven LaNt α31 expression was confirmed by WB of total protein extracts 
from transfected cells with antibodies against LaNt α31 (Fig. 4.5D). 
  
Transfected DNA Cell type 
None KERA-308 and HaCaT 
UBC-hK14 promoter-mCherry plasmid KERA-308 and HaCaT 
LaNt α31-pSecTag plasmid KERA-308 and HaCaT 
UBC hK14 promoter-LaNt α31-mCherry KERA-308 and HaCaT 
UBC hK14 promoter-LaNt α31-mCherry  
linearised DNA 
KERA-308 
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4.1.4 Litters genotyping shows that only few mice carry the 
transgene  
 
The hK14-LaNt α31-T2A-mCherry DNA construct (12241 nucleotides) was 
embryonically injected to develop LaNt α31 overexpressing animal models. A total 
of 140 embryos survived to the injection and were transferred into five recipient 
mothers. All of the recipient mothers displayed plugs the following day. 
Surprisingly, two of the mothers aborted and only three small litters of animals were 
obtained from the rest of the mothers; five mice from the first and one mouse each 
from the remaining two.   
To determine if the construct was present in the obtained offspring’s DNA, ear 
notches were taken 4 weeks after birth and DNA extracted. Standard PCR, using two 
sets of primers targeting two regions of the construct, revealed that males 1.2 and 1.3 
from Litter 1 were transgenic (Fig. 4.6A). 
Males 1.2 and 1.3 were mated with two and three females respectively, to obtain F1 
heterozygous mice. Two litters were born from male 1.2. Respectively, three and two 
mice out of five showed to have the DNA construct in their genome (Fig. 4.6B). 
Three litters were born from male 1.3. Respectively, two, two and one mice carried 
the DNA construct in their genome (Fig. 4.6C). 
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4.1.5 LaNt α31 is not expressed in tissues isolated from transgenic 
mice 
 
To determine whether LaNt α31 protein was expressed in the positively genotyped 
F1 generation’s mice, we collected protein extracts from tissues known to express 
hK14 promoter, such as skin, eye, trachea, intestine, liver or lung, alongside non-
expressing tissues like heart or kidneys [574].  
Some tissues were cryopreserved as described before, to verify mCherry expression. 
Microscopy imaging of skin sections from mice 4.1 and 6.3 (positive to the presence 
of the transgene) and from control mouse 4.3 (negative to the presence of the 
transgene) revealed only signal auto-fluorescence (Fig. 4.7A), mainly due to the 
presence of hairs, which naturally fluoresce [575]. Some other tissues were, instead, 
homogenised in preparation for WB, performed to verify LaNt α31 protein 
expression; protein extract from LaNt α31 pSecTag-transfected 293A cells was used 
as a positive control and LaNt α31 band was detected only in the positive control 
sample (Fig. 4.7B). From these analyses, the transgene-containing animals showed 
no LaNt α31 protein expression. 
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4.1.6 Early pregnancy interruption after transgenic mice timed-
mating shows incredibly low offspring and absence of LaNt α31 
overexpression 
 
The surprisingly low number of offspring obtained, the detection of the transgene in 
only two mice, but which was not associated with the protein expression, and the 
absence of specific mCherry signal in the skin, prompted us to hypothesise LaNt α31 
overexpression associated lethality. For this reason, we decided to prematurely stop 
the pregnancy at E15.5, to collect the embryos and to analyse the protein expression 
during development.  
Transgenic males 1.2 and 1.3 were timing-mated and two pregnant females were 
sacrificed at E15.5, by which time hK14 promoter has been shown to be already 
expressed [559, 560]. Intriguingly, only one foetus was found and genotyping 
analysis revealed the absence of the hK14-LaNt α31-T2A-mCherry DNA construct 
in the genome (Fig. 4.8 A,B). 
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DISCUSSION 
4a.0 LaNt α31 Overexpressing Animal Model data summary 
 
The results presented in this chapter indicate that, after DNA embryonic injection, 
LaNt α31 overexpression could not be detected in adult mouse tissues, despite the 
DNA construct being present. Moreover, when the pregnancy was interrupted at 
E15.5, we only found one foetus which did not show LaNt α31 overexpression.  
There are, at least, four possible reasons behind our observations, which are 
described below. 
 
Interpretation 1. The inserted DNA does not express 
 
Although only few animals composed the litters obtained in our study, we detected 
the presence of our DNA construct in some of them, therefore indicating that they 
carried the transgene even though they were not expressing the related protein. The 
first, most obvious, interpretation to the absence of LaNt α31 overexpression in the 
live offspring, is that the exogenous DNA may have been integrated in a region of 
the host genome where is not transcribed or translated. As the integration site is 
completely random, the exogenous DNA sequence could have been incorporated in 
the so-called non-coding DNA, DNA regions that form more than 85% of mice and 
humans’ genome [576] and do not encode protein sequences. The DNA construct 
injected in the mouse embryos could have been integrated into different non-coding 
DNA portions, such as cys- or trans- regulatory elements, introns, transposons or 
telomeres, ending up in regions that have different roles (genes transcription 
regulation, proteins binding, etc.) but are definitely not accessible to the 
transcription/translation machinery [577].  
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When integrated in the host genome, exogenous DNA can also multimerise at the 
integration’s site, leading to the integration of multiple number of copies of the 
transgene [578]. In transgenic animals, a high copy number may result in a decreased 
gene expression [579], which could be plausible in our scenario. Moreover, the 
sequence composition (e.g. the presence of enhancer or silencer sequences and the 
type of promoter used), the molecule’s size and the physical form of the vector 
carrying the transgene, as well as the injection site, are all factors that affect the 
efficiency of DNA-mediated transformation [580]. Our construct is bigger than 10 
Kb and it includes two identical silencer sequences, characteristics that could 
potentially affect the success of the DNA integration [580]. We relied on numbers of 
animals generated to counteract the random integration issues; however, we could 
have performed fluorescence in situ hybridization (FISH), looking for the transgenic 
material on our non-expressing tissue/cells to determine integration sites. 
 
Interpretation 2. The exogenous DNA and/or the host genome is 
altered following microinjection 
 
Rather than purely a lack of expression of the transgenic material, the failure to 
detect protein expression may reflect a more general issue with the host cell genome. 
After a transgenic manipulation such as the embryonic microinjection, many 
processes can occur to the DNA and to the host genome before the exogenous DNA 
get integrated. For instance, if the exogenous DNA is multimerising at the site of 
integration, as described above, the high number of tandem repeating elements can 
trigger deletion, breakage or translocation episodes [581, 582]. There are data related 
to the interruption of coding sequences due to the integration mechanism [583], and 
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evidences of extensive physical rearrangements at the site of integration after 
microinjection in mice [584-586]. Also, studies have highlighted the possibility that 
linear DNA molecules, as the construct we have used in this work, after being 
microinjected can be rearranged in concatemers, which are long continuous 
molecules containing multiple copies of the same DNA construct linked in series 
[587].   
One more reason behind the absence of protein expression after microinjection, 
which can be applied to our work, is given by the possible disruption of the recipient 
genomic loci’s natural organisation following the foreign DNA integration [588], 
inducing instability of the site. Indeed, it has been reported that the foreign DNA can 
be integrated into pericentromeric satellite DNA, essential core centromere-building 
sequences with fundamental roles in stabilising interactions between DNA-binding 
proteins and driving chromosomal segregation during mitosis [589], making the 
locus unstable [590]. As our work is the first attempt to create an animal model with 
a LaNt α31 overexpression, any of these mechanisms could be happening. 
 
Interpretation 3. The injected DNA is not integrated into the host 
genome 
 
Despite the fact that DNA microinjection in mouse embryos is now a common 
technique of genetic transformation, and there are previously published data showing 
that transferred DNA sequences can be transmitted to succeeding litter in mice [591] 
[592], it is not unusual that foreign DNA is not integrated in the host genome [578, 
593, 594]. When Gordon et al, in their study, injected an isolated gene into a one-cell 
embryo, they only succeeded in obtaining 2 transgenic mice out of 78 [591]. One 
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explanation for such a low efficiency is that the cells carrying a large amount of 
additional genetic material, as in our LaNt α31 overexpressing animal model where 
the final construct was larger than 10Kb, would not survive through development, 
with a resulting preferential survival of uninjected cells [591].  Interestingly, after 
transformation, cells can maintain the exogenous DNA independent of the host 
DNA, in structures called transgenomes [595]. Scangos et al demonstrated that about 
10% of the transformed cells lose these transgenic sequences if maintained under 
nonselective conditions [596]; if this mechanism also happens in-vivo, it may explain 
our results, since we have analysed the mice tissues only 6 weeks after birth and, 
therefore, the amplified product in our PCR screen may be coming from a 
transgenome rather than integrated DNA. In this study, we could have tested for our 
DNA construct integration using techniques such as a gel-purification assay, in 
which integrated DNA can be separated from free vector using pulsed-field gel 
electrophoresis (PFGE) on the base of the molecular weight [597], or a RAIC-PCR 
assay, capable of detecting even rare integration events in-vivo [598]. 
 
 
 
Interpretation 4. The injected DNA is lethal during development 
 
Although scenarios 1, 2 and 3 are all individually plausible for the lack of LaNt α31 
expression observed in the low number of transgenics produced, they still do not 
explain why our yield, in terms of transgenics produced, was lower than expected. If, 
on one side, this could be explained by poor technique, poor breeding stock or 
inferior quality materials however, on the other side the LaNt α31 transgenic 
production was carried out by a very experienced technician who routinely produces 
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similar animals, and was performed over multiple independent microinjection events, 
in parallel with other ongoing projects that did give rise to the expected numbers of 
transgenics. Therefore, we should consider an explanation where overexpression of 
the LaNt α31 protein is deleterious/embryonic lethal. This situation would explain 
both the low number of offspring obtained and that all the animals obtained carrying 
the transgene did not display expression of the protein.  
Our in-vitro data demonstrate that many of the hTCEpi cell behaviours are impaired 
when LaNt α31 is overexpressed. As already described, there are multiple examples 
of diseases caused by defects of various kinds in the LM network formation and 
stability, such as Pierson Syndrome,  JEB, the LM α2-Deficient Congenital Muscular 
Dystrophy or Nephrotic Syndrome [91, 96, 97, 599]. It is, therefore, not difficult to 
hypothesise that tissue formation will be affected if the LM network is disrupted, 
supporting the possibility of lethality during development. Many losses can occur 
during the pregnancy [493] and, since we analysed the outcome of our DNA 
construct integration only 6 weeks after birth, there is also the possibility that any 
initial events, if they exist, were missed, highlighting the necessity to study the foetal 
development in the early stages.  
In addition to the possible LaNt α31 effects described in chapter 3, the mouse 
BM/ECM contains numerous other interactions that we have not considered in our 
2D cell culture system. For example, the HD/LM332 complex is stabilised by 
collagen type VII anchoring fibrils, so a further explanation is that LaNt α31 could 
be competing for Col type VII binding sites. As collagen type VII binding is 
involved in determining where HDs form and is required for tissue integrity [269, 
327], if collagen type VII binding to laminin was disturbed by the presence of LaNt 
α31, the animals may present with a form of epithelial fragility similar to that 
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observed in dystrophic epidermolysis bullosa. A previously published study using a 
collagen type XVII knockout mouse model showed that more than 90% of the 
newborns die after few days, as they develop blisters and detachment of the 
epidermis [600]. As a further support to the hypothesis that a LaNt α31-induced LM 
network disruption is lethal in-vivo, there are data reporting that the LM332 knockout 
mouse model, generated with a pathogenic LAMB3 genetic variant, showed 
pronounced blistering of the entire skin surface and died within 24h [601], while the 
α3 knockout mice died within the first days of life due to severe blistering [512].  
In connection with the similarity between LaNt α31 and netrins, in-vivo negative 
effects have been observed in the presence of an overexpression of netrin 4. When 
netrin 4 was expressed in mouse skin under control of the hK14 promoter, as our 
construct, such an overexpression increased the lymphatic permeability and 
downregulating tight junction proteins [602], which could suggest a potential double 
effect of LaNt α31 on the ECM; LaNt α31 may be disrupting the LM network AND 
weakening the tight junctions, inducing a premature death of the offspring.  
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Final conclusions and future directions 
 
Irrespective of which, among the described hypotheses, underlie our results, all the 
findings described in this thesis strongly indicate that, in corneal epithelial cells, 
LaNt α31 can be considered as a key regulator of the cell to LM adhesive complex 
assembly and maturation. Furthermore, being LaNt α31 differentially distributed 
throughout the anterior segment, we can claim that this protein has context-specific 
functions.  
Previous studies on LaNts transcripts indicate extensive distribution of LaNt family 
members [461], suggesting that these relatively unstudied proteins may have 
widespread roles in multiple tissues and different developmental contexts. This 
points to a potential role for the LaNt proteins in regulating any of the processes 
where BM remodelling is required, including wound repair, tissue morphogenesis, 
differentiation, angiogenesis or pathogenic situations involving defective BM 
function, such as tumour cell invasion and metastasis.  
I think that our in-vivo study gave us strong hints, although very preliminary, about 
the importance of LaNts proteins and their association with LMs.  It would have been 
very interesting for me to repeat the functional assays using different LM isoforms, 
to understand the LM-LaNts specificity of interaction. There is still an open question 
on the LM-LaNt α31 time and order of deposition, two aspects that could be resolved 
applying live microscopy to the proteins of interest tagged with inducible 
fluorescence, or imaging techniques such as FRET and atomic-force microscopy 
(ATM). Furthermore, a ligand-binding assay or a receptor-blocking experiment could 
be extremely useful to have an insight into the LaNt α31 receptor binding activity.  
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Particularly compelling is also the study of LaNt α31 overexpression on disease’s 
tissues. The Eye and Vision Science Department in Liverpool has a large archive of 
wax-embedded eye tissues, collected from patients affected by a variety of 
pathologies; analysing the protein localisation in these tissues could possibly uncover 
novel aspects of the same projects. On the other side, many questions raised from the 
in-vivo study, which only exposed a narrow part of a big picture. Believing that an 
overexpression of LaNt α31 is lethal during the development, the next step would 
definitely be to change the DNA cloning approach to create an inducible DNA 
construct. This would allow the pregnancy to complete normally and the protein 
overexpression to be induced only after birth, giving us the possibility to study the 
LaNt α31 overexpression effects on a live animal. All these aspects establish very 
interesting future research directions, which will lead to innovative and 
interdisciplinary outcomes. 
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